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ABBREVIATIONS  
  
BSA     bovine  serum  albumin  
CASR     calcium  sensing  receptor  
CFTR   cystic  fibrosis  transmembrane  conductance  regulator  
CP     chronic  pancreatitis  
CTRC     human  chymotrypsinogen  C  
CTRB1     human  chymotrypsinogen  B1  
CTRB2     human  chymotrypsinogen  B2  
CTRL1     human  chymotrypsinogen  like  enzyme  1  
DMEM     Dulbecco’s  modified  Eagle’s  medium  
EDTA     ethylene  diamine  tetraacetic  acid  
ELA2A     human  proelastase  2A  
ELA3A     human  proelastase  3A  
ELA3B     human  proelastase  3B  
FBS     fetal  bovine  serum  
HCP     hereditary  chronic  pancreatitis  
HEK     human  embryonic  kidney  
HP     hereditary  pancreatitis  
HPLC     high-­performance  liquid  chromatography  
HRP   horseradish  peroxidase  
ICP     idiopathic  chronic  pancreatitis  
IPTG   Isopropyl  β-­D-­1-­thiogalactopyranoside  
MRCP     Magnetic  resonance  cholangiopancreatography  
MWCO     molecular  weight  cut  off  
PCR     polymerase  chain  reaction  
PRSS1     human  cationic  trypsinogen  
PRSS2     human  anionic  trypsinogen  
PRSS3     human  mesotrypsinogen  
PVDF     polyvinylidene  difluoride  
SBTI     soybean  trypsin  inhibitor  
SDS     sodium  dodecyl  sulfate  
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SDS-­PAGE     sodium   dodecyl   sulfate   polyacrylamide   gel  
electrophoresis  
SPINK1     serine  protease  inhibitor,  Kazal  type  1  
TAP     trypsinogen  activation  peptide  
TCA     trichloroacetic  acid  
TCP     tropical  chronic  pancreatitis  
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1   INTRODUCTION  
  
1.1   Chronic  pancreatitis  
Chronic  pancreatitis   (CP)   is   a  disease  of   the  pancreas  characterized   by  chronic  
inflammation,   progressive   fibrosis,   variable   pain   and   loss   of   exocrine   and   endocrine  
function.   CP   can   be   classified   into   several   subtypes   which   include   alcoholic   chronic  
pancreatitis   (ACP),   idiopathic   chronic   pancreatitis   (ICP),   tropical   chronic   pancreatitis  
(TCP)   and   hereditary   chronic   pancreatitis   (HCP).   Heavy   alcohol   consumption   is   a  
prominent   risk   factor   of   the   disease   but   the   mechanism   by   which   alcohol   induces  
pancreatic  inflammation  is  poorly  understood  [1].  In  about  10-­30%  of  the  cases,  no  causal  
agent  can   be   identified  and   these  patients  are   labeled  as   having   ICP.  TCP   is  a   juvenile  
form   of   chronic   calcific   non-­alcoholic   pancreatitis,   prevalent   in   tropical   developing  
countries.   HCP   is   an   autosomal   dominant   genetic   disorder   that   accounts   for  
approximately   1-­2   %   of   pancreatitis   patients.   Clarifying   the   pathomechanism   of  
genetically  determined  CP  helps  to  understand  the  pathophysiology  of  all  other  forms  of  
the  disorder  and  may  result  in  more  effective  therapy  and  prevention.    
1.2   Genetic  factors  in  chronic  pancreatitis  
In   recent   years,   several   genetic   risk   factors   for  CP   have   been   identified.  Rare  
mutations   affecting   the   human   cationic   trypsinogen   (PRSS1)   gene      directly   cause   the  
disease  [2,3].  Mutations  in  the  PRSS1  gene  increase  activation  of  trypsinogen  and  cause  an  
autosomal  dominant  hereditary  pancreatitis  or  act  as  a  risk   factor  for  sporadic  cases  [4].  
Surprisingly,  the  G191R  variant  in  the  human  anionic  trypsinogen  gene  (PRSS2)  protects  
against  pancreatitis  by  stimulating  trypsinogen  autodegradation  [5].  Genetic  alterations  in  
the   serine   protease   inhibitor   Kazal   type   1   (SPINK1),   an   important   pancreatic   trypsin  
inhibitor  have  been  found  in  association  with  ICP,  ACP,  and  TCP  [6,7].  Mutations  in  the  
SPINK1   gene   decrease   the   expression   of   the   inhibitory   protein,   and   thereby   increase  
trypsinogen   activation.   Another   risk   factor   for   CP   are   mutations   in   the   cystic   fibrosis  
transmembrane   conductance   regulator   gene   (CFTR)   [8,9,10,11].   CFTR   mutations   might  
impair   bicarbonate   secretion   and   facilitate   trypsinogen   activation   through   altered  
intraductal   pH   and/or   decreased   ductal   washout.   Furthermore,   recent   investigations  
confirmed   chymotrypsin   C   (CTRC),   a   significant   component   of   the   trypsin   activation  
8  
  
cascade,  as  a  new  susceptibility  gene  for  CP  [12].  CTRC  variants  can  cause  loss  of  CTRC  
function   by   different   mechanisms:   reduced   secretion,   catalytic   defect   or   increased  
degradation  by  trypsin.  Finally,  mutations   in  the  calcium  sensing  receptor  gene  (CASR)  
have   been   reported   in   CP.   CASR   might   be   a   regulator   of   pancreatic   juice   calcium  
concentration  by  stimulating  ductal  electrolyte  and  fluid  secretion  [13,14].  
1.3   Hereditary  chronic  pancreatitis  
HCP   is   a   very   rare   type   of   early   onset   chronic   pancreatitis.   It   is   defined   as   an  
autosomal  dominant  genetic  disorder  characterized  by  incomplete  penetrance  and  variable  
expressivity  [15].  HCP  is  diagnosed  when  there  are  recurrent  episodes  of  pancreatitis  from  
childhood,   a   positive   family   history   and   other   causes   of   pancreatitis   such   as   alcohol  
abuse,   trauma,   infection,   medication,   gallstones   and   metabolic   disorders   have   been  
excluded.  The  disease  was   first  described  by  Comfort  and  Steinberg   in  the  early  1950’s  
when  they  recognized  that  CP  may  accumulate   in  selected  families   suggesting  a  genetic  
background  [16].  In  1996,  an  association  between  HCP  and  the  long  arm  of  chromosome  7  
(7q35)   was   found   by   genetic   linkage   analysis   with   microsatellite   markers   by   three  
independent  teams  [17,18,19].  In  the  same  year,  Whitcomb  et  al.  identified  the  first  genetic  
defect  of   the  PRSS1  gene  when  they  sequenced  two  of   the   functional   trypsinogen  genes  
and   discovered   a   disease   causing   mutation,   which   was   the   R122H   variant   [2].  
Subsequently,  this  was  independently  confirmed  by  other  studies  [20,21,22].  
Heterozygous   mutations   in   the   serine   protease   1   (PRSS1)   gene   have   been  
identified   as   causative   genetic   changes   in   25-­80%   of   cases   in   different   studies.   The  
PRSS1  gene   encodes  human  cationic   trypsinogen,   the  dominant  digestive  proenzyme   in  
human  pancreatic  secretions.  Up  to  now,  approximately  70%  of  the  identified  HCP  cases  
carry  the  R122H  mutation  and  about  20  %  the  N29I  mutation.  In  the  remaining  10%  of  
the   documented   variants,   there   is   an   interesting   subgroup   composed   by   mutations  
affecting  the  activation  peptide  of  human  cationic  trypsinogen  [3].  The  discovery  that  the  
disease  is  associated  with  PRSS1  mutations  demonstrates  that  trypsinogen  plays  a  central  
role   in   the  pathogenesis  of   human  pancreatitis.  The   biochemical  mechanism  behind   the  
genetic  factors  involves  increased  ectopic  activation  of  trypsin  in  the  pancreas  and  failure  
of  protective  mechanisms  responsible  for  trypsin  inactivation.  
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1.4   Human  trypsinogens  
Among   the   pancreatic   enzymes   trypsinogen   is   the   most   abundant   digestive  
proteolytic   proenzyme   in   the   pancreatic   juice.   The   human   pancreas   secretes   three  
trypsinogen   isoforms   encoded   by   the   PRSS   genes   1,   2   and   3.   On   the   basis   of   their  
isoelectric   point   and   relative   electrophoretic  mobility,   the   three   trypsinogen   species   are  
commonly  referred  to  as  cationic  trypsinogen  (PRSS1),  anionic  trypsinogen  (PRSS2)  and  
mesotrypsinogen   (PRSS3).   Cationic   trypsinogen   and   anionic   trypsinogen   make   up   the  
bulk   of   secreted   trypsinogen,  whereas  mesotrypsinogen   accounts   for   2%   to   10%  [23,24].  
Human   trypsinogens   are   synthesized   as   pre-­pro-­enzymes   with   a   signal   peptide   of   15  
amino   acids   which   is   removed   on   entry   into   the   endoplasmic   reticulum   lumen.   The  
proenzymes   are   packaged   into   zymogen   granules   and   eventually   secreted   into   the  
pancreatic   juice.   Physiological   activation   of   trypsinogen   takes   place   in   the   duodenum,  
where   enteropeptidase   specifically   cleaves   the   Lys23-­Ile24   peptide   bond   and   this  
activating  cleavage  removes  a  typically  8  amino-­acid  long  activation  peptide  [25].  Trypsin  
can   also   activate   trypsinogen,   in   a   process   termed   autoactivation   which   facilitates  
digestive   zymogen   activation   in   the   duodenum,   but   may   induce   pancreatitis   if   occurs  
prematurely   in   the   pancreas.   Compared   with   trypsinogens   from   other   species,   human  
cationic   trypsinogen   exhibits   an   usually   high   propensity   for   autoactivation,   and   this  
stimulatory  effect  is  especially  strong  in  the  case  of  activation  peptide  mutations  [26,25,27].  
1.5   Mutations  in  the  trypsinogen  activation  peptide  
The  trypsinogen  activation  peptide  (TAP)  is  an  eight  amino  acid  long  N-­terminal  
sequence   containing   a   strongly   conserved   tetra-­Asp   motif   preceding   the   Lys23-­Ile24  
scissile   peptide   bond.  The   characteristic   tetra-­Asp   sequence   is   presumed   to   serve   as   an  
enteropeptidase  recognition  motif  [28].  Previous  data  from  our  laboratory  showed  that   in  
human   cationic   trypsinogen   the   negatively   charged   tetra-­Asp   sequence   plays   only   a  
limited   role   in   enteropeptidase   recognition,   but   it   is   essential   for   suppression   of  
autoactivation  [26].  It  has  also  been  demonstrated  that  millimolar  concentrations  of  Ca2+,  
which  binds  to  the  above  mentioned  tetra-­Asp  motif  in  the  activation  peptide  and  shields  
the   negative   charges,   can   increase   trypsinogen   activation   [29].   Thus,   mutations   that  
neutralize   any   of   the   Asp   residues   in   the   activation   peptide,   are   expected   to   cause  
increased   autoactivation   of   trypsinogen.   In   addition   to   the   relatively   common   A16V  
mutation,   there  were   three   other   mutations   in   the   activation   peptide   of   human   cationic  
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trypsinogen   found   in   association  with   hereditary   pancreatitis   namely  D19A,  D22G  and  
K23R  variants  (Table  1)  [22,25,30,31].    
  
Table  1.  Hereditary  pancreatitis-­associated  mutations  in  the  activation  peptide  of  human  cationic  trypsinogen.  Note  that  
only  changes  in  exon-­2  affect  the  mature  trypsinogen  protein.    
  
All   four  TAP  mutations  were   identified   in   the   heterozygous  state,   and  mutations  D22G  
and   K23R   were   found   only   in   a   single   family   each   (see   details   at  
www.pancreasgenetics.org).  Mutation  A16V  exhibited  variable  penetrance  and  was  also  
found  in  sporadic  cases  with  no  family  history  [32].    
Although   these   activation   peptide   mutations   are   fairly   rare,   their   functional  
characterization   strongly   contributed   to   the   elucidation   of   the   pathomechanism   of  
genetically  determined  pancreatitis.  Biochemical  analyses  of  TAP  mutants  D19A,  D22G  
and   K23R   revealed   that   the   common   phenotypic   change   is   a   markedly   increased  
propensity  for  autoactivation  [25,26,  27].  In  fact,  these  mutations  offered  the  first  convincing  
evidence   that   increased   autoactivation   was   a   pathologically   relevant   mechanism   in  
hereditary  pancreatitis.  However,  even  though  TAP  mutations  stimulate  autoactivation  in  
a  dramatic  manner,  these  variants  cause  the  same  clinical  phenotype  as  the  most  frequent  
R122H  and  N29I  mutations.  Mutations  D19A  and  D22G  eliminate  Asp  residues  from  the  
characteristic   tetra-­Asp  motif   and   thereby  mitigate   its   inhibitory   effect.  Mutation  K23R  
changes   the  P1  Lys   residue   to  Arg,  which   is   preferred   by   trypsin   owing   to   a   favorable  
electrostatic   interaction  in  the  specificity  pocket  of  the  protease  [25].  Mutation  A16V  has  
no   direct   effect   on   autoactivation;;   however,   it   increases   N-­terminal   processing   of   the  
activation  peptide  by  chymotrypsin  C,  which,  in  turn,  leads  to  increased  autoactivation  of  
cationic  trypsinogen  [33,34].  Recent  studies  demonstrated  that   increased  autoactivation  of  
activation   peptide  mutants   can   occur   intracellularly   and   result   in   decreased   trypsinogen  
secretion  and  apoptotic  acinar  cell  death  [27].  
1.6   The  regulatory  effect  of  chymotrypsin  C    
Functional   characterization   of   HCP-­associated   PRSS1  mutations   revealed   that  
there   are   at   least   two   pathological   pathways   mediating   increased   pancreatitis   risk.  
Mutations   exert   their   effect   via   a   so-­called   trypsin-­dependent   pathological   pathway   by  
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directly  increasing  trypsinogen  autoactivation  or  by  altering  the  chymotrypsin-­C  (CTRC)-­
dependent   activation   and/or   degradation   of   cationic   trypsinogen   [34].   Alternatively,  
PRSS1   mutations   can   cause   misfolding,   intracellular   retention   and   degradation   with  
consequent  endoplasmatic  reticulum  stress  [35].  
The   mechanism   of   action   for   the   most   frequently   found   mutations   have   been  
recently  elucidated  and  involves  increased  resistance  against  CTRC-­mediated  degradation  
and/or  increased  sensitivity  to  CTRC-­dependent  stimulation  of  autoactivation  [34].  CTRC  
is   a   pancreatic   serine   protease   which   controls   autoactivation   of   human   cationic  
trypsinogen   by   selectively   cleaving   regulatory   sites   within   the   TAP   and   the   calcium  
binding   loop.   The   dominant   effect   of   CTRC   is   trypsinogen   degradation,   which   is  
triggered  by  cleavage  of  the  Leu81-­Glu82  peptide  bond  in  the  calcium  binding  loop  and  is  
facilitated  by   a   trypsin-­mediated  autolytic  cleavage  of   the  Arg122-­Val123  peptide   bond  
[12,34].  CTRC  also  degrades  active  trypsin  by  the  same  mechanism  but  at  a  slower  rate.  It  
has  been  shown  that  HCP-­associated  mutations  N29I,  N29T,  V39A,  R122C  and  R122H  
decrease   or   block   cleavages   at   these   sites   and   thereby   increase   trypsin   levels   generated  
during  autoactivation  [34].  
A   secondary,   less   prominent   effect   of  CTRC  on   autoactivation   is  mediated   by  
cleavage   of   the   activation   peptide   of   cationic   trypsinogen   at   the   Phe18-­Asp19   peptide  
bond   (Figure   1)   [33].   In   human   cationic   trypsinogen,   inhibition   of   autoactivation   is  
dependent  on  Asp218,  which  participates   in  a  repulsive  electrostatic   interaction  with  the  
tetra-­Asp  motif.  CTRC  cleavage  at  the  Phe18-­Asp19  peptide  bond  results   in  a  shortened  
activation  peptide,  causing  partial  liberation  of  the  inhibitory  interaction  with  Asp218  and  
increased   autoactivation.   Earlier   studies   proved   that   pancreatitis-­associated   mutations  
A16V   and,   to   a   lesser   extent,   N29I   increase   N-­terminal   processing   of   the   activation  
peptide  by  CTRC  and  thereby  stimulate  trypsinogen  autoactivation  [33,34].  
  
  
Figure   1.    Amino-­acid   sequence   and   the   cleavage   sites   of   human   cationic   trypsinogen   activation  
peptide    
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2   AIMS  OF  THE  STUDY  
Mutations   in   the   PRSS1   gene   increase   autoactivation   of   human   cationic  
trypsinogen   which   explains   the   higher   risk   for   pancreatitis   in   carriers.   Based   on   the  
hypothesis   that   HCP-­associated   mutations   may   exert   their   effect   in   a   chymotrypsin   C  
(CTRC)-­dependent   manner,   autoactivation   of   trypsinogen   mutants   has   recently   been  
studied  in  the  presence  of  CTRC.  The  mechanism  of  action  for  the  most  frequently  found  
variants   involves   increased   resistance   against   CTRC-­mediated   degradation   and/or  
increased  sensitivity  to  CTRC-­dependent  stimulation  of  autoactivation.  
2.1   Characterization  of  the  K23_I24insIDK  PRSS1  mutation    
In   a   hereditary   pancreatitis   family   from   Denmark,   we   identified   a   novel  
intragenic  duplication  of  9  nucleotides  in  exon  2  of  the  PRSS1  gene  (c.63_71dup)  which  
at  the  amino-­acid  level  resulted  in  the  insertion  of  three  amino  acids  within  the  activation  
peptide   of   cationic   trypsinogen   (K23_I24insIDK).   Our   aim   was   to   characterize   the  
effect   of   the   novel   K23_I24insIDK   PRSS1   alteration   on   the   function   of   human  
cationic  trypsinogen.  Our  specific  aims  were:  
1.   To  investigate  the  effect  of  the  K23_I24insIDK  mutation  on  autoactivation    
2.   To  investigate  the  effect  of  the  K23_I24insIDK  mutation  on  enteropeptidase  and  
cathepsin  B-­mediated  trypsinogen  activation  
3.   To  investigate  the  effect  of  the  K23_I24insIDK  mutation  on  trypsinogen  secretion  
2.2   Investigation  of  trypsinogen  activation  in  the  presence  of  chymotrypsin  C    
In   light   of   the   recently   discovered  CTRC-­dependent   unifying   pathomechanism  
for   HCP,   this   study   was   further   aimed   at   clarifying   the   role   of   CTRC   in   the  
mechanism  of  action  of  the  activation  peptide  mutations.  Our  specific  aims  were:  
1.   To  investigate  the  effect  of  TAP  mutations  on  autoactivation    
2.   To  investigate  the  effect  of  CTRC  on  the  autoactivation  of  trypsinogen  activation  
peptide  mutations  
3.   To  elucidate  the  effect  of  mutations  on  CTRC  specificity  in  activation  peptide  
cleavage  
4.   To  determine  the  effect  of  mutations  on  the  Ca2+  binding  affinity  of  the  activation  
peptide  
5.   To  investigate  the  effect  of  mutations  on  trypsinogen  secretion  
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3   EXPERIMENTAL  PROCEDURES  
  
3.1   Nomenclature  
Nucleotide   numbering   in   genes   encoding   human   pancreatic   proteases   reflects  
coding  DNA  numbering  with  +1  corresponding  to  the  A  of  the  ATG  translation  initiation  
codon   in   the   reference  sequence.  Amino  acid   residues  were   numbered   starting  with   the  
initiator   methionine   of   the   primary   translation   product,   in   accordance   with   the  
recommendations  of  the  Human  Genome  Variation  Society.  Note  that  the  ELA  (elastase)  
gene   nomenclature   for   the   five   human   pancreatic   elastase   genes   have   recently   been  
changed   to   CELA   (chymotrypsin-­like   elastase).   In   this   thesis,   I   use   the   old   ELA  
nomenclature.  
3.2   Patients  
Our   study   was   approved   by   the   Scientific   Ethics   Committee   of   the   Odense  
University  Hospital   and   the  Danish  Data   Protection  Agency.   The   diagnosis   of  CP  was  
based   on   the   criteria   used   by   The   European   Registry   of   Hereditary   Pancreatitis   and  
Familial  Pancreatic  Cancer  (EUROPAC)  which  require  two  first  degree  relatives  or  three  
or   more   second   degree   relatives   in   two   or   more   generations   with   recurrent   acute  
pancreatitis,   and/or  CP   for  which   there   are   no   known   precipitating   factors.   The   family  
received  genetic  counseling  before  they  gave  their  informed  consent  to  participate  in  the  
study.   A   questionnaire   recording   symptoms,   clinical   tests   and   medical   history   was  
completed.  After  discovery  of  the  mutation,  the  grandparents  and  the  siblings  of  the  father  
were  also  tested.  
3.3   Genetic  analyses  
Blood  samples  were  drawn  from  the  index  patient,  his  brother  and  his  father   into  
tubes  with  ethylene  diamine  tetraacetic  acid  (EDTA)  and  stored  at  –20  oC.  Genomic  DNA  
was  extracted   from   full   blood  using   the  Maxwell®   (Promega,  Ramcon  Denmark)  DNA  
purification   robot.   The   samples   were   tested   for   small   deletions,   insertions   and   point  
mutations   in   all   exons   and   the   exon-­intron   boundaries   of   the   PRSS1   (GenBank  
NM_002769.3)   and   SPINK1   (GenBank   NM_003122.3)   genes   using   DHPLC   (WAVE  
3500HT  High  Sensitivity  System;;  Transgenomic  Inc,  Elancourt,  France).  Variants   in  the  
PRSS1   gene   were   categorized   as   polymorphisms   if   they   were   identified   in   control  
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samples  with  a  comparable   frequency.  Samples  with  deviating  chromatographic  profiles  
were  sequenced  in  both  directions  using  the  BigDye®  Terminator  v3.1  Cycle  Sequencing  
Kit   (Applied  Biosystems)   and   analyzed   on   an   automated  ABI  PRISM®  3100   (Applied  
Biosystems).  The  presence  of  PRSS1  gene  duplication  or  triplication  was  excluded  using  
the   rapid   polymerase   chain   reaction   (PCR)-­based  method   described   by   Chauvin   et   al.,  
2009   [36].   Genomic   DNA   was   also   tested   for   33   CFTR   (GenBank   NM_000492.3)  
mutations:   394delTT,   p.R553X,   621+1G>T,   p.R1162X,   1717-­1G>A,   3659delC,  
p.G542X,   2183A>G,   p.W1282X,   1078delT,   711+1G>T,   p.F508del,   p.S549N,   I507del,  
p.S549R,   2184delA,   p.G551D,   p.G85E,   p.N1303K,   p.R560T,   p.R117H,   p.R347H,  
p.R347P,   p.R334W,   2789+5G>A,   3849+10kbC>T,   p.A445E,   3120+1G>A,   p.V520F,  
1898+1G>A,  3876delA,  3905insT  and  IVS8-­5T.  
3.4   Plasmid  construction  and  mutagenesis  
The  pTrapT7   intein   and   pcDNA3.1(-­)   expression   plasmids   harboring   the   coding  
DNA   for   human   pancreatic   digestive   proteases   were   constructed   previously   in   our  
laboratory.  [12,33,37,38].  To  increase  expression   levels   in  cell   transfection  experiments,  the  
TAP  mutations  were  transferred  into  the  pcDNA3.1(-­)  p.K237D/p.N241D  mutant  PRSS1  
background   [39].   Mutations   in   PRSS1   were   generated   by   overlap   extension   PCR  
mutagenesis   with   the   mutagenic   primers   listed   in   Table   2.   A   typical   PCR   mixture  
contained   200  µM  dNTP,   2  µM  of   each   primer,  DNA   template,   0.05  U/µl  HotStarTaq  
DNA  Polymerase  (Qiagen)  in  a  total  volume  of  50  µL.  35  cycles  of  30  sec  denaturation  at  
94  ºC,  30  sec  annealing  at  55-­65  ºC  and  1  min  extension  at  72  ºC  were  performed.  PCR  
products   were   analyzed   by   conventional   submarine   horizontal   agarose   gel  
electrophoresis.  
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Table  2.   Oligonucleotides  used  for  PCR  mutagenesis.  
3.5   Expression  of  cationic  trypsinogen  
Wild-­type   and   mutant   trypsinogens   were   expressed   in   the   aminopeptidase   P  
deficient  LG-­3  E.  coli   strain  as   fusions  with  a   self-­splicing  mini-­intein.  This  expression  
system   produces   recombinant   trypsinogen   with   uniform,   authentic   N   termini   [37,40].  
Transformants  were  grown  in  200  mL  Luria-­Bertani  medium  (LB)  at  30  ºC.  When  culture  
density   reached  OD  0.5   at   600   nm   (OD600),   expression   of   trypsinogen  was   induced   by  
shifting  the  incubation  temperature  to  42  ºC  for  30  min  which  induces  the  expression  of  
T7   RNA   polymerase   encoded   on   plasmid   pGPI-­2   under   the   control   of   temperature-­
sensitive   λ   repressor.   Adding   isopropyl-­1-­thio-­β,D-­galactopyranoside   (IPTG)   to   a   final  
concentration  of  1  mM  derepressed  the  lac  operator  which  is  positioned  between  the  T7  
promoter  and  the  intein-­trypsinogen  fusion  gene  in  the  pTrapT7  plasmid.  After  induction,  
cells  were  grown  for  an  additional  5  h  at  30  ºC.  Expression  was  verified  by  analyzing  the  
inclusion  body  fraction  by  15%  SDS-­PAGE  and  Coomassie  Blue  staining  (Figure  2.).  
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Figure   2.    Human   cationic   trypsinogen   (PRSS1)   expressed   in   aminopeptidase   P   deficient   LG-­3   E.  
coli    cells.    Inclusion   bodies   prepared   from   1  mL   cell    culture  were   analyzed   by   15%   reducing   SDS-­
PAGE   followed  by  Coomassie  Blue  staining.     
3.6   Refolding  and  purification  of  cationic  trypsinogen  
Harvested  LG-­3  E.  coli  cells  were  resuspended  in  0.1  M  Tris-­HCl  pH  8.0,  5  mM  
K-­EDTA   at   0.8   mL   per   10   mL   original   culture   volume,   and   inclusion   bodies   were  
isolated  by  sonication  (3  x  20  s,  Heat  Systems  Ultrasonic  cell  disruptor,  Model  W-­200R  
with  a  microtip  probe,  continuous  mode,  power  setting  4)  and  centrifugation  (13,200  rpm,  
5  min,  Eppendorf  microcentrifuge,  4  ºC).  The  pellet  was  washed  twice  with  1  mL  of  0.1  
M  Tris-­HCl  (pH  8.0),  5  mM  K-­EDTA,  dissolved  in  500  µL  of  4M  guanidine-­HCl,  0.1  M  
Tris-­HCl   (pH   8.0),   2   mM   K-­EDTA,   30   mM   dithiothreitol   (final   concentrations),   and  
incubated   at   37   ºC   for   30   min   to   reduce   trypsinogens.   Denaturated   trypsinogens   were  
rapidly   diluted   in   50   mL   refolding   buffer   (0.9  M   guanidine-­HCl,   0.1  M  Tris-­HCl   (pH  
8.0),  2  mM  K-­EDTA,  1  mM  L-­cysteine,  and  1  mM  L-­cystine),  stirred  under  argon  for  5  
min,   and   incubated   overnight   at   4   ºC.  The   solution  was   diluted  with   50   mL   of   0.4  M  
NaCl,  centrifuged  for  15  min  at  15,000  rpm  and  loaded  onto  2  mL  ecotin-­affinity  column.  
The  column  was  washed  with  20  mM  Tris-­HCl   (pH  8.0)  0.2  M  NaCl  and   trypsinogens  
were  eluted  with  50  mM  HCl.  To  stabilize  trypsinogens  against  autoactivation  the  elution  
solution  also  contained  100  mM  NaCl.  
3.7   Expression  of  proelastase  2A  
The  pTrap-­T7  constructs  encoding  proelastase  2A  (ELA2A)  were  transformed  into  
E.   coli   BL21(DE3)   carrying   a   chromosomal   copy   of   T7   RNA   polymerase   under   the  
control  of   the   lacZ  promoter.  The   transformants  were  grown   in  200  mL  of  LB  medium  
containing  100  µg/mL  ampicillin  at  37  ºC.  When  culture  density  reached  OD  0.5  at  600  
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nm   (OD600),   expression   of   proelastase   was   induced   by   adding   IPTG   to   a   final  
concentration  of  1  mM.  After  induction,  cells  were  grown  for  an  additional  4  h  at  37  ºC.  
Cells  were  harvested  and  inclusion  bodies  were  isolated  by  sonication  and  centrifugation,  
as  described  above.    
3.8   Refolding  and  purification  of  proelastase  2A  
The  inclusion  body  pellet  was  washed  twice  with  1.5  mL  of  0.1  M  Tris-­HCl  (pH  
8.0)  and  dissolved  in  1  mL  of  unfolding  solution  [6  M  guanidine-­HCl,  50  mM  Tris-­HCl  
(pH  8.0)  and  5  mM  DTT]  to  ~20  mg  of   inclusion  bodies.  Dithiothreitol  was  added  to  a  
final   concentration   of   30   mM,   and   ELA2A   protein   was   completely   reduced   at   room  
temperature   for  2  h.  Denatured  ELA2A  protein  was   then   rapidly  diluted   into  50  mL  of  
refolding  buffer  (0.9  M  guanidine-­HCl,  0.1  M  Tris-­HCl  (pH  8.0),  30  mM  L-­cysteine,  30  
mM  L-­cystine),  slowly  stirred  under  argon  for  5  min  at  room  temperature,  and  kept  at  4  
°C  overnight.  To  remove  any  leftover  contaminants  and  misfolded  protein,  the  renatured  
ELA2A  protein  solution  was  diluted  2-­fold  with  50  ml  of  0.1  M  Tris-­HCl  (pH  8.0)  and  
applied  directly  to  a  2  mL  ecotin  affinity  column  [38].  The  column  was  washed  with  20  
mM  Tris-­HCl  (pH  8.0)/0.2  M  NaCl,  and  ELA2A  was  eluted  with  50  mM  HCl.  ELA2A  
was   then   activated   using   10   nM   human   anionic   trypsin   in   0.1  M  Tris   (pH  8.0),   0.05%  
Tween-­20   (final   concentrations)   and   enzyme   concentrations  were   determined   by   active  
site  titration  with  ecotin  [41].  
3.9   Expression   and   purification   of   human   chymotrypsinogens   and  
proelastase  ELA3A  and  ELA3B  
Deca-­histidine   (10   His)-­tagged   forms   of   human   chymotrypsinogens   CTRB1,  
CTRB2,   CTRC   and   CTRL1   and   proelastases   ELA3A   and   ELA3B   proteins   were  
expressed  in  human  embryonic  kidney  (HEK  293T)  cells  with  transient  transfection  using  
30  µg  of  the  pcDNA  expression  plasmid  and  then  purified  from  the  conditioned  medium  
with  nickel-­affinity  chromatography.  Approximately  150-­200  mL  of  conditioned  medium  
was   used   for   purification   on   a   nickel-­nitrilotriacetic   acid   Superflow   cartridge   (Qiagen)  
equilibrated  with  Buffer  NPI-­20  [50mM  NaH2PO4,  300  mM  NaCl,  and  20  mM  imidazole  
(pH  8.0)].  The  medium  was   loaded  onto  the  column  at  a  flow  rate  of  4  mL/min  using  a  
loading  pump,  and   the  column  was  washed  with  Buffer  NPI-­20  until   the  absorbance  at  
280  nm  returned  to  the  base  line.  The  purified  protein  was  then  eluted  with  Buffer  NPI-­
250  [50  mM  NaH2PO4,  300  mM  NaCl,  and  250  mM  imidazole  (pH  8.0)]  at  a  flow  rate  of  
2  mL/min,   and   5  mL   fractions  were   collected.  Aliquots   (100  µL)  of   the   fractions  were  
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analyzed   by   15%   SDS-­PAGE   and   Coomassie   Blue   staining,   and   peak   fractions   were  
pooled  and  dialyzed  for  24  h  against  two  changes  of  3.5  liters  of  50  mM  NaH2PO4  buffer  
(pH  8.0)  containing  300  mM  NaCl.  The  dialyzed  proenzyme  solution  was  concentrated  
using   a   Vivaspin   concentrator   (10-­kDa   molecular   mass   cutoff).   Pancreatic   zymogens  
were  then  activated  using  10  nM  human  cationic  trypsin,  and  enzyme  concentrations  were  
determined   by   active   site   titration   with   ecotin   [41].   The   final   working   CTRC   stock  
solution  was  diluted  to  500  nM  in  0.1  M  Tris-­HCl  (pH  8.0)  and  0.05%  Tween  20.  
3.10  Concentration  determination  of  pancreatic  enzymes  
The  concentration  of  proteases  were  determined  by  active-­site  titration  against  the  
pan-­protease  inhibitor  ecotin  Ecotin  was  overexpressed  previously  in  E.  coli  BL21(DE3)  
and  purified  from  the  periplasm  as  described  in  [42].  The  concentration  of  ecotin  was  then  
determined  by  titration  against  active  site-­titrated  bovine  trypsin.  This  ecotin  batch  served  
then  as  a  universal  titrant  for  all  studies.  Enzymes  at  25-­100  nM  estimated  concentration  
(calculated   from   their  ultraviolet  absorbance  at  280  nm,  using   the   theoretical  extinction  
coefficients)  was  added   to  0-­100  nM  ecotin   (two-­fold   serial  dilution   in  0.1  M  Tris-­HCl  
(pH  8.0)  with  1  mM  CaCl2)  in  a  total  volume  of  100  µL.  After  1  hour  incubation  at  room  
temperature,   free   enzyme   activity   was   measured   as   described   below.   Titrations   were  
performed   using   protease   concentrations   at   least   2   orders   of   magnitude   above   the   KD  
values.  Substrate  was  given   in  a  5  µL  volume  so  as  not  to  perturb  the  equilibrium.  The  
measured   enzyme   activity   values   were   plotted   as   a   function   of   the   total   inhibitor  
concentration.   The   equivalence   point   was   determined   by   extrapolation   of   the   linear  
portion  of  the  curve  to  the  x  axis.  This  represents  the  inhibitor  concentration  equal  to  the  
enzyme  concentration.    
3.11  Trypsin  activity  assay  
Trypsin   activity   was   measured   with   the   synthetic   chromogenic   substrate,   N-­
benzyloxycarbonyl-­Gly-­Pro-­Arg-­p-­nitroanilide   at   0.14   mM   final   concentration.   One-­
minute  time  courses  of  p-­nitroaniline  release  were  followed  at  405  nm  in  0.1  M  Tris-­HCl  
(pH  8.0)  and  1  mM  CaCl2  at  room  temperature  using  a  SpectramaxPlus  384  microplate  
reader.  Rates  of  substrate  hydrolysis  were  determined  from  fits  to  the  initial  linear  portion  
of  the  curves.  
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3.12  Trypsinogen  autoactivation  in  the  presence  of  chymotrypsin  C  
Trypsinogen  at  1  µM  concentration  was   incubated   in   the  absence  or  presence  of  
25  nM  human  CTRC,  as   indicated,  and  10   nM  cationic   trypsin   in  0.1  M  Tris-­HCl   (pH  
8.0),  100  mM  NaCl,  1  mM  CaCl2  and  0.05%  Tween-­20  (final  concentrations)  at  37  ºC.  At  
given  times,  2  µL  aliquots  were  withdrawn  and  mixed  with  48  µL  assay  buffer  containing  
0.1   M   Tris-­HCl   (pH   8.0),   1mM   CaCl2,   and   0.05%   Tween-­20.   Trypsin   activity   was  
measured   by   adding   150   µL   200   µM   N-­CBZ-­Gly-­Pro-­Arg-­p-­nitroanilide   substrate  
(dissolved  in  0.1  M  Tris-­HCl  (pH  8.0),  1  mM  CaCl2  and  0.05%  Tween-­20)  and  following  
the   release   of   the   yellow   p-­nitroanilin   at   405   nm   in   a   SpectraMax   plus384   microplate  
reader  for  1  min.  Reaction  rates  were  calculated  from  fits  to  the  initial   linear  portions  of  
the  curves.    
3.13  Gel  electrophoresis  and  densitometry  
Trypsinogen   samples   were   precipitated   with   trichloroacetic   acid   (10%   final  
concentration),  and  the  precipitate  was  recovered  by  centrifugation,  dissolved  in  20  mL  of  
Laemmli   sample   buffer   containing   100   mM   DTT   (final   concentration),   and   heat-­
denatured   at   95   °C   for   5  min.  Electrophoretic   separation  was   performed  on   15%  SDS-­
polyacrylamide  mini  gels  in  standard  Tris-­glycine  buffer.  The  samples  of  trypsinogen  N-­
terminal  processing  experiments  were  analyzed  by  15%  non-­reducing  SDS-­PAGE.  Gels  
were  stained  for  30  min  with  0.5%  Brilliant  Blue  R-­250  dissolved  in  40%  methanol  and  
10%   acetic   acid   and   destained   overnight   with   30%   methanol   and   10%   acetic   acid.  
Quantitation  of   bands  was  carried  out  with   the  Quantity  One  4.6.9   software   (Bio-­Rad).  
Rectangles  were  drawn  around  each  band  of  interest,  and  an  identical  rectangle  was  used  
in  each  lane  for  background  subtraction.  
3.14  Cell  culture  and  transfection  
HEK  293T  cells  were  cultured  in  six-­well  tissue  culture  plates  (106  cells  per  well)  
in   Dulbecco’s   modified   Eagle   medium   (DMEM)   supplemented   with   10%   fetal   bovine  
serum   (FBS),   4   mM   glutamine,   and   1%   penicillin/streptomycin   at   37   °C   in   5%   CO2.  
Transfections   were   performed   using   2   µg   expression   plasmid   and   5µL   Lipofectamine  
2000   (Invitrogen,  Carlsbad,  CA)   in   2  mL  DMEM  medium.  After   overnight   incubation,  
cells   were   washed   and   the   transfection   medium   was   replaced   with   1   mL   OptiMEM  
reduced   serum   medium.   Time   courses   of   expression   were   measured   starting   from   this  
medium  change  and  were  followed  for  12  h.  
20  
  
3.15  Measurement  of  trypsin  activity  in  conditioned  media  
Aliquots  (50  µL)  of  conditioned  media  were   supplemented  with  5  µL  1  M  Tris-­
HCl  (pH:8.0)  and  1  µL  0.5  M  CaCl2  and  trypsinogens  were  activated  by  adding  1  μL  1.4  
μg/mL  human  enteropeptidase  (R&D  Systems,  Minneapolis,  MN).  After  incubation  for  1  
h  at  37  °C,  a  50  µL  aliquot  was  removed  and  mixed  with  150  µL  200  µM  N-­CBZ-­Gly-­
Pro-­Arg-­p-­nitroanilide  substrate.  Activity  was  determined  as  described  above.  
3.16  Western  blot  analysis  
Aliquots  of  conditioned  media  (20  µL  per   lane)  were  directly  mixed  with  sample  
buffer,   electrophoresed   on   Tris-­glycine   minigels   and   transferred   onto   an   Immobilon-­P  
polyvinylidene   difluoride   (PVDF)   (Millipore   Corporation,   Bedford,  MA)   membrane   at  
300   mA   for   1.5   h.   The   membrane   was   blocked   with   5%   milk   powder   dissolved   in  
phosphate-­buffered  saline  supplemented  with  0.1%  Tween-­20  (final  concentration),  at  4  
°C   overnight.   Trypsinogen   was   detected   with   a   sheep   polyclonal   antibody   (R&D  
Systems,   #AF3848)   used   at   a   dilution   of   1:2000   followed   by   horse-­radish   peroxidase  
(HRP)-­conjugated  donkey  polyclonal  anti-­sheep  IgG  (R&D  Systems,  #HAF016)  used  at  
1:2000   dilution.   Incubations  with   primary   and   secondary   antibodies  were   performed   at  
room   temperature   for   1   h   each.   HRP   was   detected   using   the   SuperSignal   West   Pico  
Chemiluminescent  Substrate  (Thermo  Scientific).    
3.17  N-­terminal  sequencing  
N-­terminal  sequencing  uses  a  chemical  process  based  on  the  technique  developed  
by  Pehr  Edman  in  the  1950's  [43].  This  method  excises  amino  acids  sequentially  from  the  
N   terminus   of   proteins,   which   are   then   identified   by   high-­performance   liquid  
chromatography   (HPLC).   Protein   samples   were   run   on   15%   Tris-­glycine   gels   under  
reducing  conditions  and  were  transferred  to  Immobilon-­P  membrane  at  300  mA  for  1.5h.  
The  membrane  was  stained  with  Coomassie  Blue  for  5  min  followed  by  destaining  with  
50%   methanol   and   dried   at   room   temperature.   Protein   sequencing   was   performed   by  
David  McCourt  (Midwest  Analytical  Inc.,  St.  Louis,  Missouri,  USA).  
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4   RESULTS  
4.1   A   novel   mutation   in   the   PRSS1   gene   is   associated   with   hereditary  
pancreatitis  
The  criteria  of  the  diagnosis  of  HCP  have  been  changing  over  the  years  and  may  
vary   from  centre  to  centre.  We  use  the  criteria  also  used  by  EUROPAC  (The  European  
Registry   of  Hereditary  Pancreatitis   and   Familial   Pancreatic  Cancer)   based   on   two   first-­
degree  relatives  or  three  or  more  second-­degree  relatives,  in  two  or  more  generations  with  
recurrent  acute  pancreatitis,  and/or  CP  for  which  there  are  no  known  precipitating  factors  
[44].    
There  are  three  affected  members  within  the  study  family  which  satisfy  the  formal  
criteria  mentioned  above  (Figure  3).  The  index  patient  is  a  2-­year-­old  boy  from  Denmark  
who  presented  with  ascites  and  a  history  of  recurrent  attacks  of  abdominal  pain,  diarrhea  
and   vomiting   for   4   months.   A   preoperative   magnetic   resonance  
cholangiopancreatography   revealed  a  pancreatic   fistula  as   the  cause   for   the  ascites,   and  
also   disclosed   pancreas   divisum,   duct   irregularities   and  multiple   cysts   in   the   pancreatic  
head   and   tail.   The   tail   of   the   pancreas   was   resected   and   pancreatico-­jejunostomy   was  
performed.  After  resection,   the  ascites  production  ceased  and  the  patient  recovered.  The  
father  of   the   index  patient  was  diagnosed  with  CP  at   the  age  of  21,  which  was   initially  
attributed   to   a   bicycle   accident,   which   had   happened   at   age   13.   The   father   underwent  
resection  of  the  tail  of  the  pancreas  at  the  age  of  27  because  of  repeated  attacks  of  upper  
abdominal   pain.   The   index   patient’s   younger   brother   also   developed   abdominal   pain,  
diarrhea   and   elevated   blood   amylase   at   the   age   of   2,   but   pancreatic   edema   was   not  
detected   by   ultrasonography.   Interestingly,   no   other   case   of   pancreatitis   could   be  
confirmed  in  the  rest  of  the  extended  family,  suggesting  that  the  causative  mutation  may  
have  occurred  de  novo   in  the  father.  Non-­paternity  was  excluded  by  DNA  microsatellite  
analysis  (Identifiler  kit,  Applied  Biosystems).  
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Figure  3.   Pedigree  of   the   studied   family  with  hereditary  pancreatit is   from  Denmark.   Heterozygous   
carriers   of   the   c.63_71dup   (K23_I24insIDK)   mutation   are   indicated.    Subjects   affected   wi th  
idiopathic   chronic   pancreatit is   are   shown   by   solid   black   symbols.    Crossed   symbols   designate  
deceased  subjects.   The  arrow  points   to   the  index  patient.  
4.2   The  identified  intragenic  duplication  
DNA  sequence  analysis  of   the  PRSS1  gene   in   the   index  patient   showed  a   so   far  
unreported  duplication   in  exon  2.  As  demonstrated  by   the  electropherogram  (Figure  4),  
the   forward   sequencing   of   exon  2   showed  mixed   signals   starting   at   nucleotide   position  
c.72   due   to   a   heterozygous   nine-­nucleotide   insertion.   The   inserted   sequence   is  
TGACAAGAT,  which  corresponds  to  PRSS1  sequence  between  c.63  and  c.71.  Thus,  the  
insertion   represents   a   short   intragenic   duplication   (c.63_71dup),   which   has   never   been  
described   in   trypsinogen   genes   so   far.   Sequencing   of   exon   2   with   a   reverse   primer  
confirmed   the   duplication.  No  other  mutations  were   identified   in   the  PRSS1   gene.  The  
previously   reported   large-­scale   trypsinogen   duplication   and   triplication   was   excluded  
[36,45,46,47].  The  c.63_71dup  mutation  was  also  present  in  the  father  and  the  brother  but  not  
in  the  grandparents  or   in  the   father's  sister  and  half-­brother,   indicating  that  the  mutation  
was  de  novo  created  in  the  father.  All  affected  family  members  were  negative  for  SPINK1  
mutations  and  a  select  panel  of  CFTR  mutations.  From  the  same  geographical  region  200  
healthy   controls   (400  chromosomes)  were   included   in   the  mutational   screening,   but  we  
did  not  find  the  c.63_71dup  mutation  among  them.  
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Figure   4.    Sequence   analysis   of   exon-­2   of   the  PRSS1  gene   from   genomic  DNA   of   the   index   patient  
carrying  a  heterozygous  c.63_71dup  (K23_I24insIDK)  mutation.     
4.3   Changes  in  the  trypsinogen  activation  peptide  
The  activation  peptide  of  human  cationic  trypsinogen  is  an  8  amino-­acid  long  N-­
terminal  extension  which  is  cleaved  off  during  activation  at  the  Lys23-­Ile24  peptide  bond  
by   the   physiological   activator   enteropeptidase   or   by   the   pathological   activators   trypsin  
and  cathepsin  B.  The  identified  c.63_71dup  mutation  creates  an  insertion  of  the  Ile-­Asp-­
Lys  (IDK)  sequence  within  the  activation  peptide  between  amino  acids  Lys23  and  Ile24  
(K23_I24insIDK)   (Figure   5).   This   insertion   changes   the   P1-­P5   (Schechter-­Berger  
numbering  where   P1   is   Lys23)   positions   of   the   activation   peptide   to  Asp-­Lys-­Ile-­Asp-­
Lys,  effectively  eliminating  two  of  the  tetra-­Asp  residues  which  has  been  shown  to  be  an  
important   suppressor   of   trypsin-­mediated   activation   (autoactivation)   [26].   It   has   been  
previously  described  that  mutations  which  alter  the  tetra-­Asp  motif  (D19A,  D22G)  were  
shown  to  increase  autoactivation  of  cationic  trypsinogen,  suggesting  a  similar  phenotype  
for  the  K23_I24insIDK  mutant  as  well  [25,26,27,31].  With  this  insertion  the  mutation  creates  
an   extra   Lys-­Ile   peptide   bond;;   which   provides   an   additional   target   for   hydrolysis   by  
trypsin  and  enteropeptidase.  
  
Figure   5.    Nucleotide   and   amino-­acid   sequence   of   the   wild-­type   and   c.63_71dup   (K23_I24insIDK)  
mutant  cationic   trypsinogen  activation  peptides.     
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4.4   Activation   characteristics   of   K23_I24insIDK   mutant   cationic  
trypsinogen  
4.4.1   Trypsin  mediated  trypsinogen  activation:  Autoactivation    
When  we  studied  the  effect  of   the  K23_I24insIDK  mutation  on  the  activation  of  
cationic   trypsinogen,  we  observed   that   the  mutant   trypsinogen  preparations  were   highly  
unstable   and   spontaneous   conversion   to   trypsin   occurred   rapidly,   suggesting   that   the  
K23_I24insIDK   mutant   exhibits   markedly   increased   autoactivation.   Indeed,   when  
autoactivation   of   wild-­type   and   mutant   trypsinogens   were   compared   in   a   quantitative  
manner   (pH   8.0,   37   oC),   the   mutant   autoactivated   at   rates   that   were   >10-­fold   higher  
relative  to  wild-­type  trypsinogen  (Figure  6).    
  
The   catalytic   mechanism   of   trypsin   requires   an   intact   catalytic   triad   which   is  
composed  of  a  serine,  histidine  and  aspartic  acid  residues  [48].  Elimination  of  these  amino  
acids   would   result   in   a   protein   which   does   not   have   enzymatic   activity.   Therefore,   to  
characterize   the   autoactivation   kinetics   in   a   more   precise   manner,   we   generated  
catalytically   inactive   versions   of   wild-­type   and   mutant   trypsinogens   by   mutation   of  
Ser200  to  Ala  (S200A).  The  use  of  the  S200A-­trypsinogens  allowed  us  to  measure  exact  
rates  of   trypsin-­mediated  trypsinogen  activation  by  controlling  the  trypsin  concentration  
in   the   reactions.  Because  activation   of  S200A-­trypsinogen   does   not   result   in   enzymatic  
activity,  the  activation  reactions  were  followed  by  the  mobility  shift  on  SDS-­PAGE.  For  
comparison,   in   these   experiments  we   included   the  D22G  mutant   as   a   previously   well-­
characterized  example  of  the  activation  peptide  mutants  [25,27,31].  As  shown   in  Figure  7,  
100   nM   human   cationic   trypsin   converted   the   2   µM  S200A   (wild-­type)   trypsinogen   to  
Figure   6.    Effect   of   the  
K23_I24insIDK   mutation   on   the  
activation   of   human   cationic  
trypsinogen   by   trypsin  
(autoactivation).    Trypsinogens   at    2   
µM   concentration   were   incubated  
with   40   nM   human   cationic   trypsin  
(init ial    concentration)   at    37   oC   in  
0.1   M   Tris-­HCl   (pH   8.0),    1   mM  
CaCl2,    and   40   mM   NaCl   (final  
concentrations)   in   100   µL   final  
volume.   Aliquots   (2   µL)   were  
withdrawn   at    indicated   times   and  
trypsin   activity   was   determined.  
Trypsin   activity   was   expressed   as  
percentage  of   the  maximal  activity.   
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trypsin   at   a   very   low   rate   and   appreciable   trypsin   levels   were   seen   only   after   60   min  
incubation   (pH   8.0,   37   oC).   In   contrast,   K23_I24insIDK/S200A   trypsinogen   was  
completely   activated   to   trypsin   within   30   min,   whereas   complete   conversion   of   the  
D22G/S200A  mutant   took  about  60  min.  Thus,  as   judged   from   the   half-­lives  of  S200A  
trypsinogens,   the   rate   of   trypsin-­mediated   trypsinogen   activation   is>10-­fold   higher   for  
both   the   K23_I24insIDK   and   D22G   mutants,   relative   to   wild-­type   trypsinogen.   These  
data   are   in   agreement   with   the   activity   based   assay   using   catalytically   competent  
trypsinogens,  as  shown  in  (Figure  6).  
  
4.4.2   Enteropeptidase  mediated  activation  
Owing  to  the  robust  autoactivation  of  the  K23_I24insIDK  mutant,  we  were  unable  
to  measure  enteropeptidase-­mediated  trypsinogen  activation  using  the  catalytically  active  
proteins.   Therefore,   we   monitored   enteropeptidase-­mediated   activation   of   the   S200A-­
trypsinogens  on  SDS-­PAGE.  Figure  8  demonstrates  that  activation  of  the  K23_I24insIDK  
and  D22G  mutants  were  comparable  to  that  of  wild-­type  (pH  8.0,  37  oC).  The  results  are  
in  accord  with  our  previous  studies  showing  that  the  TAP  plays  no  significant  role  in  the  
recognition  of  human  cationic  trypsinogen  by  human  enteropeptidase.  
Figure   7.    Effect   of   the  
K23_I24insIDK   mutation   on   the   
activation   of   human   cationic  
trypsinogen   by   trypsin  
(autoactivation).    Trypsinogens   
carrying   the   S200A   mutation  
were   incubated   with   100   nM  
human   cationic   trypsin   at    37   oC  
in   0.1  M  Tris-­HCl   (pH  8.0)   and   1  
mM   CaCl2   in   100   µL   final  
volume.   At   the   indicated   times,  
reactions   were   precipitated   with  
10%   trichloroacetic   acid   (final  
concentration)   and   analyzed   by  
15%   SDS-­PAGE   and   Coomassie  
Blue   staining.    The   lower  
molecular   weight   bands   represent  
double-­chain   forms   of  
trypsinogen   and   trypsin   cleaved  
at    the   Arg122-­Val123   peptide  
bond.   insIDK  =  K23_I24insIDK.   
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This  finding  is  somewhat  surprising,  as  the  tetra-­Asp  motif  in  the  TAP  has  been  known  as  
a   specific   recognition   motif   for   enteropeptidase,   at   least   in   the   context   of   the   bovine  
enzymes  [28].  
4.4.3   Cathepsin  B  mediated  activation    
The   lysosomal   cysteine   protease   cathepsin   B   has   been   recognized   as   a  
pathological   activator   of   trypsinogen   in   models   of   experimental   acute   pancreatitis  
[49,50,51,52].  We  tested  the  effect  of  the  K23_I24insIDK  mutation  on  cathepsin  B-­mediated  
trypsinogen   activation   at   pH   4.0,   where   autoactivation   is   minimal.   Remarkably,   the  
mutant   was   activated   by   cathepsin   B   at   a   markedly   elevated   rate,   which   seemed  
approximately  5-­10-­fold  higher  than  that  of  wild-­type  (Figure  9).    
  
Figure   9.    Effect   of   the  
p.K23_I24insIDK   mutation   on   the  
activation   of   human   cationic  
trypsinogen   with   cathepsin   B.  
Trypsinogens   at    2   µM   concentration  
were   activated   with   human   cathepsin  
B  (37  µg/mL,  ~1.3  µM)  at   37  oC  in  0.1  
M   Na-­acetate   buffer   (pH   4.0),    1   mM  
K-­EDTA   and   1   mM   dithiothreitol  
(final   concentrations)   in   50   µL   final  
volume.   Aliquots   (2   µL)   were  
withdrawn   at    indicated   times   and  
trypsin   activity   was   determined.  
Trypsin   activity   was   expressed   as  
percentage  of   the  maximal  activity.   
Figure   8.    Effect   of   the  
K23_I24insIDK   mutation   on   the  
activation   of   human   cationic  
trypsinogen   with   enteropeptidase.  
Trypsinogens   carrying   the   S200A  
mutation   were   activated   with   human  
enteropeptidase   (28   ng/mL   final  
concentration)   at   37   oC   in  0.1  M  Tris-­
HCl   (pH   8.0)   and   1  mM  CaCl2   in   100  
μL   final   volume.   At   the   indicated  
t imes,    reactions   were   precipitated  
with   10%   trichloroacetic   acid   (final  
concentration)   and   analyzed   by   15%  
SDS-­PAGE   and   Coomassie   Blue  
staining.   insIDK  =  K23_I24insIDK.   
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Using  S200A-­trypsinogens,  we  measured  the  rates  of  conversion  in  a  more  precise  
manner  and  found  that  the  K23_I24insIDK  mutant  was  activated  by  cathepsin  B  10-­fold  
faster   than  wild-­type   cationic   trypsinogen   (Figure   10).  As   described   previously,  mutant  
D22G  was  resistant  to  cathepsin  B  mediated  activation  [27,53].  More  recently,  cathepsin  L  
was   shown   to   degrade   trypsinogen   and   active   trypsin   accumulation   during   pancreatitis  
was   attributed   not   only   to   cathepsin   B-­mediated   activation   but   also   to   a   defect   in  
cathepsin  L-­mediated  degradation   [54,55].  We   found  no  change   in   the  degradation  of   the  
K23_I24insIDK  mutant  by  cathepsin  L  (pH  4.0,  37  oC)  as  compared  to  wild-­type  cationic  
trypsinogen  (data  not  shown).  
  
Figure   10.    Effect   of   the  
K23_I24insIDK   mutation   on   the  
activation   of   human   cationic  
trypsinogen   with   cathepsin   B.  
Trypsinogens   carrying   the   p.S200A  
mutation   were   activated   with   human  
cathepsin   B   (37   µg/mL,   ~1.3   µM;;   74  
µg/mL,  ~2.6  µM  for  p.D22G)  at   37   oC  
in   0.1  M  Na-­acetate   buffer   (pH   4.0)   1  
mM  K-­EDTA   and   1  mM  dithiothreitol   
in   100   µL   final   volume.   At   the  
indicated   t imes,    reactions   were  
precipitated   with   10%   trichloroacetic  
acid   (final   concentration)   and  
analyzed   by   15%   SDS-­PAGE   and  
Coomassie   Blue   staining.    p. insIDK   =  
K23_I24insIDK.   
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4.5   Cleavage  of  the  activation  peptide  in  the  K23_I24insIDK  mutant  cationic  
trypsinogen    
The   mutant   activation   peptide   sequence   contains   two   Lys-­Ile   peptides   bonds  
(Figure   5).   Although   activation   of   trypsinogen   to   trypsin   requires   proteolysis   of   the  
second  site,  cleavage  after  the  first  Lys  may  modify  the  efficiency  of  the  second  cleavage.  
Therefore,  we  sought   to  clarify  whether   both   sites  were  cleaved.   For  these   experiments  
we   used   the   S200A-­trypsinogens   which   we   activated   with   trypsin   (pH   8.0),  
enteropeptidase   (pH   8.0)   and   cathepsin   B   (pH   4.0).   The   activation   reactions   were  
separated   on   SDS-­PAGE,   transferred   to   PVDF   membranes   and   trypsin   bands   were  
subjected   to  N-­terminal   sequence   analysis   by   Edman-­degradation.   To   capture   cleavage  
intermediates,  we  sequenced  trypsin  bands  early  in  the  reaction  when  less  than  half  of  the  
trypsinogen   was   converted   to   a   trypsin   band.   We   found   that   trypsin   and   cathepsin   B  
cleaved   the   second   (activating)   Lys-­Ile   peptide   bond   only,   whereas   enteropeptidase  
cleaved   both  Lys-­Ile  peptide   bonds  with  equal  efficacy.  Cleavage  after   the   first  Lys-­Ile  
peptide   bond   resulted   in   an   N-­terminally   truncated   trypsinogen,   which   was   eventually  
completely  cleaved  at  the  second  Lys-­Ile  peptide  bond  by  enteropeptidase  (Figure  11).  
  
  
  
  
Figure   11.    N-­terminal   sequencing   of   the  
K23_I24insIDK,   S200A   mutant   activated  
with   enteropeptidase.    Activation   was  
performed   with   human   enteropeptidase   (28  
ng/mL   final   concentration)   at    37   oC   in   0.1  
M  Tris-­HCl  (pH  8.0)  and  1mM  CaCl2   in  100  
μL   final   volume.   At   the   indicated   times  
reactions   were   precipitated   with   10%  
trichloroacetic   acid   (final   concentration)  
and   samples   were   electrophoresed   on   15%  
SDS-­PAGE.   Proteins   were   transferred   to  
Immobilon-­P   PVDF   membrane   and   stained  
with  Coomassie  Blue   for   5  min   followed   by  
destaining   with   50%   methanol.    The   trypsin  
bands  at   10  min  and  60  min  were   sequenced  
by   Edman   degradation   chemistry   and   the  
determined   N-­terminal   5   amino-­acids   are  
indicated.    The   N-­terminal   sequence   of  
K23_I24insIDK   trypsinogen   including   the  
first    5   residues   of   trypsin   is   indicated   as  
reference.  
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4.6   Autoactivation   of   hereditary   pancreatitis   associated   activation   peptide  
mutants  in  the  absence  and  presence  of  chymotrypsin  C  
In  addition  to  the  newly  identified  K23_I24insIDK  PRSS1  mutation,  we  aimed  to  
analyze  the  autoactivation  of  previously  characterized  variants  affecting  the  TAP  (Table  
1).  While  mutations  D19A,  D22G  and  K23R  were  caused  by  missense  point  mutations,  
the  K23_I24insIDK  variant  was  induced  by  an  intragenic  duplication  in  the  exon2  of  the  
PRSS1  gene.    
Studies   focusing  on  mutations   in   human  cationic   trypsinogen   have  demonstrated  
that  changes   in   the  autoactivation  may   result   in   an   increased   risk   for  CP.  A  number  of  
recent   investigations   revealed   that   cationic   trypsinogen   and   trypsin   are   under   the  
regulation  of  CTRC  which  draws  the  conclusion  that  pancreatitis  associated  mutants  may  
exert   their   effect   in   a   CTRC   dependent   manner   [34,56].   To   find   out   whether   increased  
autoactivation   is   caused   directly   by   mutational   impact   or   influenced   by   the   regulatory  
effect   of   CTRC   we   investigated   the   autoactivation   properties   of   TAP   mutations.  
Autoactivation  of  human  cationic  trypsinogen  in  the  presence  of  25  nM  CTRC  results  in  a  
slight   increase   in   the   rate   accompanied   by   a   marked   reduction   in   final   trypsin   levels  
attained  (Figure  12).  The  increased  rate  is  due  to  N-­terminal  processing  of  the  activation  
peptide   by   CTRC,   whereas   the   reduced   trypsin   levels   are   a   consequence   of   CTRC-­
dependent  trypsinogen  degradation.  Recently,  we  demonstrated  that  mutations  commonly  
associated   with   hereditary   pancreatitis   exert   their   effect   primarily   in   the   presence   of  
CTRC.   A   typical   case   is   shown   for   the   most   frequent   R122H   mutation   in   Figure   12,  
which   in   the   absence   of   CTRC   increases   autoactivation   only   slightly   (1.2-­fold).   In   the  
presence   of   CTRC,   however,   autoactivation   of   wild-­type   trypsinogen   is   drastically  
suppressed,   while   mutant   R122H   autoactivates   at   an   increased   rate   and   reaches   high  
trypsin  levels.  
  
  
  
  
  
  
Figure   12.    Autoactivation   of   wild   type   
and   R122H   mutant   human   cationic  
trypsinogen   in   the   absence   and   presence  
of   chymotrypsin   C   (CTRC).   Wild-­type   
(circles)   and   mutant   (squares)  
trypsinogen   were   incubated   at    1   µM  with  
10   nM   initial   trypsin   in   0.1   M   Tris-­HCl  
(pH  8.0),    1  mM  CaCl2,    100  mM  NaCl  and  
0.05%  Tween  20,    at   37   °C,   in   the   absence  
(empty   symbols)   or   presence   (solid  
symbols)   of   25   nM   CTRC   (final  
concentrations).    Aliquots   (2   µL)   were   
withdrawn   at    the   indicated   times   and  
trypsin   activity   was   determined   as  
described   in   Experimental   Procedures .   
Trypsin   activity   was   expressed   as  
percentage   of   the   maximal   activity   in   the  
absence   of   CTRC.   Representative  
experiments   from   two   replicates   are  
shown.     
  
30  
  
When  mutants  D19A,  D22G,  K23R  and  K23_I24insIDK  were  tested  under  similar  
conditions,   a   markedly   different   phenotype   became   apparent   (Figure   13).   All   four  
mutations   increased   the   rate   of   trypsinogen   autoactivation   robustly   (3.9-­fold,   9.2-­fold,  
5.7-­fold   and   17.5-­fold,   respectively)   even   in   the   absence   of   CTRC,   in   agreement  with  
previous   observations   [25].   Similarly,   in   the   presence   of   CTRC,   all   four   mutants  
autoactivated   markedly   faster   than   wild-­type   trypsinogen   and   reached   much   higher  
trypsin   levels,  which  then  slowly  decreased  due  to  CTRC-­mediated  trypsin  degradation.  
Peak  trypsin  levels  correlated  with  the  rate  of  autoactivation  and  were  higher   in  mutants  
D22G  and  K23_I24insIDK  versus  D19A  and  K23R.  Surprisingly,  even  in  the  presence  of  
CTRC,  TAP  mutants  autoactivated  much  faster  than  the  reference  mutant  R122H.  Thus,  
the   estimated   rates   of   autoactivation   for   mutants   D19A,   D22G,   K23R   and  
K23_I24insIDK  were  approximately  3-­fold,  10-­fold,  3-­fold  and  10-­fold  higher   than  that  
of  mutant  R122H,  in  the  presence  of  CTRC.    
  
  
  
  
Figure   13.    Autoactivation   of   human   cationic   trypsinogen   and   activation   peptide   mutants   in   the  
absence   and   presence   of   chymotrypsin   C   (CTRC).   Wild-­type   (circles)   and   mutant   (squares)  
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trypsinogens  were   incubated  at   1  µM  with  10  nM   initial   trypsin   in  0.1  M  Tris -­HCl   (pH  8.0),    1  mM  
CaCl2,    100   mM  NaCl   and   0.05%   Tween   20,    at   37   °C,   in   the   absence   (empty   symbols)   or   presence  
(solid   symbols)   of   25   nM   CTRC   (final   concentrations).    Aliquots   (2   µL)   were   withdrawn   at    the  
indicated   times   and   trypsin   activity   was   determined   as   described   in   Experimental   Procedures .   
Trypsin   activity   was   expressed   as   percentage   of   the   maximal   activity   in   the   absence   of   CTRC.   
Representative   experiments   from   two   replicates   are   shown.  Mutant  K23R_I24insIDK   is   denoted   as  
insIDK.   
4.7   Chymotrypsin   C   mediated   degradation:   Cleavage   of   the   Leu81-­Glu82  
peptide  bond  in  the  activation  peptide  mutants  
Mutation  caused  defect  in  the  CTRC-­dependent  degradation  during  autoactivation  
can  be  crucial   in   the  trypsin  activity  regulation.  Because  the  activation  peptide   is  not   in  
the   proximity   of   the   calcium   binding   loop,   mutations   D19A,   D22G,   K23R   and  
K23_I24insIDK   are   unlikely   to   affect   CTRC-­mediated   trypsinogen   degradation.   We  
tested   this   assumption   experimentally   and   found   that   cleavage   of   the   Leu81-­Glu82  
peptide   bond   by   CTRC  was   unchanged   in   the   activation   peptide   mutants   compared   to  
wild-­type  cationic  trypsinogen  (Figure  14).  
  
Figure   14.    Cleavage   of   Leu81-­Glu82   peptide   bond   in   human   cationic   trypsinogen   and   activation  
peptide  mutants  by  chymotrypsin  C  (CTRC).  Wild-­type  and  mutant   trypsinogen  were  incubated  at   2  
µM   with   20   nM   CTRC   in   0.1M   Tris-­HCl   (pH   8.0)   (final   concentrations),    at    37   °C.   Trypsinogens   
also   contained  the  S200A  mutation   to  prevent   autoactivation.   At   the  indicated  t imes   reactions  were  
terminated   by   precipitation   with   10%   trichloroacetic   acid   (final   concentration)   and   analyzed   by  
15%   reducing   SDS-­PAGE   and   Coomassie   Blue   staining.    Representative   gels   of   two   or   three  
experiments  are  shown.    
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The  densitometric  evaluation  of  SDS-­PAGE  analysis  confirmed  that  the  CTRC-­mediated  
degradation   of   wild-­type   and   acivation   peptide   mutant   trypsinogens   were   comparable  
(Figure  15).  
  
  
4.8   Elevated   autoactivation   by   chymotrypsin   C:   N-­terminal   processing   of  
activation  peptide  mutants  
CTRC   cleaves   the   Phe18-­Asp19   peptide   bond   in   the   TAP   and   removes   three  
amino   acids   from   the   N   terminus   (Figure   1).   This,   in   turn,   results   in   increased  
autoactivation  of  cationic  trypsinogen.  The  N-­terminal  truncation  of  the  activation  peptide  
is   readily   detectable   by   non-­reducing   SDS-­PAGE   as   a   small   mobility   shift.   To   assess  
whether  the  activation  peptide  mutations  altered  CTRC-­mediated  N-­terminal  processing,  
we  incubated  wild-­type  and  mutant  trypsinogens  with  50  nM  CTRC  at  pH  8.0,  in  1  mM  
CaCl2,   to   minimize   cleavage   after   Leu81.   To   prevent   autoactivation   during   the  
incubation,  we   used   an   inactive   trypsinogen   background   in  which   the   catalytic   Ser200  
was   changed   to   Ala   (S200A).   Figures   16   A   and   B   demonstrate   that   mutant   D19A  
exhibited   4-­fold   increased   N-­terminal   processing,   whereas   mutants   D22G,   K23R   and  
K23_I24insIDK  were   processed   at   rates   comparable   with   wild   type.   Inspection   of   the  
early   time  points  of   the  autoactivation  curves   in   the  presence  of  CTRC  (see  Figure  13,  
compare   black   with   white   symbols)   reveals   that   N-­terminal   processing   by   CTRC  
increases  the  rate  of  autoactivation  for  mutants  D19A,  D22G  and  K23R.  Surprisingly,  the  
enhanced   processing   of  mutant  D19A  did   not   translate   to   a  more   robust   autoactivation  
increase  than  seen  in  mutants  D22G  or  K23R  (Figure  13).  Similarly,  even  though  mutant  
Figure   15.    Cleavage   of   Leu81-­
Glu82   peptide   bond   in   human  
cationic   trypsinogen  and  activation  
peptide   mutants   by   chymotrypsin  
C   (CTRC).   Densitometric   analysis  
of   stained   gels   showing   the  
changes   in   the   intensity   of   the  
unprocessed,    intact    trypsinogen  
band.   Error   bars   were   omitted   for  
clari ty,    the   error   was   within   10%  
of   the   mean.   Mutant  
K23_I24insIDK   is   denoted   as  
insIDK.   
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K23_I24insIDK   was   processed   normally,   this   modification   had   no   impact   on  
autoactivation.  
  
Figure  16.   N-­terminal  processing  of  human  cationic   trypsinogen  and  activation  peptide  mutants  by  
chymotrypsin  C   (CTRC).A,  Wild-­type   and  mutant   trypsinogen  were   incubated  at   2   µM  with   50   nM  
CTRC  in  0.1  M  Tris-­HCl  (pH  8.0),   1  mM  CaCl2  and  100  mM  NaCl  (final  concentrations),   at   37  °C.  
Trypsinogens   also   contained   the   S200A  mutation   to   prevent   autoactivation.    At   the   indicated   t imes  
reactions   were   terminated   by   precipitation   with   10%   trichloroacetic   acid   (final   concentration)   and  
samples   were   analyzed   by   15%   non-­reducing   SDS-­PAGE   and   Coomassie   Blue   staining.    Relevant  
segments   of   representative   gels   demonstrate   the   small    mobili ty   shift    of   the   trypsinogen   band  
caused   by  CTRC-­mediated   cleavage   of   the   activation   peptide.  B,   Densitometric   analysis   of   stained  
gels   showing   the   changes   in   the   intensity   of   the   unprocessed,    intact    trypsinogen   band   as   a   
percentage  of   the  total   intensity  of   the  processed  and  unprocessed  bands.    
  
CTRC-­mediated  cleavage  of  the  Phe18-­Asp19  peptide  bond  in  the  TAP  is  highly  
specific   and   other   human   chymotrypsins   (CTRB1,   CTRB2,   CTRL1)   and   elastases  
(ELA2A,  ELA3A,  ELA3B)  do  not  catalyze  this  reaction  (Figure  17).  We  considered  the  
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possibility  that  activation  peptide  mutations  might  allow  for  cleavages  by  proteases  other  
than  CTRC,  however,  this  was  not  the  case.  None  of  the  mutant  activation  peptides  was  
cleaved  by  any  of  the  chymotrypsins  or  elastases  tested  in  Figure  17  (data  not  shown).  
  
4.9   Effect  of  the  activation  peptide  mutations  on  calcium  binding  
The   tetra-­Asp  motif   in   the  TAP  binds  Ca2+,  which  stimulates  autoactivation   in  a  
concentration-­dependent   manner.   To   determine   the   effect   of   the   activation   peptide  
mutations  on  the  calcium  binding  affinity  of  the  activation  peptide,  we  measured  the  rate  
of  N-­terminal   processing   by  CTRC  as   a   function   of   increasing   calcium  concentrations.  
For   these   experiments   we   used   trypsinogen   constructs   carrying   the   L81A   and   S200A  
mutations   to   prevent   unwanted   cleavage   at   Leu81   by   CTRC   and   to   avoid   trypsinogen  
autoactivation  during  incubations.  As  shown  in  Figure  18,  calcium  inhibited  cleavage  of  
the   Phe18-­Asp19   peptide   bond   by   CTRC   in   wild-­type   cationic   trypsinogen   with   a   KD  
value   around   1.9   mM.   Calcium   dependence   of   N-­terminal   processing   by   CTRC   was  
comparable   for   the   activation   peptide   mutants.   The   calculated   KD   values   for   mutants  
D19A,  D22G,  K23R  and  K23_I24insIDK  were  1.1  mM,  1.3  mM,  2.6  mM  and  1.3  mM,  
respectively.   Inspection   of   Figure   18B   suggests   that   these   values   fall   within   the  
experimental   error   of   the   method.   When   the   entire   dataset   including   wild-­type   and  
mutants  was  fit  with  a  single  curve  a  KD  of  1.6±0.2  mM  was  obtained.  We  conclude  that  
calcium   binding   to   the   activation   peptide   is   not   affected   by   the   activation   peptide  
mutations.  
  
Figure   17.    N-­terminal   processing   of  
the   activation   peptide   is   specific   for   
CTRC.   Wild-­type   and   mutant  
trypsinogens   were   incubated   with   50  
nM   of   the   indicated   human   pancreatic  
chymotrypsins   and   elastases   and  
reactions   were   analyzed   as   described  
above.    For   clari ty,    only   the   wild-­type   
dataset    is   shown;;   none    of   the  mutants  
was   cleaved   by   any   of   the   proteases  
tested.    Mutant   K23R_I24ins IDK   is   
denoted  as   insIDK.   
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4.10  Effect  of  calcium  on  autoactivation  of  the  activation  peptide  mutants  
Calcium  binding  to  the  tetra-­Asp  motif  in  the  TAP  stimulates  autoactivation.  Even  
though   the   activation   peptide   mutations   appear   to   bind   calcium   normally,   the   effect   of  
calcium  on  autoactivation  may  be  altered.    
When  autoactivation  of  wild-­type  and  mutant   trypsinogens  were  measured   in  the  
presence   of   0,   1,   5   and   10  mM  calcium,  wild-­type   trypsinogen   and  mutants  D19A  and  
K23R  were   stimulated   in   a   concentration   dependent  manner,  whereas   autoactivation   of  
Figure   18.    Effect   of   calcium   on   the  
N-­terminal   processing   of   the   
trypsinogen   activation   peptide   by  
chymotrypsin   C   (CTRC).   A,   Wild-­
type   and   mutant   trypsinogen   were   
incubated   at    2   µM   with   50   nM  
CTRC   in   0.1   M   Tris-­HCl   (pH   8.0)  
and   100  mM  NaCl   in   the   absence   or  
presence   of   CaCl2   (Ca
2+)   at    the  
indicated   concentrations,    at    37   °C.  
Trypsinogens   also   contained   the  
S200A   mutation   to   prevent  
autoactivation   and   the   L81A  
mutation   to   prevent   CTRC   cleavage   
after   Leu81   in   the   absence   of  
calcium.   At   the   indicated   t imes  
reactions   were   terminated   and  
analyzed   as   described   in   Figure  
19A.   As   an   example,    the   relevant  
gel   segments   for   wild-­type   are   
shown.   Similar   gel   sets   were  
generated   for   all   mutants   and   used  
to   determine   reaction   rates,    as  
described   below.   B,   Densitometric  
analysis   was   performed   as   given   in  
Figure   18B.   Rates   of   processing  
were   calculated   from   linear   fits   to  
semilogarithmic   graphs   and   plotted  
as   a   function   of   the   calcium  
concentration   with   errors   of   the   fi ts  
also   shown.  The  equilibrium  binding  
constants   (KD)   for   calcium   were  
calculated   from   fits   to   the   y   =  
y(min)+[y(max)-­y(min)]   /   
1+[Ca2+]/KD  equation  where  y   is   the  
measured   reaction   rate,    y(max)   is  
the   maximal   reaction   rate   in   the  
absence  of   calcium  and  y(min)   is   the  
residual   reaction   rate   under   fully  
saturating   calcium   concentrations.   
The   error   of   the   fi ts   is   also  
indicated.    Mutant   K23R_I24insIDK  
is  denoted  as  insIDK.  
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mutants  D22G  and  K23R_I24insIDK  was   insensitive   to   calcium   (Figure  19).  Although  
the  half-­maximal  stimulatory  calcium  concentration  was  difficult  to  determine  due  to  the  
confounding   effect   of   degradation   in   the   absence   of   calcium,   it   appeared   that   calcium  
dependence  of  autoactivation  of  wild-­type,  D19A  and  K23R  trypsinogens  was  consistent  
with  the  KD  values  obtained  for  binding  of  calcium  to  the  activation  peptide.  The  effect  of  
calcium   on   the   autoactivation   of   mutant   D19A   seemed   to   saturate   at   a   lower  
concentration   when   compared   to   mutant   K23R,   which   might   reflect   a   true   but   small  
difference   in   binding   affinity   (see   KD   values   above).   The   observations   indicate   that  
activation  peptide  mutations  do  not  affect  binding  of  calcium  to  the  activation  peptide  but  
may  diminish  the  functional  effect  of  calcium  binding.  
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Figure   19.   Effect   of   calcium   on   the   autoactivation   of   human   cationic   trypsinogen   and   activation  
peptide   mutants.    Wild-­type   and   mutant   trypsinogen   were   incubated   at   1   µM   with   10   nM   initial  
trypsin   in   0.1  M  Tris-­HCl   (pH   8.0),    100  mM  NaCl,    and   0.05%  Tween   20,    at    37   °C,   in   the   absence  
or   presence   of   CaCl2   (Ca
2+)   at    the   indicated   concentrations.    At   given   t imes   2   µL   aliquots   were  
removed   and   trypsin   activity   was   determined   as   described   in   Experimental   Procedures .    Trypsin  
activity   was   expressed   as   percentage   of   the   maximal   activity   in   the   presence   of   10   mM   CaCl 2.  
Mutant  K23_I24insIDK  is  denoted  as   insIDK.   
4.11   Secretion   of   trypsinogen   activation   peptide   mutants   from   transiently  
transfected  HEK  293T  cells  
4.11.1  Secretion  of  the  K23_I24insIDK  mutant  
The   biochemical   properties   of   the   activation   peptide   mutants   described   so   far  
suggest  that  these  mutations  should  be  associated  with  a  more  severe  clinical  phenotype  
than   mutation   R122H.   However,   this   is   not   the   case.   Recently,   we   demonstrated   that  
activation   peptide  mutants   that   undergo   robust   autoactivation   in   the   test   tube  were   also  
autoactivating   inside   living   cells   [27].   Intracellular   autoactivation   resulted   in   diminished  
trypsinogen   secretion   and   eventual   cell   death   of   acinar   cells.   To   test   whether   or   not  
secretion   of   the   strongly   autoactivating   K23_I24insIDK   mutant   would   be   reduced,   we  
transfected   HEK   293T   cells   with   wild-­type   and   K23_I24insIDK   mutant   cationic  
trypsinogen   and   measured   secretion   of   trypsinogens   from   the   conditioned   medium   by  
activity   assays   and   immunoblot.   As   shown   in   Figure   20,   mutantK23_I24insIDK   was  
secreted  to  significantly  lower  levels  than  wild-­type  cationic  trypsinogen,   indicating  that  
the  K23_I24insIDK  mutant  suffered  intracellular  autoactivation.  
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Figure   20.    Secretion   of   the   p.K23_I24insIDK   cationic   trypsinogen   mutant   from   transiently  
transfected   HEK   293T   cells.    At   8,    24,    32   and   48   hours   after   transfection   conditioned   media   were  
collected   and   20   µL  medium  was   supplemented  with   0.1  M  Tris -­HCl   (pH   8.0)   and   1  mM  CaCl2   to  
50   µL   volume   and   trypsinogen   was   activated   with   28   ng/mL   human   enteropeptidase   for   1   h   at    37   
oC.   Trypsin   activity   was   then   measured   by   adding   150   µL   of   the   chromogenic   substrate,    N-­
benzyloxycarbonyl -­Gly-­Pro-­Arg-­p-­nitroanilide   to   0.14   mM   final   concentration.    Trypsin   activit ies  
were  expressed  as  percent  of   the  48  h  wild-­type  activity.   The  average  of  2   independent   transfection  
experiments   is  shown.  For   clarity,    the   error  bars  have  been  omitted;;   the   standard  error  of   the  mean  
was   within   15%.   Inset:   Eight   hours   after   transfection   20   μL   aliquots   of   conditioned   media   were  
electrophoresed  on  15%  SDS-­polyacrylamide  gels   and  analyzed  by  western  blott ing  as  described   in  
Experimental  Procedures .   
4.11.2  Secretion  of  all  four  activation  peptide  mutants  
We  previously  found  that  secretion  of  activation  peptide  mutants  from  transfected  
cells  was   reduced,  although   the   four  mutants  have  never  been  studied   in   a  comparative  
manner  within  the  same  experiment.  To  establish  whether  this  secretion  defect  might  be  a  
mechanism   that   partly   offsets   the   drastically   increased   autoactivation,   we   quantified  
secretion   of  wild-­type   and  mutant   trypsinogens   from   transiently   transfected  HEK  293T  
cells.  For  these  experiments  we  used  a  short  time  course  (12  h)  to  prevent  autoactivation  
in  the  medium  and  consequent  trypsinization  of  the  cells.  We  measured  trypsin  activity  in  
the   conditioned   media   after   enteropeptidase-­mediated   activation   (Figure   21A)   and  
trypsinogen  levels  by  western  blotting  (Figure  21B).  We  found  that  the  activation  peptide  
mutants   were   secreted   at   significantly   lower   levels   than   wild-­type   trypsinogen,   in  
agreement  with  previous  observations.  Importantly,  secretion  rates   for   the  mutants  were  
inversely   proportional   with   their   ability   to   autoactivate   (D19A>K23R>D22G  
≈K23_I24insIDK).  
39  
  
  
  
Figure  21 .  Secretion  of  human  cationic   trypsinogen  and  activation  peptide  mutants  from  transiently  
transfected   HEK   293T   cells.   Trypsinogen   expression   constructs   also   contained   the   K237D   and  
N241D   mutations   which   improve   secretion   from   transfected   cells.    A,    At   4,    8   and   12   hours   after  
transfection   conditioned   media   were   collected   and   trypsin   activity   was   measured   as   described  
under  Experimental  Procedures .   Trypsin  activity  was  expressed  as  percentage  of   the  12  h  wild-­type  
activity.    The   average   of   three   independent   transfection   experiments   with   standard   deviation   is  
shown.  B,    Aliquots   (20   μL)   of   conditioned   media   collected   at    12   h   were   electrophoresed   on   15%  
SDS-­polyacrylamide   gels   and   analyzed   by   western   blott ing,    as   described   in   Experimental  
Procedures .    A   representative   blot   of   three   is   shown.   Mutant   K23R_I24insIDK   is   denoted   as  
insIDK.   
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5   DISCUSSION  
  
There  are  a  number  of  important  observations  in  this  study  which  set  it  apart  from  
a  typical  mutation  account.    
We  reported  first  an   intragenic  duplication  within  the  PRSS1  gene   in  association  
with  HCP.  The  human  trypsinogen  genes  are   located  on  chromosome  7q35,   intercalated  
between   the   beta  T-­cell   receptor   genes;;   at   a   locus   highly   active   in   recombination.  This  
organization   seems   beneficial   for   the   evolution   of   trypsinogens  which   tend   to   undergo  
extensive  gene-­duplication  and  gene-­loss  events  during  speciation  resulting  in  distinctive  
trypsinogen  gene  families  [25,57].  On  the  other  hand,  unwanted  genetic  rearrangements  -­-­  
such  as  gene-­conversions,  duplications  or   triplications  -­-­  can   result   in   novel  pathogenic  
alleles   in   hereditary   pancreatitis   [36,45,46,47,57,58].   In   contrast   to   the   previously   reported  
large-­scale  gene  duplications,   in  our  family  the  duplication  was  confined  only  to  a  nine-­
nucleotide   segment   within   exon   2   without   any   evidence   of   more   extensive   genetic  
changes.  Interestingly,  the  duplication  was  identified  only  in  the  father  and  his  two  sons  
(Figure  3),  while   it  was  absent   in  the  grandparents  or   in  the   father’s   siblings,   indicating  
that   it   was   de   novo   generated   in   the   father.   Ours   is   the   second   report   on   capturing   a  
mutational  event   leading  to  hereditary  pancreatitis.  Simon  et  al.   (2002)  found  a  de  novo  
R122H   mutation   in   their   cohort   and   their   subsequent   studies   indicated   that   PRSS1  
mutations  are  characteristically   not   inherited   from  a  common   founder,   even  when   local  
clustering  of  families  is  observed  [59,60].  
Intragenic   duplications   are   likely   to   result   in   a   frame   shift   and   truncated,   non-­
functional  protein.   In   this  case,  however,   the   reading   frame  was  kept  and  at   the  amino-­
acid  level  the  duplication  generated  an  insertion  within  the  TAP  (Figure  5).  As  expected  
from  this  alteration,  the  activation  properties  of  cationic  trypsinogen  have  been  affected  in  
profound  ways.   Trypsin-­mediated   trypsinogen   activation   (autoactivation)   and   cathepsin  
B-­mediated   trypsinogen   activation   were   both   increased   by   an   order-­of-­magnitude;;   an  
effect   size   never   before   seen   with   the   known   PRSS1   mutants.   With   respect   to  
autoactivation,   the   K23_I24insIDK   mutant’s   phenotype   is   consistent   with   the   reported  
properties  of  other  PRSS1  mutations  affecting  the  activation  peptide  (D19A,  D22G,  and  
K23R),  which  all  result  in  markedly  increased  autoactivation  [25,26,27,31].  Mechanistically,  
the   increased   autoactivation   of   K23_I24insIDK   is   explained   by   the   disruption   of  
inhibitory   interactions   between   the   negatively   charged   tetra-­Asp  motif   in   the   activation  
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peptide   and   trypsin   [26].   In   the   K23_I24insIDK   mutant   Asp21   is   replaced   with   a  
hydrophobic  Ile  residue  and  Asp20  by  a  positively  charged  Lys  (Figure  5).  
Cathepsin  B   has   long   been   known   as   a   pathological   activator   of   trypsinogen   in  
experimental   models   of   acute   pancreatitis,   cerulein-­induced   pancreatitis   in   particular  
[49,50,51,52].   The   effect   of   hereditary   pancreatitis-­associated   mutations   on   cathepsin   B-­
mediated   trypsinogen   activation   has   been   studied   in   detail   previously.  Mutants   D19A,  
N29I,  N29T,  E79K  and  R122H  exhibited  unchanged  activation  characteristics;;  whereas  
mutant   K23R   was   activated   slowly,   and   mutant   D22G   was   resistant   to   activation   by  
cathepsin  B  [27,51,52,61].  MutantK23_I24insIDK  is  the  first  cationic  trypsinogen  variant  that  
exhibits   increased   sensitivity   to   cathepsin   B-­mediated   activation   and   thus   stands   in  
contrast  with  all  other  PRSS1  mutants  studied  to  date.  We  believe  this  property  is  related  
to   the   longer   activation   peptide   which   allows   extended   contacts   with   the   activating  
enzyme.  
Another   important  objective  of   the  present   study  was   to   investigate   the  effect  of  
CTRC   on   the   autoactivation   of   trypsinogen   activation   peptide   mutants   D19A,   D22G,  
K23R  and  K23_I24insIDK  found  in  hereditary  pancreatitis.  Previously,  we  demonstrated  
that  wild-­type  cationic   trypsinogen   is   largely  degraded  by  CTRC  during  autoactivation,  
whereas   hereditary   pancreatitis   associated   mutants   N29I,   N29T,   V39A,   R122C   and  
R122H  exhibited   resistance   to  CTRC-­mediated   degradation   and   autoactivated   to   higher  
trypsin   levels.   In   addition,  we   found   that   mutations  A16V   and  N29I   increased  CTRC-­
mediated  cleavage  of   the  activation  peptide,  and   thereby  accelerated  autoactivation  [34].  
We   speculated   that   activation   peptide   mutants   might   also   affect   processing   of   the  
activation  peptide  by  CTRC  and/or  alter  the  effect  of  this  cleavage,  perhaps  even  resulting  
in   decreased   autoactivation.   This   would   then   offer   an   explanation   for   the   puzzling  
observation   that   the   robust   autoactivation   of   activation   peptide   mutants   is   not  
accompanied  by  a  more  severe  clinical  picture.  
Our   results   confirmed   that   even   in   the   absence   of   CTRC   activation   peptide  
mutants  autoactivated  at  markedly  increased  rates  (~4-­18-­fold).  In  the  presence  of  CTRC,  
activation   rates   were   further   increased   slightly   (D19A,   D22G,   K23R)   or   remained  
unchanged   (K23_I24insIDK),   indicating   that   the   robust   autoactivation   of   the   activation  
peptide   mutants   is   mostly   independent   of   CTRC.   Peak   trypsin   levels   attained   during  
autoactivation  positively  correlated  with   the   rate  of  autoactivation,   indicating   that   faster  
conversion   of   trypsinogen   to   trypsin   results   in   higher   trypsin   levels,   as   trypsin   is   less  
sensitive   to   CTRC-­mediated   degradation   than   trypsinogen.   As   expected,   the   mutations  
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had  no  effect  on  CTRC  cleavage  of  the  Leu81-­Glu82  peptide  bond  in  the  calcium  binding  
loop  and  consequent   trypsinogen  degradation.   Importantly,  when  compared   to   the  most  
common  pancreatitis-­associated  mutant  R122H,   in   the  presence  of  CTRC   the  activation  
peptide  mutants  still  exhibited  much  higher  rates  of  autoactivation  (~3-­10-­fold).  
N-­terminal  processing  of  the  activation  peptide  at  Phe18  by  CTRC  was  unchanged  
in  mutants  D22G,  K23R  and  K23_I24insIDK,  whereas  mutant  D19A  was  processed  at  4-­
fold   increased   rate.   This   finding   is   consistent   with   recent   mutagenesis   studies   in   the  
calcium  binding  loop  of  cationic  trypsinogen,  which  demonstrated  that  mutation  of  Glu82  
to  Ala  increased  cleavage  after  Leu81  about  3-­fold,   indicating  that  acidic  residues  at  the  
P1'  position   hinder  cleavage   by  CTRC.  Surprisingly,   however,   the   increased  processing  
of  mutant  D19A  was  paralleled  only  with  a  slight   increase   in  the  rate  of  autoactivation,  
suggesting   that   Asp19   is   important   for   mediating   the   functional   effect   of   N-­terminal  
processing.  Thus,  shortening  the  activation  peptide  by  CTRC  may  increase  autoactivation  
by  partly   relieving   the   inhibitory   interaction   between  Asp218  and  Asp19.  This  effect   is  
probably   due   to   neutralization   of   the   negative   charge   on   Asp19   by   the   newly   created  
proximity   of   the   positively   charged   amino   terminus.   Similarly,   mutation   D19A  would  
increase  autoactivation  by  neutralizing  Asp19  but  at  the  same  time  it  would  diminish  the  
effect  of  N-­terminal  processing  by  CTRC.  This   notion   is   supported  by   the  observations  
that  the  extent  of   the  autoactivation   increase  either  by  CTRC  processing  or  by  mutation  
D19A   is  comparable,  approximately  3-­4-­fold.  The  stimulatory  effect  of  CTRC  cleavage  
on   autoactivation  was   also   abolished   in  mutant  K23_I24insIDK,  which  may   be   readily  
explained  by  sterical  uncoupling  of  the  original  tetra-­Asp  motif  from  the  activation  site  by  
the   three-­amino-­acid   insertion   (Figure   5).   Furthermore,   previous   experiments   indicated  
that  trypsin-­mediated  activation  (i.e.  autoactivation)  of   the  K23_I24insIDK  mutant  most  
likely   proceeds   by   sequential   cleavage   of   the   two   lysyl   peptide   bonds   found   in   the  
mutated  activation  peptide.  In  this  case,  cleavage  of  the  N-­terminal  Lys-­Ile  peptide  bond  
would   eliminate   the   N-­terminal   eight   amino   acids   together   with   any   effect   of   CTRC-­
dependent  processing.  
Calcium   in   millimolar   concentrations   stimulates   autoactivation   presumably   by  
binding  to  the  activation  peptide  and  shielding  the  inhibitory  negative  charges  of  the  tetra-­
Asp  motif.  Using   the  CTRC-­dependent   processing   of   the   activation   peptide   as   readout,  
we  determined   the  calcium  binding  affinity  of  wild-­type  and  mutant  activation  peptides  
(Figure   19).   Unexpectedly,   mutant   and   wild-­type   trypsinogens   bound   calcium   at   the  
activation   peptide   with   comparable   affinities,   1.6   mM   on   average.   This   observation  
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suggests  that  calcium  probably  engages  only  two  or  three  Asp  side  chains  and  elimination  
of  one  of  the  four  Asp  residues  either  by  mutation  D19A  or  D22G  is  tolerated.  When  the  
functional   effect   of   calcium   binding   was   investigated,   however,   we   found   that  
autoactivation   of   mutants  D22G   and  K23_I24insIDK  were   insensitive   to   calcium.   The  
results  suggest   that  the  stimulatory  effect  calcium  on  autoactivation   is  mediated  through  
binding   to  Asp22  and   neutralizing   its   negative  charge.  During  autoactivation,  Asp22   in  
the  activation  peptide  binds  to  the  S2  subsite  on  trypsin,  a  conserved  hydrophobic  pocket  
formed  by  His63,  Leu104  and  Trp216,  and  this  unfavorable  interaction  may  be  alleviated  
by  calcium.  In  the  K23_I24insIDK  mutant,  calcium  likely  binds  only  to  the  original  tetra-­
Asp  motif,  which  is  now  further  removed  from  the  activation  peptide  bond.  The  Asp-­Ile-­
Lys-­Asp  sequence  preceding  the  activation  site  does  not  seem  competent  to  bind  calcium.  
Furthermore,   as   pointed   out   above,   during   autoactivation   the   N-­terminal   eight   amino  
acids  are  removed  before  cleavage  at  the  activation  peptide  takes  place.  
The  biochemical  properties  of  the  TAP  mutants  do  not  explain  why  the  markedly  
increased   autoactivation   is   not   associated   with   a   more   severe   clinical   presentation   of  
hereditary  pancreatitis  with  complete  penetrance   and   early  onset.  Typical  penetrance  of  
hereditary  pancreatitis   in   families  with   the  R122H  mutation   is  70-­90%  and   the  average  
age  of  onset   is  14   years  with  a   range  of  2-­20   years.  Although  clinical   data   for   the   rare  
activation  peptide  mutations  is  relatively  scant,  mutation  D22G  was  also  identified  in  the  
unaffected   20   year   old   sister   of   the   index   patient,   indicating   incomplete   penetrance.  
Published  ages  of  diagnosis   indicated  some  early  onset  (K23_I24insIDK  2  y,  D22G  8  y)  
and   some   late   onset   cases   (D19A   17   y,   K23_I24insIDK   21   y),   consistent  with   typical  
HCP.   Previously,   we   observed   that   secretion   of   activation   peptide   mutants   was  
compromised   from   transfected   cells   due   to   intracellular   autoactivation   and   ensuing  
degradation.  We   extended   these   studies   here   and   quantitatively   compared,   for   the   first  
time,   cellular   secretion   of   all   four   activation   peptide   mutants   to   determine   whether  
reduced   secretion   could   offset   the   effect   of   increased   autoactivation.   Indeed,   we  
confirmed  not  only  that  all  four  activation  peptide  mutants  were  secreted  at  lower  levels  
than  wild-­type  trypsinogen,  but  also  that  the  secretion  defect  inversely  correlated  with  the  
rates  of  autoactivation.  Our  observations  indicate  that  nature  carefully  titrated  trypsinogen  
secretion   against   autoactivation   propensity,   to   curb   the   risk   for   excessive   pathological  
intra-­pancreatic  trypsinogen  activation  in  carriers  of  the  activation  peptide  mutations.  
Our  results  define  the  TAP  mutations  D19A,  D22G,  K23R  and  K23_I24insIDK  as  
a   special   subset   of   hereditary-­pancreatitis   associated   mutations   which   stimulate  
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autoactivation   largely   independently  of  CTRC  and   this   robust  effect   is   compensated   by  
their   reduced   secretion.  Taken   together  with   previous   studies,   the   observations   indicate  
that   human   cationic   trypsinogen   mutations   may   increase   autoactivation   by   several  
independent   but   not  mutually   exclusive   mechanisms   in  HCP   (Figure   22):   (i)   increased  
secretion,   as   seen   with   copy   number   mutations;;   (ii)   resistance   to   CTRC-­mediated  
degradation;;  (iii)   increased  processing  of  the  activation  peptide  by  CTRC  and  (iv)  direct  
stimulation  of  autoactivation,  as  demonstrated  here  for  the  activation  peptide  mutations.  
Despite   considerable   progress   in   the   field,   greater   understanding   into   the  
underlying   mechanisms   of   disease   is   much   needed.   The   central   role   of   trypsin   is   also  
supported  by  observations  based  on  protective  mechanisms  evolved  to  curtail  premature  
activation   of   the   zymogen.   It   has   been   shown   that   under   physiological   conditions  
bicarbonate   secretion   by   pancreatic   ductal   epithelial   cells   is   not   only   important   for  
elevating  the  pH  in  the  duodenum,  but  also  for  keeping  digestive  enzymes  in  an  inactive  
state.   This   raises   the   question  whether   the   decreased   pH  would   contribute   in   the   early  
trypsin   activation.   Our   research   group   found   that   prematurely   activated   trypsin   in   the  
ductal   tree   inhibits   bicarbonate   transport   leading   to  a  vicious   cycle  generating  a   further  
decrease   in  pH  and  enhanced   trypsinogen  activation,  which  will   favour  development  of  
pancreatitis  [62].    
The  complex  understanding  of   inflammatory  disorders   invokes   further   insight  of  
other   pathomechanistic   processes   involving   the   role   of   ion   transporters   in   the   disease  
development.  It  has  been  reported  that  acid/base  transporters  have  a  great  impact  on  cell  
function  and  they  also  may  have  specific  contributions  to  cancer  development  [63].  Since  
individuals  with  CP  have  an  increased  risk  for  pancreatic  cancer  -­which  is  still  one  of  the  
deadliest   of   human   tumors-­   extending   the   research   towards   ion   exchangers   should   be  
considered.    
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Figure   23.   Mechanisms   of   increased   autoactivation   in   hereditary   pancreati t is   associated   with  
human   cationic   trypsinogen   mutations.    Copy   number   mutations   (CNM)   increase   trypsinogen  
expression.    Activation   peptide   mutat ions   D19A,   D22G,   K23R,   and   K23_I24insIDK   directly  
st imulate   autoactivation.    Mutations   N29I,    N29T,   V39A,   R122C,   and   R122H   inhibit    CTRC-­
dependent   trypsinogen   degradation.   Mutations   A16V   and   N29I   st imulate   N-­terminal   processing   of  
the   trypsinogen   activation   peptide   by   CTRC.   A   prominent   example   for   each   mechanism   is  
indicated.  
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6   SUMMARY  
  
Hereditary  chronic  pancreatitis  is  caused  by  missense  mutations  in  human  cationic  
trypsinogen.   A   subset   of   mutations   alters   the   activation   peptide   and   increases  
autoactivation   of   trypsinogen   to   trypsin.   It   has   recently   been   demonstrated   that  
trypsinogen  mutations  cause  hereditary  pancreatitis   by  altering   its  proteolytic   regulation  
by  chymotrypsin  C  (CTRC).  CTRC  stimulates   trypsinogen  autoactivation  by  processing  
the   activation   peptide   to   a   shorter   form  and   also   promotes   degradation   by   cleaving   the  
calcium   binding   loop   in   trypsinogen.  Mutations   render   trypsinogen   resistant   to   CTRC-­
mediated  degradation  and/or  increase  processing  of  the  activation  peptide  by  CTRC.  
In   a   hereditary   pancreatitis   family   from   Denmark   we   identified   an   intragenic  
duplication   of   9   nucleotides   in   exon-­2   of   the   PRSS1   gene   which   at   the   protein   level  
results   in   a   3   amino-­acid   insertion  within   the   activation   peptide   (K23_I24insIDK).  The  
aim  of  this  work  was  to  study  and  characterize  the  novel  K23_I24insIDK  PRSS1  mutation  
on  the  function  of  human  cationic  trypsinogen.  In  light  of  the  recently  discovered  CTRC-­
dependent   unifying   pathomechanism   for   hereditary-­pancreatitis,   this   study   was   further  
aimed  at  clarifying  the  role  of  CTRC  in  the  mechanism  of  action  of  the  activation  peptide  
mutations.  
Human   pancreatic   enzymes   were   produced   recombinantly   and   purified   to  
homogeneity.  Trypsinogen  activation  was  followed  by  enzymatic  assays  and  SDS-­PAGE.  
Trypsinogen  secretion  was  measured  from  transfected  HEK  293T  cells.    
Our   results  demonstrate   that  activation  of   the  K23_I24insIDK  mutant  by   trypsin  
or   by   cathepsin   B   is   markedly   increased   confirming   the   significance   of   the   trypsin-­
dependent   pathological   pathway   in   hereditary   pancreatitis.   When   we   investigated   the  
autoactivation   properties   of   all   four   trypsinogen   activation   peptide   mutations   (D19A,  
D22G,  K23R,  and  K23_I24insIDK)  and  their  possible  interaction  with  CTRC,  we  found  
that   all   four   activation   peptide  mutations   robustly   increased   trypsinogen   autoactivation,  
both  in  the  presence  and  absence  of  CTRC.  Degradation  of  activation  peptide  mutants  by  
CTRC  was  unchanged  and  processing  of  the  activation  peptide  was  increased  only  in  the  
D19A  mutant  by  4-­fold.  Surprisingly,   however,   increased  processing   had  essentially   no  
effect   on   autoactivation.   Finally,   the   activation   peptide   mutants   exhibited   reduced  
secretion   from   transfected   cells,   and   secreted   trypsinogen   levels   were   inversely  
proportional  with  autoactivation  rates.  
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We  conclude  that  D19A,  D22G,  K23R  and  K23_I24insIDK  form  a  special  subset  
of  hereditary  pancreatitis-­associated  mutations  characterized  by  robust  autoactivation  that  
is   largely   independent   of   CTRC   and   decreased   cellular   secretion,   which   is   inversely  
proportional   to  their  ability   to  autoactivate.  The   combination  of   these  unique  properties  
adequately  explains  the  observed  clinical  effects  of  these  mutations.  
48  
  
7   ACKNOWLEDGEMENTS  
  
I  am  grateful  to  professors  János  Lonovics  and  Tibor  Wittmann,  past  and  present  
chairs  of   the  First  Department  of  Medicine,  University  of  Szeged,   for  affording  me   the  
opportunity  to  participate  in  their  Ph.D.  program.  
I  would  like  to  express  my  deepest  and  sincere  gratitude  to  my  mentors  and  advisors  
professor  Miklós  Sahin-­Tóth  at   the  Department  of  Molecular  and  Cell  Biology   in   the  
Boston  University  Medical  Center  and  professor  Péter  Hegyi  at  the  First  Department  of  
Medicine,  University  of  Szeged.  I  admire  their  broad  knowledge  of  science,  their  way  of  
analyzing  scientific  problems,  and  their  ability  to  come  up  with  exciting  new  ideas.  I  am  
most  grateful  for  their  patient  guidance  and  inspiration  during  my  Ph.D.  studies.  
It   also   gives   me   great   pleasure   to   acknowledge   the   support   and   help   of   associate  
professor  Zoltán  Rakonczay  Jr.  and  thank  him  for  constructive  discussions  of  my  work  
and  for  his  valuable  suggestions.    
I  would  also  like  to  thank  my  colleagues  at  Boston  University,  Zsolt  Rónai,  Éva  
Keresztúri,  András  Szabó,  Melinda  Bence  and  Vera  Sahin-­Tóth  for  introducing  me  to  
all  the  research  techniques  and  for  their  caring  support  during  my  first  steps  in  the  Sahin-­
Tóth  laboratory.  I  owe  warm  thanks  to  all  of  my  colleagues  at  the  University  of  Szeged  
for  all  the  emotional  support,  their  weekly  dose  of  humor,  their  kindness  and  for  having  
had  the  opportunity  to  work  with  them.  
This   work   was   supported   by   National   Development   Agency   grants   in   Szeged  
(TÁMOP-­4.2.2.A-­11/1/KONV-­2012-­0035,   TÁMOP-­4.2.2.A-­11/1/KONV-­2012-­0073,  
TÁMOP-­4.2.2-­11/1/KONV-­2012-­0052),   NIH   grants   R01DK058088,   R01DK082412,  
R01DK082412-­S2   and   R01DK095753   in   Boston,   a   scholarship   from   the   Rosztoczy  
Foundation,  and  a  mini-­sabbatical  grant  from  the  American  Pancreatic  Association.    
I  dedicate  this  thesis  to  my  parents  who  always  valued  education  and  taught  me  
hard  work,   perseverance,   humility,   honesty   and   integrity.   I   thank   you   for   your   endless  
love,  support  and  encouragement.  
  
49  
  
8   REFERENCES  
  
1.  Ammann,  R.  W.  The  natural  history  of  alcoholic  chronic  pancreatitis.  Intern.  Med.  40,  
368–375  (2001).  
2.  Whitcomb,  D.  C.  et  al.  Hereditary  pancreatitis   is  caused  by  a  mutation  in  the  cationic  
trypsinogen  gene.  Nat.  Genet.  14,  141–145  (1996).  
3.  Szmola,   R.   &   Sahin-­Tóth,   M.   Uncertainties   in   the   classification   of   human   cationic  
trypsinogen  (PRSS1)  variants  as  hereditary  pancreatitis-­associated  mutations.  J.  Med.  
Genet.  47,  348–350  (2010).  
4.  Whitcomb,  D.  C.  et   al.  Common  genetic   variants   in   the  CLDN2   and  PRSS1-­PRSS2  
loci  alter  risk  for  alcohol-­related  and  sporadic  pancreatitis.  Nat.  Genet.  44,  1349–1354  
(2012).  
5.  Witt,  H.  et   al.  A  degradation-­sensitive   anionic   trypsinogen   (PRSS2)   variant   protects  
against  chronic  pancreatitis.  Nat.  Genet.  38,  668–673  (2006).  
6.  Witt,  H.  et  al.  Mutations  in  the  gene  encoding  the  serine  protease  inhibitor,  Kazal  type  
1  are  associated  with  chronic  pancreatitis.  Nat.  Genet.  25,  213–216  (2000).  
7.  Pfützer,  R.  H.  et  al.  SPINK1/PSTI  polymorphisms  act  as  disease  modifiers  in  familial  
and  idiopathic  chronic  pancreatitis.  Gastroenterology  119,  615–623  (2000).  
8.  Sharer,   N.   et   al.   Mutations   of   the   cystic   fibrosis   gene   in   patients   with   chronic  
pancreatitis.  N.  Engl.  J.  Med.  339,  645–652  (1998).  
9.  Cohn,  J.  A.  et  al.  Relation  between  mutations  of  the  cystic  fibrosis  gene  and  idiopathic  
pancreatitis.  N.  Engl.  J.  Med.  339,  653–658  (1998).  
10.   Noone,  P.  G.  et  al.  Cystic  fibrosis  gene  mutations  and  pancreatitis  risk:  relation  to  
epithelial   ion   transport   and   trypsin   inhibitor   gene   mutations.  Gastroenterology   121,  
1310–1319  (2001).  
11.   Truninger,  K.  et  al.  Mutations  of  the  cystic  fibrosis  gene  in  patients  with  chronic  
pancreatitis.  Am.  J.  Gastroenterol.  96,  2657–2661  (2001).  
12.   Szmola,  R.  &  Sahin-­Tóth,  M.  Chymotrypsin  C   (caldecrin)  promotes  degradation  
of  human  cationic  trypsin:   identity  with  Rinderknecht’s  enzyme  Y.  Proc.  Natl.  Acad.  
Sci.  U.S.A.  104,  11227–11232  (2007).  
50  
  
13.   Baudry,   C.   et   al.   Recurrent   acute   pancreatitis   caused   by   association   of   a   novel  
mutation   of   the   calcium-­sensing   receptor   gene   and   a   heterozygous   mutation   of   the  
SPINK1  gene.  Pancreas  39,  420–421  (2010).  
14.   Felderbauer,   P.   et   al.  Mutations   in   the   calcium-­sensing   receptor:   a   new   genetic  
risk  factor  for  chronic  pancreatitis?  Scand.  J.  Gastroenterol.  41,  343–348  (2006).  
15.   Rebours,  V.  et  al.  The  natural  history  of  hereditary  pancreatitis:  a  national  series.  
Gut  58,  97–103  (2009).  
16.   COMFORT,  M.  W.  &  STEINBERG,  A.  G.  Pedigree  of  a   family  with  hereditary  
chronic  relapsing  pancreatitis.  Gastroenterology  21,  54–63  (1952).  
17.   Whitcomb,  D.  C.  et   al.  A  gene   for   hereditary   pancreatitis  maps   to   chromosome  
7q35.  Gastroenterology  110,  1975–1980  (1996).  
18.   Le   Bodic,   L.   et   al.   The   hereditary   pancreatitis   gene   maps   to   long   arm   of  
chromosome  7.  Hum.  Mol.  Genet.  5,  549–554  (1996).  
19.   Pandya,  A.  et   al.   Linkage   studies   in   a   large   kindred  with   hereditary   pancreatitis  
confirms  mapping  of  the  gene  to  a  16-­cM  region  on  7q.  Genomics  38,  227–230  (1996).  
20.   Gorry,  M.  C.  et  al.  Mutations  in  the  cationic  trypsinogen  gene  are  associated  with  
recurrent  acute  and  chronic  pancreatitis.  Gastroenterology  113,  1063–1068  (1997).  
21.   Teich,   N.,   Mössner,   J.   &   Keim,   V.   Mutations   of   the   cationic   trypsinogen   in  
hereditary  pancreatitis.  Hum.  Mutat.  12,  39–43  (1998).  
22.   Férec,   C.   et   al.   Mutations   in   the   cationic   trypsinogen   gene   and   evidence   for  
genetic  heterogeneity  in  hereditary  pancreatitis.  J.  Med.  Genet.  36,  228–232  (1999).  
23.   Guy,   O.,   Lombardo,   D.,   Bartelt,   D.   C.,   Amic,   J.   &   Figarella,   C.   Two   human  
trypsinogens.   Purification,   molecular   properties,   and   N-­terminal   sequences.  
Biochemistry  17,  1669–1675  (1978).  
24.   Rinderknecht,  H.,  Renner,  I.  G.,  Abramson,  S.  B.  &  Carmack,  C.  Mesotrypsin:  a  
new  inhibitor-­resistant  protease  from  a  zymogen  in  human  pancreatic  tissue  and  fluid.  
Gastroenterology  86,  681–692  (1984).  
25.   Chen,   J.-­M.  et  al.  Evolution  of   trypsinogen  activation  peptides.  Mol.  Biol.  Evol.  
20,  1767–1777  (2003).  
26.   Nemoda,  Z.  &  Sahin-­Tóth,  M.  The  tetra-­aspartate  motif   in   the  activation  peptide  
of   human   cationic   trypsinogen   is   essential   for   autoactivation   control   but   not   for  
enteropeptidase  recognition.  J.  Biol.  Chem.  280,  29645–29652  (2005).  
51  
  
27.   Kereszturi,   E.   &   Sahin-­Tóth,   M.   Intracellular   autoactivation   of   human   cationic  
trypsinogen   mutants   causes   reduced   trypsinogen   secretion   and   acinar   cell   death.   J.  
Biol.  Chem.  284,  33392–33399  (2009).  
28.   Lu,  D.  et   al.  Crystal   structure  of   enteropeptidase   light   chain   complexed  with   an  
analog  of  the  trypsinogen  activation  peptide.  J.  Mol.  Biol.  292,  361–373  (1999).  
29.   Kukor,  Z.,  Tóth,  M.  &  Sahin-­Tóth,  M.  Human  anionic  trypsinogen:  properties  of  
autocatalytic  activation  and  degradation  and  implications  in  pancreatic  diseases.  Eur.  J.  
Biochem.  270,  2047–2058  (2003).  
30.   Witt,  H.,  Luck,  W.  &  Becker,  M.  A  signal  peptide  cleavage  site  mutation   in   the  
cationic   trypsinogen   gene   is   strongly   associated   with   chronic   pancreatitis.  
Gastroenterology  117,  7–10  (1999).  
31.   Teich,  N.  et  al.  Chronic  pancreatitis  associated  with  an  activation  peptide  mutation  
that  facilitates  trypsin  activation.  Gastroenterology  119,  461–465  (2000).  
32.   Grocock,  C.  J.  et  al.  The  variable  phenotype  of   the  p.A16V  mutation  of  cationic  
trypsinogen  (PRSS1)  in  pancreatitis  families.  Gut  59,  357–363  (2010).  
33.   Nemoda,   Z.   &   Sahin-­Tóth,   M.   Chymotrypsin   C   (caldecrin)   stimulates  
autoactivation   of   human   cationic   trypsinogen.   J.   Biol.   Chem.   281,   11879–11886  
(2006).  
34.   Szabó,   A.   &   Sahin-­Tóth,   M.   Increased   activation   of   hereditary   pancreatitis-­
associated  human  cationic  trypsinogen  mutants  in  presence  of  chymotrypsin  C.  J.  Biol.  
Chem.  287,  20701–20710  (2012).  
35.   Kereszturi,   É.   et   al.   Hereditary   pancreatitis   caused   by   mutation-­induced  
misfolding   of   human   cationic   trypsinogen:   A   novel   disease   mechanism.   Human  
Mutation  30,  575–582  (2009).  
36.   Chauvin,  A.  et  al.  Elucidation  of   the  complex  structure  and  origin  of   the  human  
trypsinogen  locus  triplication.  Hum.  Mol.  Genet.  18,  3605–3614  (2009).  
37.   Király,  O.  et   al.   Expression   of   human   cationic   trypsinogen  with   an   authentic  N  
terminus  using  intein-­mediated  splicing  in  aminopeptidase  P  deficient  Escherichia  coli.  
Protein  Expr.  Purif.  48,  104–111  (2006).  
38.   Szepessy,  E.  &  Sahin-­Tóth,  M.  Inactivity  of  recombinant  ELA2B  provides  a  new  
example   of   evolutionary   elastase   silencing   in   humans.   Pancreatology   6,   117–122  
(2006).  
39.   Rónai,  Z.  et  al.  A  common  African  polymorphism  abolishes  tyrosine  sulfation  of  
human  anionic  trypsinogen  (PRSS2).  Biochem.  J.  418,  155–161  (2009).  
52  
  
40.   Király,  O.,  Guan,  L.  &  Sahin-­Tóth,  M.  Expression  of   recombinant  proteins  with  
uniform  N-­termini.  Methods  Mol.  Biol.  705,  175–194  (2011).  
41.   Szabó,  A.  et  al.  High  affinity   small  protein   inhibitors  of  human  chymotrypsin  C  
(CTRC)  selected  by  phage  display  reveal  unusual  preference  for  P4’  acidic  residues.  J.  
Biol.  Chem.  286,  22535–22545  (2011).  
42.   Lengyel,   Z.,   Pál,   G.   &   Sahin-­Tóth,   M.   Affinity   purification   of   recombinant  
trypsinogen  using  immobilized  ecotin.  Protein  Expr.  Purif.  12,  291–294  (1998).  
43.   Edman  et  al..  Method  for  Determination  of  the  Amino  Acid  Sequence  in  Peptides.  
ACTA  CHEM  SCAND  vol.  4,  283–293  
44.   Howes,  N.  et  al.  Clinical  and  genetic  characteristics  of   hereditary  pancreatitis   in  
Europe.  Clin.  Gastroenterol.  Hepatol.  2,  252–261  (2004).  
45.   Masson,  E.,  Le  Maréchal,  C.,  Delcenserie,  R.,  Chen,  J.-­M.  &  Férec,  C.  Hereditary  
pancreatitis   caused   by   a   double   gain-­of-­function   trypsinogen  mutation.  Hum.  Genet.  
123,  521–529  (2008).  
46.   Le   Maréchal,   C.   et   al.   Hereditary   pancreatitis   caused   by   triplication   of   the  
trypsinogen  locus.  Nat.  Genet.  38,  1372–1374  (2006).  
47.   Masson,  E.  et  al.  Trypsinogen  copy  number  mutations  in  patients  with  idiopathic  
chronic  pancreatitis.  Clin.  Gastroenterol.  Hepatol.  6,  82–88  (2008).  
48.   Polgár,  L.  The  catalytic   triad  of  serine  peptidases.  Cell.  Mol.  Life  Sci.  62,  2161–
2172  (2005).  
49.   Figarella,  C.,  Miszczuk-­Jamska,  B.  &  Barrett,  A.  J.  Possible  lysosomal  activation  
of   pancreatic   zymogens.  Activation   of   both   human   trypsinogens   by   cathepsin  B   and  
spontaneous  acid.  Activation  of  human  trypsinogen  1.  Biol.  Chem.  Hoppe-­Seyler  369  
Suppl,  293–298  (1988).  
50.   Halangk,  W.  et  al.  Role  of  cathepsin  B  in  intracellular  trypsinogen  activation  and  
the  onset  of  acute  pancreatitis.  J.  Clin.  Invest.  106,  773–781  (2000).  
51.   Kukor,   Z.   et   al.   Presence   of   cathepsin   B   in   the   human   pancreatic   secretory  
pathway   and   its   role   in   trypsinogen   activation   during   hereditary   pancreatitis.  J.  Biol.  
Chem.  277,  21389–21396  (2002).  
52.   Saluja,  A.  K.,  Lerch,  M.  M.,   Phillips,   P.  A.  &  Dudeja,  V.  Why  does   pancreatic  
overstimulation  cause  pancreatitis?  Annu.  Rev.  Physiol.  69,  249–269  (2007).  
53.   Teich,   N.,   Bödeker,   H.   &   Keim,   V.   Cathepsin   B   cleavage   of   the   trypsinogen  
activation  peptide.  BMC  Gastroenterol  2,  16  (2002).  
53  
  
54.   Mareninova,  O.  A.  et   al.   Impaired   autophagic   flux  mediates   acinar   cell   vacuole  
formation   and   trypsinogen   activation   in   rodent  models   of   acute   pancreatitis.  J.  Clin.  
Invest.  119,  3340–3355  (2009).  
55.   Wartmann,   T.   et   al.   Cathepsin   L   inactivates   human   trypsinogen,   whereas  
cathepsin   L-­deletion   reduces   the   severity   of   pancreatitis   in   mice.  Gastroenterology  
138,  726–737  (2010).  
56.   Schnúr,  A.,  et  al..  Functional  effects  of  13  rare  PRSS1  variants  presumed  to  cause  
chronic  pancreatitis.  Gut  (2013).  doi:10.1136/gutjnl-­2012-­304331  
57.   Chen,   J.  M.  &  Ferec,  C.  Gene  conversion-­like  missense  mutations   in   the   human  
cationic   trypsinogen   gene   and   insights   into   the   molecular   evolution   of   the   human  
trypsinogen  family.  Mol.  Genet.  Metab.  71,  463–469  (2000).  
58.   Teich,   N.   et   al.   Gene   conversion   between   functional   trypsinogen   genes   PRSS1  
and  PRSS2  associated  with  chronic  pancreatitis  in  a  six-­year-­old  girl.  Hum.  Mutat.  25,  
343–347  (2005).  
59.   Simon,   P.   et   al.   Spontaneous   and   sporadic   trypsinogen   mutations   in   idiopathic  
pancreatitis.  JAMA  288,  2122  (2002).  
60.   Weiss,   F.   U.   et   al.   Local   clustering   of   PRSS1   R122H   mutations   in   hereditary  
pancreatitis   patients   from  Northern  Germany.  Am.   J.  Gastroenterol.  103,   2585–2588  
(2008).  
61.   Teich,   N.   et   al.   Interaction   between   trypsinogen   isoforms   in   genetically  
determined  pancreatitis:  mutation  E79K   in  cationic  trypsin  (PRSS1)  causes   increased  
transactivation  of  anionic  trypsinogen  (PRSS2).  Hum.  Mutat.  23,  22–31  (2004).  
62.   Pallagi,   P.   et   al.   Trypsin   reduces   pancreatic   ductal   bicarbonate   secretion   by  
inhibiting  CFTR  Cl−   channels   and   luminal   anion   exchangers.  Gastroenterology   141,  
2228–2239.e6  (2011).  
63.   Czepán,   M.   et   al.   NHE1   activity   contributes   to   migration   and   is   necessary   for  
proliferation  of  human  gastric  myofibroblasts.  Pflugers  Arch.  463,  459–475  (2012).  
  
  
 
 
 
 
 
 
 
Articles closely related to the subject of the thesis and cited in the thesis 
 
  
 
 
 
 
 
 
 
I. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/febs.12292 
This article is protected by copyright. All rights reserved. 
Received Date : 05-Feb-2013 
Revised Date   : 30-Mar-2013 
Accepted Date : 14-Apr-2013 
 
Robust autoactivation, chymotrypsin C independence and diminished secretion define a 
subset of hereditary pancreatitis associated cationic trypsinogen mutants 
 
 
Andrea Geisz1,2, Péter Hegyi2 and Miklós Sahin-Tóth1* 
 
1Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, 
Boston University, Boston, MA 02118; 2First Department of Medicine, University of Szeged, 
Szeged, Hungary 
 
Running title: Trypsinogen activation peptide mutants 
 
Article type: Original Article 
 
*Correspondence to Miklós Sahin-Tóth, 72 East Concord Street, Evans-433; Boston, MA 02118; 
Tel: (617) 414-1070; Fax: (617) 414-1041; E-mail: miklos@bu.edu 
 
Keywords: trypsinogen, trypsin, chymotrypsin C, autoactivation, calcium binding, hereditary 
pancreatitis 
 
SUMMARY 
Mutations in human cationic trypsinogen cause hereditary pancreatitis by altering its proteolytic 
regulation of activation and degradation by chymotrypsin C (CTRC). CTRC stimulates 
trypsinogen autoactivation by processing the activation peptide to a shorter form but also 
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promotes degradation by cleaving the calcium binding loop in trypsinogen. Mutations render 
trypsinogen resistant to CTRC-mediated degradation and/or increase processing of the activation 
peptide by CTRC. Here we demonstrate that activation peptide mutations D19A, D22G, K23R 
and K23_I24insIDK robustly increased the rate of trypsinogen autoactivation, both in the 
presence and absence of CTRC. Degradation of the mutants by CTRC was unchanged and 
processing of the activation peptide was increased only in the D19A mutant by 4-fold. 
Surprisingly, however, this increased processing had only a minimal effect on autoactivation. 
The tetra-aspartate motif in the trypsinogen activation peptide binds calcium (KD ~1.6 mM), 
which stimulates autoactivation. Unexpectedly, calcium binding was not compromised by any of 
the activation peptide mutations. Despite normal binding, autoactivation of mutants D22G and 
K23_I24insIDK was not stimulated by calcium. Finally, the activation peptide mutants exhibited 
reduced secretion from transfected cells, and secreted trypsinogen levels were inversely 
proportional with autoactivation rates. We conclude that D19A, D22G, K23R and 
K23_I24insIDK form a mechanistically distinct subset of hereditary pancreatitis associated 
mutations, which exert their effect primarily through direct stimulation of autoactivation, 
independently of CTRC. The potentially severe clinical impact of the markedly increased 
autoactivation is offset by diminished secretion, resulting in a clinical phenotype 
indistinguishable from typical hereditary pancreatitis. 
 
Mutations in the serine protease 1 (PRSS1) gene that encodes human cationic trypsinogen cause 
hereditary pancreatitis [1, 2]. The mechanism of action for the most frequently found mutations 
have been recently elucidated and involves increased resistance against chymotrypsin C 
(CTRC)-mediated degradation and/or increased sensitivity to CTRC-dependent stimulation of 
autoactivation [3]. CTRC is a pancreatic serine protease which controls autoactivation of human 
cationic trypsinogen by selectively cleaving regulatory sites within the trypsinogen activation 
peptide and the calcium binding loop. The dominant effect of CTRC is trypsinogen degradation, 
which is triggered by cleavage of the Leu81-Glu82 peptide bond in the calcium binding loop and 
is facilitated by a trypsin-mediated autolytic cleavage of the Arg122-Val123 peptide bond [3, 4]. 
CTRC also degrades active trypsin by the same mechanism but at a slower rate. Hereditary 
pancreatitis-associated mutations N29I, N29T, V39A, R122C and R122H decrease or block 
cleavages at these sites and thereby increase trypsin levels generated during autoactivation [3]. 
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 A secondary, less prominent effect of CTRC on autoactivation is mediated by cleavage of 
the activation peptide of cationic trypsinogen at the Phe18-Asp19 peptide bond (Figure 1) [5]. 
The activation peptide is an 8 amino-acid N-terminal extension on trypsinogen, which becomes 
cleaved at the Lys23-Ile24 peptide bond during activation to trypsin (Figure 1). The activating 
cleavage may be catalyzed by the brush-border serine protease enteropeptidase (enterokinase) in 
the duodenum or by trypsin (i.e. autoactivation) in the pancreas. A characteristic feature of the 
activation peptide is the conserved tetra-Asp sequence, which is presumed to serve as an 
enteropeptidase recognition motif [6]. We found, however, that individual or combined 
mutations of these Asp residues had minimal effect on activation of human cationic trypsinogen 
by human enteropeptidase [7]. On the other hand, the tetra-Asp sequence was shown to inhibit 
autoactivation of trypsinogen, which is partly relieved by millimolar concentrations of calcium 
[7]. In human cationic trypsinogen, inhibition of autoactivation is also dependent on Asp218, 
which participates in a repulsive electrostatic interaction with the tetra-Asp motif [7]. CTRC 
cleavage at the Phe18-Asp19 peptide bond results in a shortened activation peptide, causing 
partial liberation of the inhibitory interaction with Asp218 and increased autoactivation [5] 
(Figure 1). Pancreatitis-associated mutations A16V and, to a lesser extent, N29I increase N-
terminal processing of the activation peptide by CTRC and thereby stimulate trypsinogen 
autoactivation [3, 5]. 
 
 In addition to the relatively common A16V mutation [8], there were four other mutations, 
D19A, D22G, K23R and K23_I24insIDK, in the activation peptide of human cationic 
trypsinogen found in association with hereditary pancreatitis (Figure 1) [9-12]. The 
K23_I24insIDK mutation results in the insertion of the Ile-Asp-Lys sequence between Lys23 and 
Ile24, which normally form the activating peptide bond (Figure 1). This insertion changes the 
tetra-Asp motif preceding Lys23 to Asp-Lys-Ile-Asp; effectively eliminating two of the 
inhibitory Asp residues. A number of previous studies demonstrated that mutations D19A, 
D22G, K23R and K23_I24insIDK markedly increased autoactivation of cationic trypsinogen [7, 
9, 12, 13]. In fact, these mutations offered the first convincing evidence that increased 
autoactivation was a pathologically relevant mechanism in hereditary pancreatitis. 
 In light of the recently discovered CTRC-dependent unifying pathomechanism for 
hereditary-pancreatitis, the present study was aimed at clarifying the role of CTRC in the 
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mechanism of action of the activation peptide mutations. Because of their location, the mutations 
are unlikely to affect trypsinogen degradation but may have profound effects on CTRC-mediated 
processing of the activation peptide. Furthermore, we sought to elucidate how the biochemical 
phenotype of strikingly increased autoactivation can be reconciled with the clinical phenotype of 
these mutations which is typical of hereditary pancreatitis and does not indicate increased 
severity or penetrance. Our results demonstrate that D19A, D22G, K23R and K23_I24insIDK 
form a special subset of hereditary pancreatitis-associated mutations characterized by robust 
autoactivation that is largely independent of CTRC and decreased cellular secretion, which is 
inversely proportional to their ability to autoactivate. The combination of these unique properties 
adequately explains the observed clinical effect of these mutations. 
 
RESULTS 
Autoactivation of activation peptide mutants in absence and presence of CTRC. We studied 
four mutations which cause alterations in the conserved region of the activation peptide of 
human cationic trypsinogen, D19A, D22G, K23R and K23_I24insIDK (Figure 1). The A16V 
mutation which affects the N-terminal residue of the activation peptide was characterized in a 
recent study [3]. 
 Autoactivation of human cationic trypsinogen in the presence of 25 nM CTRC resulted in 
a slight increase in the rate accompanied by a marked reduction in final trypsin levels attained 
(Figure 2). The increased rate is due to N-terminal processing of the activation peptide by CTRC, 
whereas the reduced trypsin levels are a consequence of CTRC-dependent trypsinogen 
degradation [3]. Recently, we demonstrated that mutations commonly associated with hereditary 
pancreatitis exert their effect primarily in the presence of CTRC [3]. A typical case is shown for 
the archetypal R122H mutation in Figure 2, which in the absence of CTRC increased 
autoactivation only slightly (1.2-fold). In the presence of CTRC, however, autoactivation of 
wild-type trypsinogen was drastically suppressed, while mutant R122H autoactivated at an 
increased rate and reached high trypsin levels. 
 When mutants D19A, D22G, K23R and K23_I24insIDK were tested under similar 
conditions, a markedly different phenotype became apparent. All four mutations increased the 
rate of trypsinogen autoactivation robustly (3.9-fold, 9.2-fold, 5.7-fold and 17.5-fold, 
respectively) even in the absence of CTRC, in agreement with previous observations [9, 12]. 
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Similarly, in the presence of CTRC, all four mutants autoactivated markedly faster than wild-
type trypsinogen and reached much higher trypsin levels, which then slowly decreased due to 
CTRC-mediated trypsin degradation. Peak trypsin levels correlated with the rate of 
autoactivation and were higher in mutants D22G and K23_I24insIDK versus D19A and K23R. 
Surprisingly, even in the presence of CTRC, activation peptide mutants autoactivated much 
faster than the reference mutant R122H. Thus, the estimated rates of autoactivation were 
approximately 3-fold higher for mutants D19A and K23R and 10-fold higher for mutants D22G 
and K23_I24insIDK, relative to mutant R122H. 
 
Cleavage of the Leu81-Glu82 peptide bond by CTRC in activation peptide mutants. 
Because the activation peptide is not in the proximity of the calcium binding loop, mutations 
D19A, D22G, K23R and K23_I24insIDK are unlikely to affect CTRC-mediated trypsinogen 
degradation. We tested this assumption experimentally and found that cleavage of the Leu81-
Glu82 peptide bond by CTRC was unchanged in the activation peptide mutants compared to 
wild-type cationic trypsinogen (Figure 3). 
 
N-terminal processing of activation peptide mutants by CTRC. CTRC cleaves the Phe18-
Asp19 peptide bond in the trypsinogen activation peptide and removes three amino acids from 
the N terminus (Figure 1) [5]. This, in turn, results in increased autoactivation of cationic 
trypsinogen. The N-terminal truncation of the activation peptide is readily detectable by non-
reducing SDS-PAGE as a small mobility shift. To assess whether the activation peptide 
mutations altered CTRC-mediated N-terminal processing, we incubated wild-type and mutant 
trypsinogens with 50 nM CTRC at pH 8.0, in 1 mM CaCl2, to minimize cleavage after Leu81. To 
prevent autoactivation during the incubation, we used an inactive trypsinogen background in 
which the catalytic Ser200 was changed to Ala (S200A). Figure 4A and B demonstrate that 
mutant D19A exhibited 4-fold increased N-terminal processing, whereas mutants D22G, K23R 
and K23_I24insIDK were processed at rates comparable with wild type. Inspection of the early 
time points of the autoactivation curves in the presence of CTRC (see Figure 2, compare black 
with white symbols) reveals that N-terminal processing by CTRC increased the rate of 
autoactivation for mutants D19A, D22G and K23R. Surprisingly, the enhanced processing of 
mutant D19A did not translate to a more robust autoactivation increase than seen in mutants 
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D22G or K23R (see Figure 2). Similarly, even though mutant K23_I24insIDK was processed 
normally, this modification had no impact on autoactivation. 
CTRC-mediated cleavage of the Phe18-Asp19 peptide bond in the trypsinogen activation peptide 
is highly specific and other human chymotrypsins (CTRB1, CTRB2, CTRL1) and elastases 
(ELA2A, ELA3A, ELA3B) do not catalyze this reaction (Figure 4C). We considered the 
possibility that activation peptide mutations might allow for cleavages by proteases other than 
CTRC, however, this was not the case. None of the mutant activation peptides was cleaved by 
any of the chymotrypsins or elastases tested in Figure 4C (data not shown). 
 
Effect of activation peptide mutations on calcium binding. To determine the effect of the 
activation peptide mutations on the calcium binding affinity of the activation peptide, we 
measured the rate of N-terminal processing by CTRC as a function of increasing calcium 
concentrations. For these experiments we used trypsinogen constructs carrying the L81A and 
S200A mutations to prevent unwanted cleavage at Leu81 by CTRC and to avoid trypsinogen 
autoactivation during incubations. As shown in Figure 5, calcium inhibited cleavage of the 
Phe18-Asp19 peptide bond by CTRC in wild-type cationic trypsinogen with a KD value around 
1.9 mM. Calcium dependence of N-terminal processing by CTRC was comparable for the 
activation peptide mutants (Figure 5B). The calculated KD values for mutants D19A, D22G, 
K23R and K23_I24insIDK were 1.1 mM, 1.3 mM, 2.6 mM and 1.3 mM, respectively. Inspection 
of Figure 5B suggests that these values fall within the experimental error of the method. When 
the entire dataset including wild-type and mutants was fitted with a single curve a KD of 1.6±0.2 
mM was obtained. We conclude that calcium binding to the activation peptide is not affected by 
the activation peptide mutations. 
 
Effect of calcium on autoactivation of activation peptide mutants. Calcium binding to the 
tetra-aspartate motif in the trypsinogen activation peptide stimulates autoactivation [14, 15]. 
Even though the activation peptide mutants appear to bind calcium normally, the effect of 
calcium on autoactivation may be altered. When autoactivation of wild-type and mutant 
trypsinogens was measured in the presence of 0, 1, 5 and 10 mM calcium, wild-type trypsinogen 
and mutants D19A and K23R were stimulated in a concentration dependent manner, whereas 
autoactivation of mutants D22G and K23_I24insIDK was insensitive to calcium (Figure 6). 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Although the half-maximal stimulatory calcium concentration was difficult to determine due to 
the confounding effect of degradation in the absence of calcium, it appeared that calcium 
dependence of autoactivation of wild-type, D19A and K23R trypsinogens was consistent with 
the KD values obtained for binding of calcium to the activation peptide. The effect of calcium on 
the autoactivation of mutant D19A seemed to saturate at a lower concentration when compared 
to mutant K23R, which might reflect a true but small difference in binding affinity (see KD 
values above). The observations indicate that activation peptide mutations do not affect binding 
of calcium to the activation peptide but may diminish the functional effect of calcium binding. 
 
Secretion of activation peptide mutants from transfected 293T cells. The biochemical 
properties of the activation peptide mutants described so far suggest that these mutations should 
be associated with a more severe clinical phenotype than mutation R122H. However, this is not 
the case. Previously, we found that secretion of activation peptide mutants from transfected cells 
was reduced, although the four mutants have never been studied in a comparative manner within 
the same experiment [12, 13]. We also demonstrated that the secretion loss was related to 
intracellular autoactivation and degradation [13]. To establish whether this secretion defect might 
be a mechanism that partly offsets the drastically increased autoactivation, we quantified 
secretion of wild-type and mutant trypsinogens from transiently transfected human embryonic 
kidney (HEK) 293T cells. The use of HEK 293T cells for cellular secretion studies is a 
compromise, as efficient transfection of pancreatic acinar cells is not feasible. For these 
experiments we used a short time course (12 h) to prevent autoactivation in the medium and 
consequent trypsinization of the cells. We measured trypsin activity in the conditioned media 
after enteropeptidase-mediated activation (Figure 7A) and trypsinogen levels by western blotting 
(Figure 7B). We found that the activation peptide mutants were secreted at significantly lower 
levels than wild-type trypsinogen, in agreement with previous observations [12, 13]. Importantly, 
secretion rates for the mutants were inversely proportional with their ability to autoactivate 
(D19A > K23R > D22G § K23_I24insIDK). 
 
DISCUSSION 
The primary objective of the present study was to investigate the effect of CTRC on the 
autoactivation of trypsinogen activation peptide mutants D19A, D22G, K23R and 
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K23_I24insIDK found in hereditary pancreatitis. Previously, we demonstrated that wild-type 
cationic trypsinogen is largely degraded by CTRC during autoactivation, whereas hereditary 
pancreatitis associated mutants N29I, N29T, V39A, R122C and R122H exhibited resistance to 
CTRC-mediated degradation and autoactivated to higher trypsin levels [3]. In addition, we found 
that mutations A16V and N29I increased CTRC-mediated cleavage of the activation peptide, and 
thereby accelerated autoactivation (see Figure 1) [3, 5]. We speculated that activation peptide 
mutants might also affect processing of the activation peptide by CTRC and/or alter the effect of 
this cleavage, perhaps even resulting in decreased autoactivation. This would then offer an 
explanation for the puzzling observation that the robust autoactivation of activation peptide 
mutants is not accompanied by a more severe clinical picture. 
 
 Our results confirmed that even in the absence of CTRC activation peptide mutants 
autoactivated at markedly increased rates (~4-18-fold) [9, 12]. In the presence of CTRC, 
activation rates were further increased slightly (D19A, D22G, K23R) or remained unchanged 
(K23_I24insIDK), indicating that the robust autoactivation of the activation peptide mutants is 
mostly independent of CTRC. Peak trypsin levels attained during autoactivation positively 
correlated with the rate of autoactivation, indicating that faster conversion of trypsinogen to 
trypsin results in higher trypsin levels, as trypsin is less sensitive to CTRC-mediated degradation 
than trypsinogen. As expected, the mutations had no effect on CTRC cleavage of the Leu81-
Glu82 peptide bond in the calcium binding loop and consequent trypsinogen degradation. 
Importantly, when compared to the most common pancreatitis-associated mutant R122H, in the 
presence of CTRC the activation peptide mutants still exhibited much higher rates of 
autoactivation (~3-10-fold). 
 
 N-terminal processing of the activation peptide at Phe18 by CTRC was unchanged in 
mutants D22G, K23R and K23_I24insIDK, whereas mutant D19A was processed at 4-fold 
increased rate. This finding is consistent with recent mutagenesis studies in the calcium binding 
loop of cationic trypsinogen, which demonstrated that mutation of Glu82 to Ala increased 
cleavage after Leu81 about 3-fold, indicating that acidic residues at the P1' position hinder 
cleavage by CTRC [16]. Surprisingly, however, the increased processing of mutant D19A was 
paralleled only with a slight increase in the rate of autoactivation, suggesting that Asp19 is 
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important for mediating the functional effect of N-terminal processing. Thus, shortening the 
activation peptide by CTRC may increase autoactivation by partly relieving the inhibitory 
interaction between Asp218 and Asp19 [5, 7]. This effect is probably due to neutralization of the 
negative charge on Asp19 by the newly created proximity of the positively charged amino 
terminus. Similarly, mutation D19A would increase autoactivation by neutralizing Asp19 but at 
the same time it would diminish the effect of N-terminal processing by CTRC. This notion is 
supported by the observations that the extent of the autoactivation increase either by CTRC 
processing or by mutation D19A is comparable, approximately 3-4-fold [5, 9]. The stimulatory 
effect of CTRC cleavage on autoactivation was also abolished in mutant K23_I24insIDK, which 
may be readily explained by sterical uncoupling of the original tetra-Asp motif from the 
activation site by the three-amino-acid insertion (see Figure 1). Furthermore, previous 
experiments indicated that trypsin-mediated activation (i.e. autoactivation) of the 
K23_I24insIDK mutant most likely proceeds by sequential cleavage of the two lysyl peptide 
bonds found in the mutated activation peptide [12]. In this case, cleavage of the N-terminal Lys-
Ile peptide bond would eliminate the N-terminal eight amino acids together with any effect of 
CTRC-dependent processing (see Figure 1). 
 
 Calcium in millimolar concentrations stimulates autoactivation presumably by binding to 
the activation peptide and shielding the inhibitory negative charges of the tetra-Asp motif [14, 
15]. Using the CTRC-dependent processing of the activation peptide as readout, we determined 
the calcium binding affinity of wild-type and mutant activation peptides (see Figure 5). 
Unexpectedly, mutant and wild-type trypsinogens bound calcium at the activation peptide with 
comparable affinities, 1.6 mM on average. This observation suggests that calcium probably 
engages only two or three Asp side chains and elimination of one of the four Asp residues either 
by mutation D19A or D22G is tolerated. When the functional effect of calcium binding was 
investigated, however, we found that autoactivation of mutants D22G and K23_I24insIDK were 
insensitive to calcium. The results seem to lend some credence to the speculation that the 
stimulatory effect calcium on autoactivation is mediated through binding to Asp22 and 
neutralizing its negative charge. During autoactivation, Asp22 in the activation peptide binds to 
the S2 subsite on trypsin, a conserved hydrophobic pocket formed by His63, Leu104 and 
Trp216, and this unfavorable interaction may be alleviated by calcium. In the K23_I24insIDK 
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mutant, calcium likely binds only to the original tetra-Asp motif, which is now further removed 
from the activation peptide bond. The Asp-Lys-Ile-Asp sequence preceding the activation site 
does not seem competent to bind calcium. Furthermore, as pointed out above, during 
autoactivation the N-terminal eight amino acids are removed before cleavage at the activation 
peptide bond takes place (see Figure 1) [12]. Alternatively, another plausible interpretation for 
the data may be that for wild-type trypsinogen and mutants D19A and K23R the rate limiting 
step in the autoactivation reaction is calcium dependent, whereas for the rapidly autoactivating 
mutants D22G and K23_I24insIDK a calcium-insensitive step becomes rate determining. 
 
 The biochemical properties of the trypsinogen activation peptide mutants do not explain 
why the markedly increased autoactivation is not associated with a more severe clinical 
presentation of hereditary pancreatitis; i.e. with complete penetrance and earlier onset. Typical 
penetrance of hereditary pancreatitis in families with the R122H mutation is 70-90% and the 
median age of onset is 12 years with wide individual variability [1, 17]. Although clinical data 
for the rare activation peptide mutations is relatively scant, mutation D22G was also identified in 
the unaffected 20 year old sister of the index patient, indicating incomplete penetrance [10]. 
Published ages of diagnosis indicated both early onset (D22G 8 y, K23_I24insIDK 2 y) and late 
onset cases (D19A 17 y, K23_I24insIDK 21 y), consistent with typical hereditary pancreatitis [9, 
10, 12]. Previously, we observed that secretion of activation peptide mutants was compromised 
from transfected cells due to intracellular autoactivation and ensuing degradation [12, 13]. We 
extended these studies here and quantitatively compared, for the first time, cellular secretion of 
all four activation peptide mutants to determine whether reduced secretion could offset the effect 
of increased autoactivation. Indeed, we confirmed not only that all four activation peptide 
mutants were secreted to lower levels than wild-type trypsinogen, but also that secretion rates 
inversely correlated with the rates of autoactivation. Our observations indicate that nature 
carefully titrated trypsinogen secretion against autoactivation propensity, to curb the risk for 
excessive pathological intra-pancreatic trypsinogen activation in carriers of the activation peptide 
mutations. 
 In summary, our results define the trypsinogen activation peptide mutations D19A, 
D22G, K23R and K23_I24insIDK as a special subset of hereditary-pancreatitis associated 
mutations which stimulate autoactivation largely independently of CTRC and this robust effect is 
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compensated by their reduced secretion. Taken together with previous studies, the observations 
indicate that human cationic trypsinogen mutations may increase autoactivation by several 
independent but not mutually exclusive mechanisms in hereditary pancreatitis (Figure 8): (i) 
increased secretion, as suggested for copy number mutations [18, 19]; (ii) resistance to CTRC-
mediated degradation [3, 4]; (iii) increased processing of the activation peptide by CTRC [3, 5] 
and (iv) direct stimulation of autoactivation, as demonstrated here for the activation peptide 
mutations.  
 
EXPERIMENTAL PROCEDURES 
 Nomenclature. Amino-acid residues in human cationic trypsinogen were numbered 
starting with the initiator methionine of the primary translation product, in accordance with the 
recommendations of the Human Genome Variation Society. 
 Plasmid construction and mutagenesis. The pTrapT7 intein-PRSS1, pcDNA3.1(-) 
PRSS1 and other expression plasmids harboring the coding DNA for human pancreatic digestive 
proteases have been described previously. [4, 5, 20, 21]. To increase expression levels in 
transfected HEK 293T cells, the trypsinogen activation peptide mutations were transferred to the 
pcDNA3.1(-) K237D/N241D background [22]. Mutations in human cationic trypsinogen were 
generated by PCR mutagenesis, cloned into the expression plasmids and verified by DNA 
sequencing. 
 Expression and purification of protease zymogens. Wild-type and mutant trypsinogens 
were expressed in the aminopeptidase P deficient LG-3 E. coli strain as fusions with a self-
splicing mini-intein, as described in [20, 23]. This expression system produces recombinant 
trypsinogen with uniform, authentic N termini. Refolding and purification of trypsinogen by 
ecotin affinity chromatography was carried out as reported previously [23] with the following 
modification. To stabilize trypsinogens against autoactivation, the elution solution contained 50 
mM HCl and 100 mM NaCl. Concentrations of trypsinogen preparations were determined from 
the UV absorbance at 280 nm using the extinction coefficient 37,525 M-1 cm-1. 
 Expression in E. coli, in vitro refolding and purification of human proelastase ELA2A 
was performed as described previously [21]. Histidine-tagged forms of human 
chymotrypsinogens CTRB1, CTRB2, CTRC and CTRL1 and proelastases ELA3A and ELA3B 
were expressed in HEK 293T cells and purified from the conditioned medium using nickel-
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affinity chromatography, as reported previously [3, 16]. ELA2A was activated using 10 nM 
human anionic trypsin [21] and other proteases were activated with immobilized bovine trypsin 
(Pierce/Thermo Fisher Scientific, Rockford, IL) in 0.1 M Tris-HCl (pH 8.0) and 0.05% Tween 
20 (final concentrations) and the trypsin beads were removed by centrifugation. Active protease 
concentrations were determined by active site titration with ecotin, as described [24]. 
 Trypsinogen autoactivation. Trypsinogen at 1 µM concentration was incubated in the 
absence or presence of 25 nM human CTRC, as indicated, and 10 nM cationic trypsin in 0.1 M 
Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM CaCl2 and 0.05% Tween 20 (final concentrations) at 37 
ºC. At given times, 2 µL aliquots were withdrawn and mixed with 48 µL assay buffer containing 
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20. Trypsin activity was measured by 
adding 150 µL 200 µM N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate (dissolved in 0.1 M Tris-
HCl (pH 8.0), 1 mM CaCl2 and 0.05% Tween 20) and following the release of the yellow p-
nitroanilin at 405 nm in a SpectraMax plus 384 microplate reader (Molecular Devices, 
Sunnyvale, CA) for 1 min. Reaction rates were calculated from fits to the initial linear portions 
of the curves. Note that in the present study all experiments were performed in the presence of 
100 mM NaCl, which resulted in slower autoactivation, compared to previous studies. 
 Cell culture and transfection. HEK 293T cells were cultured and transfected as 
described previously [25]. Transfections were performed using 2 µg expression plasmid and 5 
µL Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 2 mL Dulbecco's Modified Eagle Medium 
(Invitrogen). After overnight incubation, cells were washed and the transfection medium was 
replaced with 1 mL OPTI-MEM I Reduced Serum Medium (Invitrogen). Time courses of 
expression were measured starting from this medium change and were followed for 12 hours. 
Trypsin activity in the conditioned media was measured after enteropeptidase activation, as 
described in [26]. 
 Gel electrophoresis and densitometry. Trypsinogen samples (75 µL of a 2 µM solution, 
corresponding to approximately 3.8 µg protein) were precipitated with trichloroacetic acid (10% 
final concentration), and the precipitate was recovered by centrifugation, dissolved in 20 µL 
Laemmli sample buffer with 100 mM dithiothreitol (final concentration), and heat-denatured at 
95 °C for 5 min. Where non-reducing conditions are indicated, dithiothreitol was omitted from 
the sample buffer. Electrophoretic separation was performed on 15% SDS-polyacrylamide mini 
gels in standard Tris glycine buffer. Gels were stained with Brilliant Blue R-250 and destained as 
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described earlier [15]. Quantitation of bands was carried out with the Quantity One 4.6.9 
software (Bio-Rad, Hercules, CA). 
 Western blot analysis. Aliquots (20 µL) of conditioned media were mixed with sample 
buffer, heat-denatured, electrophoresed on Tris-glycine minigels and transferred onto an 
Immobilon-P membrane (Millipore Corporation, Bedford, MA) at 300 mA for 1.5 h. The 
membrane was blocked with 5% milk powder dissolved in phosphate-buffered saline 
supplemented with 0.1% Tween 20 (final concentration), at 4 °C overnight. Trypsinogen was 
detected with a sheep polyclonal antibody (#AF3848, R&D Systems, Minneapolis, MN) used at 
a dilution of 1:2000 followed by horse-radish peroxidase (HRP)-conjugated donkey polyclonal 
anti-sheep IgG (#HAF016, R&D Systems) used at 1:2000 dilution, as described previously [26]. 
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Figure 1. Pancreatitis-associated mutations in the activation peptide of human cationic 
trypsinogen. Proteolytic cleavage sites for trypsin and chymotrypsin C (CTRC) and the putative 
Ca2+ binding site are also indicated. See text for details. Note that the N-terminal amino-acid of 
mature trypsinogen is Ala16, as the 15 amino-acid long secretory signal peptide is removed in 
the endoplasmic reticulum. Properties of the A16V mutant were published recently and it was 
not included in the present study [3, 5]. 
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Figure 2. Autoactivation of human cationic trypsinogen and activation peptide mutants in the 
absence and presence of chymotrypsin C (CTRC). For comparison, mutant R122H was also 
included. Wild-type (circles) and mutant (squares) trypsinogen were incubated at 1 µM with 10 
nM initial trypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, 100 mM NaCl and 0.05% Tween 20, 
at 37 °C, in the absence (empty symbols) or presence (solid symbols) of 25 nM CTRC (final 
concentrations). Aliquots (2 µL) were withdrawn at the indicated times and trypsin activity was 
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determined as described in Experimental Procedures. Trypsin activity was expressed as 
percentage of the maximal activity in the absence of CTRC. Representative experiments from 
two or three replicates are shown. Mutant K23_I24insIDK is denoted as insIDK. 
 
 
 
Figure 3. Cleavage of the Leu81-Glu82 peptide bond in human cationic trypsinogen and 
activation peptide mutants by chymotrypsin C (CTRC). Wild-type and mutant trypsinogen were 
incubated at 2 µM with 20 nM CTRC in 0.1 M Tris-HCl (pH 8.0) (final concentrations), at 37 
°C. Trypsinogens contained the S200A mutation to prevent autoactivation. A, At the indicated 
times reactions were terminated by precipitation of 75 µL aliquots (~3.8 µg protein) with 10% 
trichloroacetic acid (final concentration) and analyzed by 15% reducing SDS-PAGE and 
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Coomassie Blue staining. Representative gels of two or three experiments are shown. B, 
Densitometric analysis of stained gels showing the changes in the intensity of the unprocessed, 
intact trypsinogen band. Error bars were omitted for clarity, the error was within 10% of the 
mean. Mutant K23_I24insIDK is denoted as insIDK. 
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Figure 4. N-terminal processing of human cationic trypsinogen and activation peptide mutants 
by chymotrypsin C (CTRC). A, Wild-type and mutant trypsinogen were incubated at 2 µM with 
50 nM CTRC in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2 and 100 mM NaCl (final 
concentrations), at 37 °C. Trypsinogens contained the S200A mutation to prevent autoactivation. 
At the indicated times reactions were terminated by precipitation of 75 µL aliquots (~3.8 µg 
protein) with 10% trichloroacetic acid (final concentration) and samples were analyzed by 15% 
non-reducing SDS-PAGE and Coomassie Blue staining. Relevant segments of representative 
gels demonstrate the small mobility shift of the trypsinogen band caused by CTRC-mediated 
cleavage of the activation peptide (see Figure 1). B, Densitometric analysis of stained gels 
showing the changes in the intensity of the unprocessed, intact trypsinogen band as percent of the 
total intensity of the processed and unprocessed bands. C, N-terminal processing of the 
activation peptide is specific for CTRC. Wild-type and mutant trypsinogen were incubated with 
50 nM of the indicated human pancreatic chymotrypsins and elastases and reactions were 
analyzed as described above. For clarity, only the wild-type dataset is shown; none of the 
mutants was cleaved by any of the proteases tested. Mutant K23_I24insIDK is denoted as 
insIDK. 
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Figure 5. Effect of calcium on the N-terminal processing of the trypsinogen activation peptide 
by chymotrypsin C (CTRC). A, Wild-type and mutant trypsinogen were incubated at 2 µM with 
50 nM CTRC in 0.1 M Tris-HCl (pH 8.0) and 100 mM NaCl in the absence or presence of CaCl2 
(Ca2+) at the indicated concentrations, at 37 °C. Trypsinogens contained the S200A mutation to 
prevent autoactivation and the L81A mutation to prevent CTRC cleavage after Leu81 in the 
absence of calcium. At the indicated times reactions were terminated and analyzed as described 
in Figure 4A. As an example, the relevant gel segments for wild type are shown. Similar gel sets 
were generated for all mutants and used to determine reaction rates, as described below. B, 
Densitometric analysis was performed as given in Figure 4B. Rates of processing were 
calculated from linear fits to semilogarithmic graphs and plotted as a function of the calcium 
concentration with errors of the fits shown. The equilibrium binding constants (KD) for calcium 
were calculated from fits to the y = y(min)+[y(max)-y(min)] / 1+[Ca2+]/KD equation where y is 
the measured reaction rate, y(max) is the maximal reaction rate in the absence of calcium and 
y(min) is the residual reaction rate under fully saturating calcium concentrations. The error of the 
fits is also indicated. Mutant K23_I24insIDK is denoted as insIDK. 
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Figure 6. Effect of calcium on the autoactivation of human cationic trypsinogen and activation 
peptide mutants. Wild-type and mutant trypsinogen were incubated at 1 µM with 10 nM initial 
trypsin in 0.1 M Tris-HCl (pH 8.0), 100 mM NaCl, and 0.05% Tween 20, at 37 °C, in the 
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absence or presence of CaCl2 (Ca2+) at the indicated concentrations. At given times 2 µL aliquots 
were removed and trypsin activity was determined as described in Experimental Procedures. 
Trypsin activity was expressed as percentage of the maximal activity in the presence of 10 mM 
CaCl2. Representative experiments from two or three replicates are shown. Mutant 
K23_I24insIDK is denoted as insIDK. 
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Figure 7. Secretion of human cationic trypsinogen and activation peptide mutants from 
transiently transfected HEK 293T cells. Trypsinogen expression constructs contained the K237D 
and N241D mutations which improve secretion from transfected cells [22]. A, At 4, 8 and 12 
hours after transfection conditioned media were collected and trypsin activity was measured as 
described under Experimental Procedures. Trypsin activity was expressed as percent of the 12 h 
wild-type activity. The average of three independent transfection experiments with standard 
deviation is shown. B, Aliquots (20 ȝL) of conditioned media collected at 12 h were 
electrophoresed on 15% SDS-polyacrylamide gels and analyzed by western blotting, as 
described in Experimental Procedures. A representative blot of three is shown. Mutant 
K23_I24insIDK is denoted as insIDK. 
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Figure 8. Mechanisms of increased autoactivation in hereditary pancreatitis associated with 
human cationic trypsinogen mutations. Copy number mutations (CNM) increase trypsinogen 
expression. Mutations N29I, N29T, V39A, R122C and R122H inhibit CTRC-dependent 
trypsinogen degradation. Mutations A16V and N29I stimulate N-terminal processing of the 
trypsinogen activation peptide by CTRC. Activation peptide mutations D19A, D22G, K23R and 
K23_I24insIDK directly stimulate autoactivation. A prominent example for each mechanism is 
indicated. See text for details. 
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Intragenic Duplication
A Novel Mutational Mechanism in Hereditary Pancreatitis
Maiken T. Joergensen, MD, PhD,* Andrea Geisz, MS,Þ Klaus Brusgaard, MS, PhD,þ
Ove B. Schaffalitzky de Muckadell, MD, DMSci,* Pe´ter Hegyi, MD, PhD,§
Anne-Marie Gerdes, MD, PhD,þ and Miklo´s Sahin-To´th, MD, PhDÞ
Objectives: In a hereditary pancreatitis family from Denmark, we
identified a novel intragenic duplication of 9 nucleotides in exon-2 of
the human cationic trypsinogen (PRSS1) gene (c.63_71dup) which at the
amino-acid level resulted in the insertion of 3 amino acids within the
activation peptide of cationic trypsinogen (p.K23_I24insIDK). The aim
of the present study was to characterize the effect of this unique genetic
alteration on the function of human cationic trypsinogen.
Methods: Wild-type and mutant cationic trypsinogens were produced
recombinantly and purified to homogeneity. Trypsinogen activation was
followed by enzymatic assays and sodium dodecyl sulfateYpolyacrylamide
gel electrophoresis. Trypsinogen secretion was measured from transfected
HEK 293T cells.
Results: Recombinant cationic trypsinogen carrying the p.K23_
I24insIDK mutation exhibited greater than 10-fold increased autoactiva-
tion. Activation by human cathepsin B also was accelerated by 10-fold.
Secretion of the p.K23_I24insIDK mutant from transfected cells was
diminished, consistent with intracellular autoactivation.
Conclusions: This is the first report of an intragenic duplication within
the PRSS1 gene causing hereditary pancreatitis. The accelerated acti-
vation of p.K23_I24insIDK by cathepsin B is a unique biochemical
property not found in any other pancreatitis-associated trypsinogen
mutant. In contrast, the robust autoactivation of the novel mutant
confirms the notion that increased autoactivation is a disease-relevant
mechanism in hereditary pancreatitis.
Key Words: hereditary pancreatitis, human cationic trypsinogen,
PRSS1, intragenic duplication, autoactivation, cathepsin B,
enteropeptidase
(Pancreas 2011;40: 540Y546)
Hereditary chronic pancreatitis is an autosomal dominantgenetic disorder characterized by incomplete penetrance and
variable expressivity.1Y6 Heterozygous mutations in the serine
protease 1 (PRSS1) gene have been identified as causative ge-
netic changes in 25% to 80% of cases in different studies. The
PRSS1 gene encodes human cationic trypsinogen, the most
abundant digestive proenzyme in human pancreatic secretions.
Approximately 70% of the mutation positive hereditary pan-
creatitis families carry the p.R122H mutation and approximately
20% the p.N29I mutation. In the remaining 10% of families, at
least 10 different, relatively rare mutations have been identified,
including a subset of mutations affecting the trypsinogen ac-
tivation peptide (p.A16V, p.D19A, p.D22G, and p.K23R)
(reviewed in 7). The literature also reports 23 additional rare
PRSS1 variants, which have been found in patients with chronic
pancreatitis; however, their pathogenic significance, if any,
remains unknown (reviewed in 7). Functional characterization of
pancreatitis-associated PRSS1 mutants revealed that increased
trypsinogen autoactivation (trypsin-mediated trypsinogen acti-
vation) is a common phenotypic alteration at the protein level
(see 1Y8 and references therein). The increased propensity for
autoactivation was especially notable in the activation peptide
mutants.9 More recent studies demonstrated that increased
autoactivation of activation peptide mutants can occur intracel-
lularly and result in decreased trypsinogen secretion and apo-
ptotic acinar cell death.10
Although the vast majority of hereditary pancreatitis cases
are caused by missense point mutations, other genetic mecha-
nisms also have been recognized as potentially disease relevant.
Mutation p.R122H is rarely caused by a dinucleotide change,
possibly through a gene-conversion mechanism.11,12 Gene con-
version and duplication also can create functional hybrid tryp-
sinogen genes carrying the p.N29I mutation.13,14 Finally,
duplication and triplication of the trypsinogen locus was de-
scribed to result in hereditary pancreatitis in all likelihood
because of a gene dosage effect.14Y17 In the present study, we
report a novel mutational mechanism in a hereditary pancre-
atitis family from Denmark. We found that intragenic dupli-
cation of a 9 nucleotide sequence in exon-2 resulted in a
3Yamino acid insertion in the trypsinogen activation peptide
that dramatically altered the activation properties of human
cationic trypsinogen.
MATERIALS AND METHODS
Materials
Human recombinant cathepsin B was a generous gift from
Paul M. Steed (Research Department, Novartis Pharmaceuticals,
Summit, NJ). Before use, cathepsin B was activated with 90 mM
dithiothreitol (final concentration) for 30 minutes on ice. The N-
benzyloxycarbonyl-Gly-Pro-Arg-p-nitroanilide trypsin substrate
was from Sigma-Aldrich (St Louis, Mo). Recombinant human
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pro-enteropeptidase (holoenzyme) was from R & D Systems
(Minneapolis, Minn). Human pro-enteropeptidase (at 0.07 mg/mL,
È640 nM concentration) was activated with 50 nM human
cationic trypsin in 0.1 M Tris-HCl (pH 8.0), 10 mM CaCl2, and
2 mg/mL bovine serum albumin (final concentrations) for
30 minutes at room temperature. Ecotin was expressed and
purified as reported previously.18Y20 Cell culture media and
reagents were obtained from Invitrogen (Carlsbad, Calif ).
Patients
This study was approved by the Scientific Ethics Commit-
tee and the Danish Data Protection Agency. The family received
genetic counseling before they gave their informed consent to
participate in the study. A questionnaire recording symptoms,
clinical tests, and medical history was completed. A blood
sample was drawn from the index patient, his brother, and his
father into tubes with EDTA and stored at Y20-C. After dis-
covery of the mutation, the grandparents and the siblings of the
father also were tested.
Nomenclature
Nucleotide numbering reflects coding DNA numbering
with +1 corresponding to the A of the ATG translation initiation
codon in the reference sequence. Amino acid residues are
numbered starting with Met1 of human cationic pretrypsinogen.
The first amino acid of cationic trypsinogen is Ala16.
Genetic Analyses
Genomic DNA was extracted from full blood using the
Maxwell DNA purification robot (Promega, Ramcon, Denmark).
The samples were tested for small deletions, insertions, and
point mutations in all exons and the exon-intron boundaries of
the PRSS1 (GenBank NM_002769.3) and SPINK1 (GenBank
NM_003122.3) genes using DHPLC (WAVE 3500HT High
Sensitivity System; Transgenomic Inc, Elancourt, France).
Samples with deviating chromatographic profiles were se-
quenced in both directions using the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Carlsbad, Calif ) and
analyzed on an automated ABI PRISM 3100 (Applied Biosys-
tems). The presence of PRSS1 gene duplication or triplication
was excluded using the rapid polymerase chain reactionYbased
method described by Chauvin et al.17
Genomic DNA also was tested for 33 CFTR (GenBank
NM_000492.3) mutations: 394delTT, p.R553X, 621+1G9T,
p.R1162X, 1717-1G9A, 3659delC, p.G542X, 2183A9G,
p.W1282X, 1078delT, 711+1G9T, p.F508del, p.S549N,
I507del, p.S549R, 2184delA, p.G551D, p.G85E, p.N1303K,
p.R560T, p.R117H, p.R347H, p.R347P, p.R334W, 2789+5G9A,
3849+10kbC9T, p.A445E, 3120+1G9A, p.V520F, 1898+
1G9A, 3876delA, 3905insT, and IVS8-5T.
Plasmid Construction and Mutagenesis
The pTrapT7 PRSS1, pTrapT7 PRSS1 p.S200A, and
pcDNA3.1(j) PRSS1 expression plasmids were constructed pre-
viously.21Y24 The p.K23_I24insIDK mutation was generated by
overlap extension polymerase chain reaction mutagenesis and
cloned into the pTrapT7 and pcDNA3.1(j) expression plasmids.
The p.K23_I24insIDK p.S200A and p.D22G p.S200A mutants
were created in the pTrapT7 PRSS1 plasmid by cut and paste
using the NcoI and XhoI restriction sites and the appropriate
parent plasmids.
Expression and Purification of
Cationic Trypsinogen
Wild-type, p.K23_I24insIDK, p.S200A, p.K23_I24insIDK/
p.S200A, and p.D22G/p.S200A cationic trypsinogens were ex-
pressed in Escherichia coli BL21(DE3) as cytoplasmic inclusion
bodies. Refolding and purification of trypsinogen on immobi-
lized ecotin was carried out as reported previously20Y22 with the
following modification. To stabilize the p.K23_I24insIDKmutant
against autoactivation, 100 mM NaCl was included with the
50 mM HCl elution solution during ecotin affinity chromatog-
raphy. Concentrations of trypsinogen solutions were determined
from the UVabsorbance at 280 nm using the extinction coefficient
36,160 Mj1 cmj1 (http://ca.expasy.org/tools/protparam.html).
Trypsin Activity Assay
Trypsin activity was measured with the synthetic chromo-
genic substrate,N-benzyloxycarbonyl-Gly-Pro-Arg-p-nitroanilide
at 0.14 mM final concentration. One-minute time courses of
p-nitroaniline release were followed at 405 nm in 0.1 M Tris-
HCl (pH 8.0) and 1 mM CaCl2 at room temperature using a
Spectramax Plus 384 microplate reader (Molecular Devices,
Sunnyvale, Calif ).
Cell Culture and Transfection
HEK 293T cells were cultured in 6-well tissue culture plates
(106 cells per well) in Dulbecco modified Eagle medium sup-
plemented with 10% fetal bovine serum, 4 mM glutamine, and
1% penicillin/streptomycin at 37-C in 5% CO2. Transfections
were performed using 2 Kg expression plasmid and 10 KL
Lipofectamine 2000 in 2 mL Dulbecco modified Eagle medium.
After overnight incubation at 37-C, cells were washed, and the
transfection medium was replaced with 2 mL OptiMEM reduced
serum medium. Time courses of expression were measured
starting from this medium change and were followed for 48 hours.
Western Blot Analysis
Aliquots of conditioned media (20 KL per lane) were
electrophoresed on Tris-glycine minigels and transferred onto
an Immobilon-P membrane (Millipore, Billerica, Mass). The
membrane was blocked with 5% milk powder solution at 4-C
overnight and incubated with sheep polyclonal antibody against
human cationic trypsinogen (R&D Systems, AF3848) at a di-
lution of 1:2000 for 1 hour at room temperature, followed by
incubation with horseradish peroxidaseYconjugated donkey poly-
clonal antisheep immunoglobulin G (R&D Systems, HAF016),
used at 1:2000 dilution, for 1 hour at room temperature. Horse-
radish peroxidase was detected using the SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, Ill).
RESULTS
A Novel Intragenic Duplication in the PRSS1 Gene
Is Associated With Hereditary Pancreatitis
The index patient is a 2-year-old boy from Denmark who
presented with ascites and a history of recurrent attacks of ab-
dominal pain, diarrhea, and vomiting for 4 months. A preoper-
ative magnetic resonance cholangiopancreatography revealed a
pancreatic fistula as the cause for the ascites and also showed
pancreas divisum, duct irregularities, and multiple cysts in the
pancreatic head and tail. The cauda of the pancreas was resected,
and pancreaticojejunostomy was performed. After resection, the
ascites production ceased, and the patient recovered. The father
of the index patient was diagnosed with chronic pancreatitis
at the age of 21 years, which was initially attributed to a bicycle
accident, which had happened at age 13 years. The father un-
derwent resection of the cauda of the pancreas at the age of
27 years because of repeated attacks of upper abdominal pain.
The index patient’s younger brother also developed abdominal
pain, diarrhea, and elevated blood amylase at the age of 2 years,
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but pancreatic edema was not detected by ultrasonography. The
3 affected members within this family satisfy the formal crite-
ria of autosomal dominant hereditary pancreatitis (Fig. 1A).
Curiously, however, no other case of pancreatitis could be con-
firmed in the rest of the extended family, suggesting that the
causative mutation may have occurred de novo in the father.
This assumption was later confirmed by the genetic studies de-
tailed below. Nonpaternity was excluded by DNA microsatel-
lite analysis (Identifiler kit; Applied Biosystems).
DNA sequence analysis of the PRSS1 gene in the index
patient found no known mutations but showed a yet unreported
duplication in exon-2. As demonstrated by the electrophero-
grams (see Supplementary Figure 1, Supplemental Digital
Content 1, http://links.lww.com/MPA/A38), the forward se-
quencing of exon-2 showed mixed signals starting at nucleotide
position c.72 because of a heterozygous 9-nucleotide insertion.
The inserted sequence is TGACAAGAT, which corresponds
to PRSS1 sequence between c.63 and c.71. Thus, the insertion
represents a short intragenic duplication (c.63_71dup), which
has never been described in trypsinogen genes so far. Se-
quencing of exon-2 with a reverse primer confirmed the du-
plication (see Supplementary Figure 1, Supplemental Digital
Content 1, http://links.lww.com/MPA/A38). No other mutations
were identified in the PRSS1 gene. The previously reported
large-scale trypsinogen duplication and triplication were
excluded.14Y17 The c.63_71dup mutation also was present in the
father and the brother but not in the grandparents or in the
father’s sister and half brother, indicating that the mutation was
de novo created in the father (Fig. 1A). All affected family
members were negative for SPINK1 mutations and a select
panel of CFTR mutations (see ‘‘Materials and Methods’’ sec-
tion). We did not find the c.63_71dup duplication in 200 healthy
controls (400 chromosomes) from the same geographical region.
At the amino acid level, the c.63_71dup mutation creates
an insertion of the Ile-Asp-Lys (IDK) sequence between amino
acids Lys23 and Ile24 (p.K23_I24insIDK) (Fig. 1B). This region
of trypsinogen is the so-called activation peptide, an 8 amino
acid long N-terminal extension that is cleaved off during acti-
vation at the Lys23-Ile24 peptide bond by the physiological
activator enteropeptidase or by the pathological activators tryp-
sin and cathepsin B.
The tetra-Asp motif (Asp19-Asp22) preceding Lys23 is
an important suppressor of trypsin-mediated activation (auto-
activation).23 In the p.K23_I24insIDK mutant, the tetra-Asp
motif before the activating peptide bond is replaced with an
Asp-Lys-Ile-Asp sequence. Previously described mutations that
alter the tetra-Asp motif (p.D19A, p.D22G) were shown to in-
crease autoactivation of cationic trypsinogen, suggesting a sim-
ilar phenotype for the p.K23_I24insIDK mutant as well.9,10,23,25
Activation Characteristics of p.K23_I24insIDK
Mutant Cationic Trypsinogen
To study the effect of the p.K23_I24insIDKmutation on the
activation of cationic trypsinogen, we have generated recombi-
nant versions of wild-type and mutant trypsinogens and purified
them to homogeneity. The mutant trypsinogen preparations were
highly unstable, and spontaneous conversion to trypsin occurred
rapidly, suggesting that the p.K23_I24insIDK mutant exhibits
markedly increased autoactivation. Indeed, when autoactivation
of wild-type and mutant trypsinogens were compared in a
quantitative manner (pH 8.0, 37-C), the mutant autoactivated at
rates that were greater than 10-fold higher relative to wild-type
trypsinogen (Fig. 2A). To better characterize the autoactivation
kinetics, we generated catalytically inactive versions of wild-
type and mutant trypsinogens by mutation of Ser200 to Ala
(p.S200A). The use of the p.S200A-trypsinogens allowed us to
measure exact rates of trypsin-mediated trypsinogen activation
by controlling the trypsin concentration in the reactions. Because
activation of p.S200A-trypsinogen does not result in enzymatic
activity, the activation reactions were followed by the mobility
shift on sodium dodecyl sulfateYpolyacrylamide gel electro-
phoresis (SDS-PAGE). For comparison, in these experiments, we
included the p.D22G mutant as a previously well-characterized
example of the activation peptide mutants.9,10,25 As shown in
Figure 2B, 100 nM human cationic trypsin converted the 2 KM
p.S200A (wild-type) trypsinogen to trypsin at a very slow rate,
and appreciable trypsin levels were seen only after 60-minute
incubation (pH 8.0, 37-C). In contrast, p.K23_I24insIDK/
p.S200A trypsinogen was completely activated to trypsin within
30 minutes, whereas complete conversion of the p.D22G/
p.S200A mutant took approximately 60 minutes. Thus, as
judged from the half-lives of p.S200A trypsinogens, the rate of
trypsin-mediated trypsinogen activation is greater than 10-fold
higher for both the p.K23_I24insIDK and p.D22G mutants,
relative to wild-type trypsinogen. These data are in agreement
with the activity-based assay using catalytically competent
trypsinogens, as shown in Figure 2A for the p.K23_I24insIDK
mutant and published previously for the p.D22G mutant.9
Owing to the robust autoactivation of the p.K23_I24insIDK
mutant, we were unable to measure enteropeptidase-mediated
trypsinogen activation using the catalytically active proteins.
Therefore, we monitored enteropeptidase-mediated activation of
the p.S200A-trypsinogens on SDS-PAGE. Supplementary Figure 2
(Supplemental Digital Content 2, http://links.lww.com/MPA/A40)
demonstrates that activation of the p.K23_I24insIDK and
p.D22G mutants was comparable to that of wild type (pH 8.0,
37-C). The results are in accord with our previous studies show-
ing that the trypsinogen activation peptide plays no significant
role in the recognition of human cationic trypsinogen by human
enteropeptidase.23 This finding is somewhat surprising, as the
FIGURE 1. Association of the c.63_71dup intragenic
duplication in the cationic trypsinogen (PRSS1) gene with
hereditary pancreatitis in a family from Denmark. A, Pedigree
of the study family. Heterozygous carriers of the c.63_71dup
(p.K23_I24insIDK) mutation are indicated. Subjects affected with
chronic pancreatitis are shown by solid black symbols. Crossed
symbols designate deceased subjects. The arrow points to the
index patient. B, Nucleotide and amino acid sequence of the
wild-type and c.63_71dup (p.K23_I24insIDK) mutant cationic
trypsinogen activation peptides. The location of the previously
described pancreatitis-associated PRSS1 mutations within the
activation peptide also is indicated.
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tetra-Asp motif in the trypsinogen activation peptide has been
known as a specific recognition motif for enteropeptidase, at least
in the context of the bovine enzymes.26
The lysosomal cysteine protease cathepsin B has been
recognized as a pathological activator of trypsinogen in acute
models of experimental pancreatitis.27Y30 We tested the effect
of the p.K23_I24insIDK mutation on cathepsin BYmediated
trypsinogen activation at pH 4.0, where autoactivation is
minimal. Remarkably, the mutant was activated by cathepsin
B at a markedly elevated rate, which seemed approximately
FIGURE 2. Effect of the p.K23_I24insIDK mutation on the
activation of human cationic trypsinogen by trypsin
(autoactivation). A, Trypsinogens at 2 KM concentration
were incubated with 40 nM human cationic trypsin (initial
concentration) at 37-C in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2,
and 40 mM NaCl (final concentrations) in 100-KL final volume.
Aliquots (2 KL) were withdrawn at indicated times, and trypsin
activity was determined. Trypsin activity was expressed as
percentage of the maximal activity. The inset shows the first
10 minutes of the time course. B, Trypsinogens carrying the
p.S200A mutation were incubated with 100 nM human cationic
trypsin at 37-C in 0.1 M Tris-HCl (pH 8.0) and 1 mM CaCl2 in
100-KL final volume. At the indicated times, reactions were
precipitated with 10% trichloroacetic acid (final concentration)
and analyzed using 15% SDS-PAGE and Coomassie Blue staining.
The lower molecular weight bands represent double-chain forms
of trypsinogen and trypsin cleaved at the Arg122-Val123 peptide
bond. p.insIDK = p.K23_I24insIDK.
FIGURE 3. Effect of the p.K23_I24insIDK mutation on the
activation of human cationic trypsinogen with cathepsin B. A,
Trypsinogens at 2-KM concentration were activated with human
cathepsin B (37 Kg/mL, È1.3 KM) at 37-C in 0.1 M Na-acetate
buffer (pH 4.0), 1 mM EDTA, and 1 mM dithiothreitol (final
concentrations) in 50-KL final volume. Aliquots (2 KL) were
withdrawn at indicated times, and trypsin activity was determined.
Trypsin activity was expressed as percentage of the maximal
activity. B, Trypsinogens carrying the p.S200A mutation were
activated with human cathepsin B (37 Kg/mL, È1.3 KM;
74 Kg/mL, È2.6 KM for p.D22G) at 37-C in 0.1 M Na-acetate
buffer (pH 4.0) 1 mM K-EDTA, and 1 mM dithiothreitol in 100-KL
final volume. At the indicated times, reactions were precipitated
with 10% trichloroacetic acid (final concentration) and
analyzed using 15% SDS-PAGE and Coomassie Blue staining.
p.insIDK = p.K23_I24insIDK.
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5- to 10-fold higher than that of wild type (Fig. 3A). Using
p.S200A-trypsinogens, we measured the rates of conversion in a
more precise manner and found that the p.K23_I24insIDK
mutant was activated by cathepsin B 10-fold faster than wild-
type cationic trypsinogen (Fig. 3B). As described previously,
mutant p.D22G was resistant to cathepsin BYmediated activa-
tion.10,31 More recently, cathepsin L was shown to degrade
trypsinogen, and active trypsin accumulation during pancreatitis
was attributed not only to cathepsin BYmediated activation but
also to a defect in cathepsin LYmediated degradation.32,33 We
found no change in the degradation of the p.K23_I24insIDK
mutant by cathepsin L (pH 4.0, 37-C) as compared with wild-
type cationic trypsinogen (data not shown).
Cleavage of the Activation Peptide in the
p.K23_I24insIDK Mutant Cationic Trypsinogen
The mutant activation peptide sequence contains 2 Lys-Ile
peptides bonds (Fig. 1B). Although activation of trypsinogen
to trypsin requires proteolysis of the second site, cleavage after
the first Lys may modify the efficiency of the second cleavage.
Therefore, we sought to clarify whether both sites were cleaved.
For these experiments, we used the p.S200A-trypsinogens that
we activated with trypsin (pH 8.0), enteropeptidase (pH 8.0),
and cathepsin B (pH 4.0). The activation reactions were sep-
arated on SDS-PAGE, transferred to polyvinylidine fluoride
membranes, and trypsin bands were subjected to N-terminal
sequence analysis by Edman degradation. To capture cleavage
intermediates, we sequenced trypsin bands early in the reaction
when less than half of the trypsinogen was converted to a tryp-
sin band. We found that trypsin and cathepsin B cleaved only
the second (activating) Lys-Ile peptide bond, whereas enter-
opeptidase cleaved both Lys-Ile peptide bonds with equal effi-
cacy. Cleavage after the first Lys-Ile peptide bond resulted in
an N-terminally truncated trypsinogen, which was eventually
completely cleaved at the second Lys-Ile peptide bond by
enteropeptidase (see Supplementary Figure 3, Supplemental
Digital Content 3, http://links.lww.com/MPA/A41).
Secretion of the p.K23_I24insIDK Mutant From
Transfected Cells
Recently, we demonstrated that activation peptide mutants
that undergo robust autoactivation in the test tube also were
autoactivating inside living cells.10 Intracellular autoactivation
resulted in diminished trypsinogen secretion. To test whether
secretion of the strongly autoactivating p.K23_I24insIDK
mutant would be reduced, we transfected HEK 293T cells with
wild-type and p.K23_I24insIDK mutant cationic trypsinogen
and measured secretion of trypsinogens from the conditioned
medium by activity assays and immunoblot. The transfected
cells exhibited healthy morphology during the time course
studied with no signs of cell death. As shown in Figure 4, mu-
tant p.K23_I24insIDK was secreted to significantly lower levels
than wild-type cationic trypsinogen, suggesting that the
p.K23_I24insIDK mutant suffered intracellular autoactivation.
DISCUSSION
There are a number of important observations in this study
which set it apart from a typical mutation report. This is the first
account of an intragenic duplication within the PRSS1 gene in
association with hereditary pancreatitis. The human trypsinogen
genes are located on chromosome 7q35, intercalated between the
beta T-cell receptor genes, at a locus highly active in recombi-
nation. This organization seems beneficial for the evolution of
trypsinogens that tend to undergo extensive gene-duplication
and gene-loss events during speciation, resulting in distinctive
trypsinogen gene families.9,34 On the other hand, unwanted ge-
netic rearrangements, such as gene conversions, duplications, or
triplications, can result in novel pathogenic alleles in hereditary
pancreatitis.13Y17,34 In contrast to the previously reported large-
scale gene duplications, in our family, the duplication was con-
fined only to a 9-nucleotide segment within exon-2 without any
evidence of more extensive genetic changes.
Interestingly, the duplication was identified only in the fa-
ther and his 2 sons (Fig. 1A), whereas it was absent in the
grandparents or the father’s siblings, indicating that it was de
novo generated in the father. Ours is the second report on cap-
turing a mutational event leading to hereditary pancreatitis.
Simon et al.35 found a de novo p.R122Hmutation in their cohort,
and their subsequent studies indicated that PRSS1 mutations
are characteristically not inherited from a common founder,
even when local clustering of families is observed.36
Intragenic duplications are likely to result in a frame shift
and truncated, nonfunctional protein. In this case, however, the
reading frame was kept, and at the amino acid level, the dupli-
cation generated an insertion within the trypsinogen activation
peptide (Fig. 1B). As expected from this alteration, the activation
properties of cationic trypsinogen have been affected in pro-
found ways. Trypsin-mediated trypsinogen activation (auto-
activation) and cathepsin BYmediated trypsinogen activation
were both increased by an order of magnitude, an effect size
never before seen with the known PRSS1 mutants. With respect
to autoactivation, the p.K23_I24insIDK mutant’s phenotype is
consistent with the reported properties of other PRSS1mutations
FIGURE 4. Secretion of the p.K23_I24insIDK cationic
trypsinogen mutant from transiently transfected HEK 293T cells.
At 8, 24, 32, and 48 hours after transfection, conditioned media
were collected, and 20-KL medium was supplemented with
0.1 M Tris-HCl (pH 8.0) and 1 mM CaCl2 in 50-KL volume,
and trypsinogen was activated with 28 ng/mL human
enteropeptidase for 1 hour at 37-C. Trypsin activity was then
measured by adding 150 KL of the chromogenic substrate,
N-benzyloxycarbonyl-Gly-Pro-Arg-p-nitroanilide, to 0.14-mM
final concentration. Trypsin activities were expressed as
percentage of the 48-hour wild-type activity. The average of
2 independent transfection experiments is shown. For clarity,
the error bars have been omitted; the SEM was within 15%.
Inset: 8 hours after transfection, 20-KL aliquots of conditioned
media were electrophoresed on 15% SDS-PAGE and analyzed
using Western blotting as described in the ‘‘Materials and
Methods’’ section.
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affecting the activation peptide (p.D19A, p.D22G, and p.K23R),
which all result in markedly increased autoactivation.9,10,23,25
Mechanistically, the increased autoactivation of p.K23_
I24insIDK is explained by the disruption of inhibitory inter-
actions between the negatively charged tetra-Asp motif in the
activation peptide and trypsin.23 In the p.K23_I24insIDK mu-
tant, Asp21 is replaced with a hydrophobic Ile residue, and
Asp20 is replaced with a positively charged Lys (Fig. 1B). A
recent study found that, at the cellular level, increased auto-
activation results in diminished trypsinogen secretion and
eventual apoptotic death of acinar cells.10 We confirmed using
HEK 293T cells that the p.K23_I24insIDK mutant was secreted
at markedly reduced rates, indicating that it also undergoes
autoactivation inside living cells.
Cathepsin B has long been known as a pathological acti-
vator of trypsinogen in experimental models of acute pancrea-
titis, cerulein-induced pancreatitis in particular.27Y30 The effect
of hereditary pancreatitis-associated mutations on cathepsin
BYmediated trypsinogen activation has been studied in detail
previously. Mutants p.D19A, p.N29I, p.N29T, p.E79K, and
p.R122H exhibited unchanged activation characteristics,
whereas mutant p.K23R was activated slowly, and mutant
p.D22G was resistant to activation by cathepsin B.10,29,31,37
Mutant p.K23_I24insIDK is the first cationic trypsinogen var-
iant that exhibits increased sensitivity to cathepsin BYmediated
activation and thus stands in contrast with all other PRSS1
mutants studied to date. We believe that this property is related
to the longer activation peptide that allows extended contacts
with the activating enzyme.
In summary, we identified a unique intragenic duplication
within exon-2 of the PRSS1 gene (c.63_71dup) in a hereditary
pancreatitis family from Denmark. The duplication results in
the p.K23_I24insIDK insertional mutation within the activation
peptide of cationic trypsinogen. Activation of the p.K23_
I24insIDK mutant by trypsin (autoactivation) or by cathepsin B
is markedly increased, confirming the significance of the trypsin-
dependent pathological pathway in hereditary pancreatitis.
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Trypsin Reduces Pancreatic Ductal Bicarbonate Secretion by Inhibiting
CFTR Cl! Channels and Luminal Anion Exchangers
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BACKGROUND & AIMS: The effects of trypsin on pan-
creatic ductal epithelial cells (PDECs) vary among species
and depend on the localization of proteinase-activated
receptor 2 (PAR-2). We compared PAR-2 localization in
human and guinea-pig PDECs, and used isolated guinea
pig ducts to study the effects of trypsin and a PAR-2
agonist on bicarbonate secretion. METHODS: PAR-2 lo-
calization was analyzed by immunohistochemistry in
guinea pig and human pancreatic tissue samples (from 15
patients with chronic pancreatitis and 15 without pancre-
atic disease). Functionally, guinea pig PDECs were studied
by microperfusion of isolated ducts, measurements of
intracellular pH and intracellular Ca2! concentration, and
patch clamp analysis. The effect of pH on trypsinogen
autoactivation was assessed using recombinant human
cationic trypsinogen. RESULTS: PAR-2 localized to the
apical membrane of human and guinea pig PDECs. Tryp-
sin increased intracellular Ca2! concentration and intra-
cellular pH and inhibited secretion of bicarbonate by the
luminal anion exchanger and the cystic fibrosis trans-
membrane conductance regulator (CFTR) Cl" channel.
Autoactivation of human cationic trypsinogen accelerated
when the pH was reduced from 8.5 to 6.0. PAR-2 expres-
sion was strongly down-regulated, at transcriptional and
protein levels, in the ducts of patients with chronic pan-
creatitis, consistent with increased activity of intraductal
trypsin. Importantly, in PAR-2 knockout mice, the effects
of trypsin were markedly reduced. CONCLUSIONS:
Trypsin reduces pancreatic ductal bicarbonate secre-
tion via PAR-2–dependent inhibition of the apical
anion exchanger and the CFTR Cl! channel. This
could contribute to the development of chronic pan-
creatitis by decreasing luminal pH and promoting
premature activation of trypsinogen in the pancreatic
ducts.
Keywords: Acinar Cells; Ductal Epithelium; Animal Model;
Pancreatic Enzymes.
Trypsinogen is the most abundant digestive proteasein the pancreas. Under physiologic conditions,
trypsinogen is synthesized and secreted by acinar cells,
transferred to the duodenum via the pancreatic ducts, and
then activated by enteropeptidase in the small intestine.1
There is substantial evidence that early intra-acinar2,3 or
luminal4,5 activation of trypsinogen to trypsin is a key and
common event in the development of acute and chronic
pancreatitis. Importantly, almost all forms of acute pan-
creatitis are due to autodigestion of the gland by pancre-
atic enzymes.6
Several studies have shown that trypsin stimulates en-
zyme secretion from acinar cells via proteinase-activated
receptor 2 (PAR-2),7,8 whereas the effect of trypsin on
pancreatic ductal epithelial cells (PDECs) is somewhat
controversial. Trypsin activates ion channels in dog
PDECs9 and stimulates bicarbonate secretion in the CA-
PAN-1 human pancreatic adenocarcinoma cell line,10
whereas it dose-dependently inhibits bicarbonate efflux
from bovine PDECs.11 The effect of trypsin differs not
only among species, but also with respect to the localiza-
tion of PAR-2. When PAR-2 is localized to the basolateral
membrane and activated by trypsin, the result is stimula-
tion of bicarbonate secretion.9,10 In contrast, when the
receptor is localized to the luminal membrane, the effect
is inhibition.11 Interestingly, there are no data available
concerning the effects of trypsin on guinea pig PDECs
which, in terms of bicarbonate secretion, are an excellent
model of human PDECs.12
The human pancreatic ductal epithelium secretes an
alkaline fluid that may contain up to 140 mmol/L
NaHCO3.12,13 The first step in HCO3" secretion is the
accumulation of HCO3" inside the cell, which is driven by
basolateral Na!/HCO3" cotransporters, Na!/H! exchang-
ers, and H!-adenosine triphosphatases.12,13 Only 2 trans-
porters have been identified on the apical membrane of
Abbreviations used in this paper: BAPTA-AM, 1,2-bis(o-aminophe-
noxy)ethane-N,N,N=,N=-tetraacetic acid; CFTR, cystic fibrosis transmem-
brane conductance regulator Cl! channel; CFTRinh-172, CFTR inhibitor-
172; [Ca2"]i, intracellular Ca2" concentration; H2DIDS, dihydro-4,4=-
diisothiocyanostilbene-2,2=-disulfonic acid; PAR-2, proteinase-activated
receptor-2; PAR-2-AP, PAR-2 activating peptide; PAR-2-ANT, PAR-2 an-
tagonist; PDEC, pancreatic ductal epithelial cell; pHi, intracellular pH;
pHL, luminal pH; SBTI, soybean trypsin inhibitor; SLC26, solute carrier
family 26.
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cells in the proximal ducts that are the major sites of
HCO3" secretion: cystic fibrosis transmembrane conduc-
tance regulator (CFTR) and the solute carrier family 26
(SLC26) anion exchangers.12,13 How these transporters act
in concert to produce a high HCO3" secretion is contro-
versial.14 Most likely, HCO3" is secreted through the an-
ion exchanger until the luminal concentration reaches
about 70 mmol/L, after which the additional HCO3"
required to raise the luminal concentration to 140
mmol/L is transported via CFTR.15,16
The role of PAR-2 in experimental acute pancreatitis is
also controversial and highly dependent on the model of
pancreatitis studied. PAR-2 was found to be protective
in secretagogue-induced pancreatitis in mice7,17–19 and
rats.20 However, PAR-2 is clearly harmful when pancreati-
tis is evoked by the clinically more relevant luminal ad-
ministration of bile salts in mice.17
In this study, we show for the first time that (1) PAR-2
is localized to the apical membrane of the human proxi-
mal PDECs, (2) the localization of PAR-2 in the guinea pig
pancreas is identical to that in the human gland, (3)
trypsin markedly reduces bicarbonate efflux through a
dihydro-4,4=-diisothiocyanostilbene-2,2=-disulfonic acid
(H2DIDS)-sensitive apical SLC26 anion exchanger and
strongly inhibits CFTR, (4) a decrease in pH within the
ductal lumen will strongly accelerate the autoactivation of
trypsinogen, and (5) trypsin down-regulates PAR-2 expres-
sion at both transcriptional and protein levels in PDECs
of patients with chronic pancreatitis.
Materials and Methods
A brief outline of the materials and methods is given in
the following text. For further details, please see Supplementary
Materials and Methods.
Solutions
The compositions of the solutions used for microfluo-
rimetry are shown in Table 1.
Isolation of Pancreatic Ducts and Individual
Ductal Cells
Small intralobular proximal ducts and individual ductal
cells were isolated from guinea pigs or PAR-2 wild-type (PAR-
2!/!) and knockout (PAR-2"/") mice with a C57BL6 back-
ground by microdissection as described previously.21
Measurement of Intracellular pH and Ca2"
Concentration
Intracellular pH (pHi) and calcium concentration ([Ca2!]i)
were estimated by microfluorimetry using the pH- and Ca2!-sensi-
tive fluorescent dyes 2,7-bis-(2-carboxyethyl)-5-(and-6-)carboxyfluo-
rescein, acetoxymethyl ester (BCECF-AM) and 2-(6-(bis(carboxy-
methyl)amino)-5-(2-(2-(bis(carboxymethyl)amino)-5-methylphenoxy)-
ethoxy)-2-benzofuranyl)-5-oxazolecarboxylic acetoxymethyl ester
(FURA 2-AM), respectively.
Microperfusion of Intact Pancreatic Ducts
The luminal perfusion of the cultured ducts was per-
formed as described previously.22
Electrophysiology
CFTR Cl" channel activity was investigated by whole cell
patch clamp recordings on guinea pig single pancreatic ductal
cells.
Measuring Autoactivation of Trypsinogen
Autoactivation of human cationic trypsinogen was de-
termined in vitro at pH values ranging from 6.0 to 8.5. Experi-
mental details are described in Supplementary Materials and
Methods.
Immunohistochemistry
Five guinea pig, 2 PAR-2!/!, 2 PAR-2"/", and 30 human
pancreata were studied to analyze the expression pattern of
PAR-2 protein. Relative optical densitometry was used to quan-
tify the protein changes in the histologic sections. Patients’ data
and the full methods are described in Supplementary Supple-
mentary Materials and Methods.
Real-Time Reverse-Transcription Polymerase
Chain Reaction
RNA was isolated from 30 human pancreata. Following
reverse transcription, messenger RNA (mRNA) expression of
PAR-2 and !-actin was determined by real-time polymerase
chain reaction analysis.
Results
Expression of PAR-2 in Guinea Pig and
Human Pancreata
PAR-2 was highly expressed in the luminal mem-
brane of small intralobular and interlobular ducts (Figure
1A [i]; cuboidal epithelial cells forming the proximal pan-
creatic ducts) but was almost undetectable in the larger
interlobular ducts (Figure 1A [ii]; columnar epithelial cells
forming the distal pancreatic ducts). The localization of
PAR-2 in the human pancreas was identical to that in the
guinea pig gland (Figure 1A [iv–vi]). Measurements of
relative optical density confirmed the significant differ-
ences between the expression of PAR-2 in small intralob-
ular and interlobular ducts and the larger interlobular
ducts in both species (Figure 1C).
Table 1. Composition of Solutions for Microfluorimetry
Studies
Standard Standard Cl"-free Ca2!-free
HEPES HCO3" HCO3" HEPES
NaCl 130 115 132
KCl 5 5 5
MgCl2 1 1 1
CaCl2 1 1
Sodium HEPES 10 10
Glucose 10 10 10 10
NaHCO3 25 25
Sodium gluconate 115
Magnesium gluconate 1
Calcium gluconate 6
Potassium sulfate 2.5
NOTE. Values are concentrations in mmol/L.
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Luminal Administration of PAR-2-AP and
Trypsin Induces Dose-Dependent [Ca2"]i
Signals
Because PAR-2 expression was detected only on the
luminal membrane of intralobular duct cells, we used the
microperfusion technique to see whether these receptors
can be activated by PAR-2 agonists. First, the experiments
were performed at pH 7.4 to understand the effects of
trypsin and PAR-2 under quasi-physiologic conditions
(Figure 2). The fluorescent images in Figure 2A clearly
show that luminal administration of PAR-2 activating
peptide (PAR-2-AP) increased [Ca2!]i in perfused pancre-
atic ducts. The [Ca2!]i response was dose dependent and
consisted of a peak in [Ca2!]i that decayed in the contin-
ued presence of the agonist, possibly reflecting PAR-2
inactivation or depletion of intracellular Ca2! stores (Fig-
ure 2B). Pretreatment of PDECs with 10 "mol/L PAR-2
antagonist (PAR-2-ANT) for 10 minutes completely
blocked the effects of 10 "mol/L PAR-2-AP on [Ca2!]i
(Figure 2A and C). Removal of extracellular Ca2! had no
effect on the increase in [Ca2!]i evoked by luminal admin-
istration of 10 "mol/L PAR-2-AP; however, preloading
ducts with the calcium chelator 1,2-bis(o-aminophe-
noxy)ethane-N,N,N=,N=-tetraacetic acid (BAPTA-AM) at 40
"mol/L totally blocked the response (Figure 2A and C).
Trypsin also induced a dose-dependent elevation in
[Ca2!]i similar to that evoked by PAR-2-AP (Figure 2E and
F). Addition of 5 "mol/L soybean trypsin inhibitor
(SBTI), 10 "mol/L PAR-2-ANT, and 40 "mol/L
BAPTA-AM totally blocked the increase in [Ca2!]i (Figure
2D and F). These data show that trypsin activates PAR-2
on the luminal membrane of the duct cell, which leads to
release of Ca2! from intracellular stores and an elevation
of [Ca2!]i.
Because the pH of pancreatic juice can vary between
approximately 6.8 and 8.0,23,24 we also evaluated the ef-
fects of trypsin and PAR-2-AP on [Ca2!]i at these pH
values (Supplementary Figures 1 and 2, respectively). The
Figure 1. Localization of PAR-2 on human and guinea pig pancreatic ducts. Light micrographs of (A [i–iii]) guinea pig and (A [iv–vi]) human pancreas
are shown. (i) PAR-2 is localized to the luminal membrane of PDECs in small intralobular and interlobular ducts (original magnification 400#). (ii) Large
interlobular ducts do not express PAR-2 (original magnification 200#). (iii) No primary antiserum (original magnification 200#). (iv and v) Sections from
human pancreas exhibit a similar localization of PAR-2 compared with the guinea pig gland (original magnification 400# and 200#). (vi) No primary
antiserum (original magnification 200#). (B) Western blot analysis was used to determine the specificity of the PAR-2 antibody. Polyclonal anti–PAR-2
showed a single 44-kilodalton band. (C) Quantitative measurement of relative optical densities (RO-Density) of small intralobular and interlobular
ducts (A.i,iv), and large interlobular ducts (A.ii,v) is shown. n$ 12. *P% .05 vs A.ii or A.v, respectively. Scale bar$ 50 "m for A (i, iv) and 100 "m for
A (ii and iii) and A (v and vi).
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elevations of [Ca2!]i at pH 6.8 and 8.0 were generally very
similar to the changes observed at pH 7.4. However, the
increases in [Ca2!]i evoked by 1 "mol/L PAR-2-AP and 0.1
"mol/L trypsin were significantly lower at pH 6.8 com-
pared with either pH 7.4 or 8.0 (Supplementary Figure 3).
Luminal Exposure to PAR-2-AP and Trypsin
Evokes Intracellular Alkalosis in PDECs
Figure 3 shows pHi recordings from microperfused
pancreatic ducts. Luminal application of the CFTR inhib-
itor (CFTRinh) 172 (10 "mol/L) and the anion exchanger
inhibitor H2DIDS (500 "mol/L) induced intracellular al-
kalization in PDECs (Figure 3A [i]). These data indicate
that when bicarbonate efflux across the luminal mem-
brane of PDECs (ie, bicarbonate secretion) is blocked,
elevation of duct cell pHi occurs, presumably because the
basolateral transporters continue to move bicarbonate
ions into the duct cell. Note also that the increase in pHi
evoked by the inhibitors is not sustained and begins to
reverse before the inhibitors are withdrawn (Figure 3A [i]),
which might be explained by the regulation of pHi by
basolateral acid/base transporters.
Both luminal PAR-2-AP and trypsin induced a dose-depen-
dent elevation of pHi (Figure 3A [ii and iii]), suggesting that
activation of PAR-2 inhibits bicarbonate efflux across the apical
membrane of the duct cell. Preincubation of PDECswith either
10 "mol/L PAR-2-ANT or 5 "mol/L SBTI or 40 "mol/L
BAPTA-AM for 30 minutes totally blocked the effect of trypsin
on pHi (Figure 3A [iv]). The inhibitory effect of the calcium
chelator BAPTA-AM suggests that the actions of trypsin and
PAR-2-AP on pHi are mediated by the increase in [Ca2!]i that
they evoke (Figure 2). Therefore, in this case, the transient
nature of the pHi response may reflect the transient effect that
PAR-2 activators have on [Ca2!]i (Figure 2B and E), as well as
pHi regulation by basolateral acid/base transporters.
Next we tested the effects of trypsin on pHi in Cl"-free
conditions and during pharmacologic inhibition of the
Figure 2. Effects of PAR-2-AP and trypsin on [Ca2!]i in microperfused guinea pig pancreatic ducts at pH 7.4. (A) Light (1) and fluorescent ratio
images (2 and 3) of microperfused pancreatic ducts showing the effects of luminal administration of 10 "mol/L PAR-2-AP, 10 "mol/L PAR-2-ANT,
or 40 "mol/L BAPTA-AM on [Ca2!]i. Images were taken before (1 and 2) and after (3) exposure of the ducts to PAR-2-AP or trypsin. (B and C)
Representative experimental traces and summary data of the changes in [Ca2!]i. (D) The same protocol was used to evaluate the effects of trypsin.
Addition of 5 "mol/L SBTI was used to inhibit trypsin activity. (E and F) Representative experimental traces and summary data of the changes in
[Ca2!]i. n $ 5 for all groups. *P % .05 vs 1 "mol/L PAR-2-AP or 0.1 "mol/L trypsin, respectively. **P % .001 vs 10 "mol/L PAR-2-AP or 10 "mol/L
trypsin, respectively.
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Figure 3. Effects of PAR-2-AP and trypsin on pHi in microperfused guinea pig pancreatic ducts. (A) Representative pHi traces showing the effects
of luminal administration of different agents in microperfused pancreatic ducts. (i) A total of 10 "mol/L CFTRinh-172 and/or 500 "mol/L H2DIDS
caused alkalization of pHi. (ii) PAR-2-AP and (iii) trypsin induced a dose-dependent pHi elevation. (iv) Preincubation of ductal cells with 10 "mol/L
PAR-2-ANT or 5 "mol/L SBTI or 40 "mol/L BAPTA-AM totally blocked the alkalization caused by 10 "mol/L trypsin. (v) Removal of luminal Cl" or
(vi) administration of H2DIDS (500 "mol/L) decreased, but did not totally abolish, the effects of 10 "mol/L trypsin on pHi. (vii) Pretreatment with 10
"mol/L CFTRinh-172 also decreased the effects of trypsin (10"mol/L) on pHi. (viii) Simultaneous administration of H2DIDS andCFTRinh-172 strongly
inhibited the effect of 10 "mol/L trypsin. (B and C) Summary of the effects of PAR-2-AP and trypsin on changes in pHi. &pHmax was calculated from
the experiments shown in A. (D) Effects of Cl"-free conditions. Cl"-free conditions, H2DIDS, CFTRinh-172, and a combination of the inhibitors all
induced an intracellular alkalosis. Trypsin further increased the alkalinization of pHi, although the effect wasmarkedly reduced when both H2DIDS and
CFTRinh-172 were present. n $ 4–5 for all groups. (B) *P % .05 vs 0.1 "mol/L trypsin; **P % .001 vs 10 "mol/L trypsin. (C) *P % .05 vs 0.1 "mol/L
PAR-2-AP; **P % .001 vs 10 "mol/L PAR-2-AP. (D) *P % .05 vs the respective filled column.
BA
SIC
A
N
D
TRA
N
SLA
TIO
N
A
L
PA
N
CREA
S
2232 PALLAGI ET AL GASTROENTEROLOGY Vol. 141, No. 6
luminal anion exchangers and/or CFTR (Figure 3A [v–
viii]). Luminal Cl"-free conditions increased the pHi of
PDECs, presumably by driving HCO3" influx on the api-
cal anion exchangers (Figure 3A [v]). Note that luminal
administration of trypsin further elevated pHi in Cl"-free
conditions (Figure 3A [v]) and also in the presence of
H2DIDS (Figure 3A [vi]) and CFTRinh-172 (Figure 3A
[vii]). However, pretreatment of ducts with a combination
of H2DIDS and CFTRinh-172 markedly reduced the effect
of trypsin on pHi (Figure 3A [viii]).
Figure 3B–D is a summary of the pHi experiments.
Trypsin (Figure 3B) and PAR-2-AP (Figure 3C) both in-
duced statistically significant, dose-dependent increases in
pHi and these effects were blocked by PAR-2-ANT, SBTI,
and BAPTA-AM. Exposure of the ducts to luminal Cl"-
free conditions, H2DIDS, CFTRinh-172, or a combination
of the inhibitors also induced an intracellular alkalosis
(Figure 3D). Also shown in Figure 3D is the additional,
statistically significant increase in pHi caused by trypsin in
ducts exposed to Cl"-free conditions and the individual
inhibitors. However, when ducts were exposed to both
CFTRinh-172 and H2DIDS simultaneously, the effect of
trypsin on pHi was markedly reduced, although it re-
mained statistically significant (Figure 3D). We interpret
these results as indicating that trypsin inhibits both
Cl"-dependent (ie, anion exchanger mediated; revealed
when CFTR is blocked by CFTRinh-172) and Cl"-inde-
pendent (ie, CFTR mediated; revealed in Cl"-free con-
ditions and when the luminal exchangers are blocked
by H2DIDS) bicarbonate secretory mechanisms in
PDECs. Reduced bicarbonate secretion will lead to a
decrease in intraductal pH.
Trypsin and PAR-2-AP Inhibit CFTR
Exposure of guinea pig PDECs to 5 "mol/L fors-
kolin, which elevates intracellular adenosine 3=5=-cyclic
monophosphate levels, increased basal whole cell currents
(Figure 4A–D [i]) from 8.9 ' 2.3 to 91.2 ' 13.5 pA/pF
(Figure 4A–D [ii]) at !60 mV in 78% of cells (38/49). The
forskolin-activated currents were time- and voltage-inde-
pendent, with a near linear I/V relationship and a reversal
potential of "5.15 ' 1.12 mV (Figure 4A–D [iv]). These
biophysical characteristics indicate that the currents are
carried by CFTR.
Exposure of PDECs to 10 "mol/L trypsin did not affect
the basal currents; however, administration of either 10
"mol/L PAR-2-AP (Figure 4A [iii]) or 10 "mol/L trypsin
(Figure 4B [iii]) inhibited forskolin-stimulated CFTR cur-
rents by 51.7% ' 10.5% and 57.4% ' 4.0%, respectively. In
both cases, the inhibition was voltage independent and
irreversible. Pretreatment with either SBTI (10 "mol/L;
Figure 4C [iii]) or PAR-2-ANT (10 "mol/L; Figure 4D [iii])
completely prevented the inhibitory effect of trypsin on
the forskolin-stimulated CFTR currents. Figure 4E is a
summary of these data, which suggest that trypsin inhib-
its CFTR Cl" currents by activation of PAR-2.
Autoactivation of Trypsinogen Is pH
Dependent
Trypsinogen can undergo autocatalytic activation
during which trace amounts of trypsin are generated,
which, in turn, can further activate trypsinogen in a self-
amplifying reaction. Human trypsinogens are particularly
prone to autoactivation, and mutations that facilitate
autoactivation are associated with hereditary pancreatitis.
To assess the effect of a decrease in intraductal pH (caused
by reduced bicarbonate secretion) on trypsinogen activa-
tion, we measured autoactivation of human cationic
trypsinogen in vitro at pH values ranging from 6.0 to 8.5
using a mixture of various buffers. As shown in Figure 5A,
the rate at which cationic trypsinogen autoactivates was
markedly increased as the pH was reduced from 8.5 to 7.0
when the buffer solution contained 1 mmol/L CaCl2 and
no NaCl. However, a further reduction in pH, from 7.0 to
6.0, had little effect (Figure 5A [i]).
To rule out that the differences observed in autoacti-
vation were due to the different ionic strengths of the
buffers used, we repeated the experiments in the presence
of a higher concentration of sodium (100 mmol/L NaCl,
Figure 5A [ii]) or lower concentration of calcium (0.1
mmol/L CaCl2, Figure 5A [iii]). Although the overall au-
toactivation rates were much slower in the presence of
NaCl, the pH profile of autoactivation was essentially
identical to that observed in the absence of added salt
(Figure 5A [ii]). Also, pH-dependent changes in the auto-
activation of trypsinogen were still detectable when the
experiments were performed using a low calcium buffer
(Figure 5A [iii]).
PAR-2 Is Down-regulated in Patients With
Chronic Pancreatitis
It has been documented that there is activated
trypsin in the pancreatic ductal lumen in chronic pancre-
atitis in humans.25–28 If trypsin activity is elevated in the
duct lumen, PAR-2 down-regulation should occur, which
could be due to either (1) changes in PAR-2 mRNA tran-
scription and/or (2) receptor internalization and translo-
cation to the cytoplasm. Our data show a marked
reduction in membranous PAR-2 protein level but no
significant changes in cytoplasmic PAR-2 protein in
chronic pancreatitis (Figure 5B [i–iv] and C). Furthermore,
PAR-2 mRNA expression was markedly reduced in
chronic pancreatitis (Figure 5D), suggesting that reduced
PAR-2 mRNA transcription may cause PAR-2 down-regu-
lation in chronic pancreatitis.
Luminal Exposure to R122H Mutant Cationic
Trypsin Induces Elevation of [Ca2"]i and
Evokes Alkalosis in PDECs
It has been shown that mutations in cationic
trypsinogen increase the risk of chronic pancreatitis, most
likely because of the enhanced autoactivation exhibited
by the mutant trypsinogens.29 Here we tested whether
the commonest mutation in cationic trypsin, R122H, af-
fected the ability of the protease to interact with PAR-2.
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Figure 6A and B shows that 1 "m of R122H human
cationic trypsin causes comparable changes in pHi and
[Ca2!]i to 0.4 "mol/L wild-type bovine trypsin, suggesting
that a trypsin-mediated inhibition of bicarbonate secre-
tion could play a role in the pathogenesis of hereditary as
well as chronic pancreatitis.
Activation of PAR-2 Is Diminished in
PAR-2!/! Mice
Finally, we investigated the effects of both PAR-
2-AP and trypsin on PDECs isolated from PAR-2!/! and
PAR-2"/" mice (Figure 6C–E). First we confirmed using
Figure 4. Effects of trypsin and PAR-2-AP on CFTR Cl" currents of guinea pig pancreatic duct cells. Representative fast whole cell current
recordings from PDECs. (A–D) (i) Unstimulated currents, (ii) currents after stimulation with 5 "mol/L forskolin, and (iii) currents following 3-minute
exposure to (A) 10"mol/L PAR-2-AP, (B) 10 "mol/L trypsin, (C) 10 "mol/L trypsin/5 "mol/L SBTI, and (D) 10 "mol/L trypsin/10 "mol/L PAR-2-ANT.
(iv) I/V relationships. Diamonds represent unstimulated currents, squares represent forskolin-stimulated currents, and triangles represent forskolin-
stimulated currents in the presence of the tested agents (see previous text). (E) Summary of the current density (pA/pF) data obtained from A–D
measured at Erev' 60 mV. Exposing PDECs to either PAR-2-AP or trypsin blocked the forskolin-stimulated CFTR Cl" currents, while administration
of SBTI or PAR-2-ANT prevented the inhibitory effect of trypsin. n$ 6 for all groups. *P% .05 vs the unstimulated cells, **P% .05 vs forskolin. FORSK,
forskolin; TRYP, trypsin.
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immunohistochemistry that PAR-2!/! mice do, whereas
PAR-2"/" mice do not, express PAR-2 in their PDECs
(Figure 6C [i and iii]). Accordingly, our functional data
clearly show that the pHi and [Ca2!]i responses to luminal
administration of either trypsin or PAR-2-AP were mark-
edly diminished in PAR-2"/" PDECs (Figure 6D and E).
Discussion
The human pancreatic ductal epithelium secretes 1
to 2 L of alkaline fluid every 24 hours that may contain up
to 140 mmol/L NaHCO3.12,13 The physiologic function of
this alkaline secretion is to wash digestive enzymes down
the ductal tree and into the duodenum and to neutralize
acidic chyme entering the duodenum from the stomach.
There are important lines of evidence supporting the idea
that pancreatic ducts play a role in the pathogenesis of
pancreatitis: (1) ductal fluid and bicarbonate secretion are
compromised in acute and chronic pancreatitis,30,31 (2)
one of the main end points of chronic pancreatitis is the
destruction of the ductal system,32,33 (3) mutations in
CFTR may increase the risk of pancreatitis,30,31,34–36 and
(4) etiologic factors for pancreatitis, such as bile acids or
ethanol in high concentration, inhibit pancreatic ductal
bicarbonate secretion.37–39 Despite the previously men-
Figure 5. The effects of pH on trypsinogen activation and analyses of PAR-2 expression in human pancreatic samples. The autoactivation of human
cationic trypsinogen was determined in vitro at pH values ranging from 6.0 to 8.5. (A) (i) Trypsinogen at 2 "mol/L concentration was incubated with
40 nmol/L trypsin at 37oC in 0.1 mol/L Tris ! HEPES ! 2-(N-morpholino)ethanesulfonic acid2-(N-morpholino)ethanesulfonic acid buffer mixture
containing 1 mmol/L CaCl2. (ii) The same protocol was used in high (100 mmol/L) NaCl buffer solution. Autoactivation of cationic trypsinogen
significantly increased as the pH was reduced from 8.5 to 6.0. (iii) The same protocol was used in low (0.1 mmol/L) Ca2!-buffered solution buffer
solution. (B) (i–iv) PAR-2 expression. (i) Representative section of normal human pancreas. (ii) No primary antiserum. (iii) Representative section of
human pancreas from a patient with chronic pancreatitis (CP). (iv) No primary antiserum. (C) Relative optical density. n $ 15. *P % .05 vs CP
membrane. (D) Real-time reverse-transcription polymerase chain reaction analysis of PAR-2 mRNA expression of human pancreas. Data are given
in 2^dCT. n $ 15. *P % .05 vs CP.
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tioned data, the role of PDECs in the development of
pancreatitis has received relatively little attention.40
There are important species differences regarding the
localization of PAR-2 in pancreatic ducts and in the effect
of its activation on bicarbonate secretion. For example,
CAPAN-1 cells10 and dog PDECs9 express PAR-2 only on
the basolateral membrane, whereas bovine PDECs express
PAR-2 on the luminal membrane.11 Therefore, one of our
Figure 6. Experiments using R122H human
mutant cationic trypsin and PAR-2"/" mice.
Representative (A) pHi and (B) [Ca2!]i mea-
surements using luminal administration of
normal and R122H mutant cationic trypsin in
microperfused guinea pig pancreatic ducts.
n $ 5 for all experiments. (C) (i–iv) PAR-2–
expressing cells were visualized by immuno-
histochemistry as described in Figure 1. (i)
Representative section of the pancreas re-
moved from PAR-2!/!mice. (ii) Section with-
out primary antiserum. (iii) Pancreas removed
from PAR-2"/" mice. (iv) Section without pri-
mary antiserum. (D) pHi and (E) [Ca2!]i mea-
surements using luminal administration of
trypsin in microperfused pancreatic ducts
isolated from PAR-2 knockout (red curve)
and PAR-2 wild-type mice (black curve). n $
5 for all experiments. *P % .05 vs 10 "mol/L
trypsin PAR-2!/!, **P % .05 vs 10 "mol/L
PAR-2-AP PAR-2!/!.
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first aims was to determine which animal model best
mimics human PAR-2 expression and thus would be the
best for studying the effects of trypsin on PDEC function.
Our results showed that in the human pancreas PAR-2 is
localized to the luminal membrane of small proximal
pancreatic ducts, which are probably the major site of
bicarbonate and fluid secretion. Because CAPAN-1 cells
and dog PDECs express PAR-2 only on the basolateral
membrane, they do not mimic the human situation. Rats
or mice are also not good models for the human gland
because they secrete only 70 to 80 mmol/L bicarbon-
ate.41,42 However, the guinea pig pancreas secretes (140
mmol/L bicarbonate, as does the human gland, and the
regulation of bicarbonate secretion is similar in both
species.41,42 Because PAR-2 expression in the guinea pig
pancreas was localized to the luminal membrane of duct
cells, we performed our experiments on isolated guinea
pig ducts.
First we characterized the effects of PAR-2 activation by
trypsin and PAR-2-AP on PDECs. Previously, it has been
shown that activation of the G protein–coupled PAR-2 by
proteinases requires proteolytic cleavage of the receptor,
which is followed by an elevation of [Ca2!]i.43–45 As ex-
pected, luminal trypsin and PAR2-AP caused a dose-de-
pendent elevation of [Ca2!]i in guinea pig ducts. Impor-
tantly, the trypsin inhibitor SBTI, PAR-2-ANT, and the
intracellular calcium chelator BAPTA-AM all completely
blocked the elevation of [Ca2!]i, whereas removal of ex-
tracellular Ca2! had no effect. Acidosis (pH 6.8) also
slightly reduced the changes in [Ca2!]i evoked by trypsin,
most probably due to reduced cleavage activity of trypsin
at an acidic pH. Next we characterized the effects of PAR-2
activation on pHi. Luminal application of trypsin and
PAR-2-AP both caused a dose-dependent intracellular al-
kalosis in PDECs. This alkalosis is most likely explained
either by a reduction in the rate of bicarbonate efflux (ie,
secretion) across the apical membrane of PDECs or by an
increase in the rate of bicarbonate influx at the basolateral
side of the cell. We favor the former explanation because
luminal application of the anion exchange inhibitor
H2DIDS or the CFTR inhibitor CFTRinh-172 produced a
similar intracellular alkalization.22,46 Thus, PAR-2 activa-
tion inhibits bicarbonate secretion in PDECs by inhibit-
ing SLC26 anion exchangers and CFTR Cl" channels
expressed on the apical membrane of the duct cell. In
similarity with the [Ca2!]i signals, the effect of PAR-2
activation on pHi was blocked by SBTI, PAR-2-ANT, and
BAPTA-AM, with the action of BAPTA-AM suggesting
that the inhibition of bicarbonate secretion follows from
the increase in [Ca2!]i. Interestingly, an elevation of
[Ca2!]i is crucial for both stimulatory (eg, acetylcholine,13
low concentrations of bile acids,39 and ethanol38) and
inhibitory pathways (eg, basolateral adenosine triphos-
phate, arginine vasopressin, and high concentrations of
ethanol) that control bicarbonate secretion by PDECs.
Such marked differences in the outcome of [Ca2!]i signals
in PDECs probably reflect differences in the source of
Ca2! and/or in the intracellular compartmentalization of
[Ca2!]i signals generated by different secretory agonists
and antagonists.
Remarkably, trypsin was still able to evoke an elevation
of pHi when Cl" was removed from the duct lumen and
when PDECs were pretreated with H2DIDS, conditions
that should inhibit bicarbonate efflux on the exchanger.
These results suggested the involvement of CFTR, the
only other known bicarbonate efflux pathway on the api-
cal membrane, in the inhibitory effect of trypsin. This
hypothesis was confirmed by patch clamp experiments in
which trypsin decreased CFTR whole cell currents in iso-
lated guinea pig PDECs by 50% to 60%. Finally, the fact
that the trypsin-induced alkalinization was completely
blocked by a combination of CFTRinh-172 and H2DIDS
confirms the involvement of both CFTR and SLC26 anion
exchangers. Our conclusion from these pHi and patch
clamp data is that PAR-2 activation inhibits both the
SLC26 anion exchanger (probably SLC26A6 [PAT-1]47 be-
cause SLC26A3 [DRA] is only weakly inhibited by disul-
fonic stilbenes47,48) and CFTR Cl" channels expressed on
the apical membrane of the duct cell.
The pH of pancreatic juice (and therefore the luminal
pH [pHL] in the duct) can vary between approximately 6.8
and 8.0. It has recently been shown that protons core-
leased during exocytosis cause significant acidosis (up to 1
pH unit) in the lumen of the acini.23 However, Ishiguro et
al49 have clearly shown that the pHL in pancreatic ducts is
dependent on the level of bicarbonate secretion. pHL can
be elevated from 7.2 to 8.5 by stimulation with secretin or
forskolin, and this effect was strictly dependent on the
presence of bicarbonate.24,49,50 Also, inhibition of ductal
bicarbonate secretion with H2DIDS can decrease the pHL
to less than 8.0.49 In view of these results, we tested
whether trypsinogen autoactivation was affected by pH
over the range of 6.0 to 8.5. Autoactivation of trypsinogen
was relatively slow at pH 8.5, but decreasing the pH from
8.5 to 7 progressively stimulated autoactivation. These
results suggest that under physiologic conditions bicar-
bonate secretion by PDECs is not only important for
elevating the pH in the duodenum, but also for keeping
pancreatic enzymes in an inactive state in the ductal
system of the gland.
Receptor down-regulation is a phenomenon that occurs
in the continued presence of an agonist and leads to a
reduction in the sensitivity of the cell to the agonist.
Potentially, there are 2 mechanisms that could underlie
receptor down-regulation of PAR-2: (1) after proteolytic
activation, the PAR-2 is internalized by a clathrin-medi-
ated mechanism and then targeted to lysosomes45 and (2)
if trypsin is present for a longer time in the lumen, PAR-2
may be down-regulated at the transcriptional level. In this
study, we provide evidence that the second mechanism,
transcriptional down-regulation, explains the reduced ex-
pression of PAR-2 seen in chronic pancreatitis.
Conflicting data can be found in the literature concern-
ing the role of PAR-2 in acute pancreatitis. Singh et al7
showed that in secretagogue-induced experimental pan-
creatitis, PAR-2 deletion is associated with a more severe
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pancreatitis. Although Laukkarinen et al17 confirmed
these results in cerulein-induced pancreatitis, they also
clearly showed that in taurocholate-induced pancreatitis,
PAR-2 deletion markedly reduced the severity of the dis-
ease. There is no evidence to suggest that clinical pancreatitis
is evoked by supramaximal secretagogue stimulation; how-
ever, the taurocholate-induced pancreatitis model may
mimic the clinical situation. Therefore, Laukkarinen et al17
speculated that PAR-2 activation promotes the worsening of
clinical pancreatitis and our data are consistent with that
hypothesis.
Besides the clear pathophysiologic role of the tryp-
sin/PAR-2 interaction in chronic pancreatitis, there is
still a debate as to why PAR-2 are localized to the
luminal membrane of PDEC in small ducts close to the
acinar cells. What could the physiologic role of this
PAR-2 be? A number of agents have been shown to have
dual effects on PDECs at different concentrations. For
example, bile acids in low concentrations stimulate but
in high concentrations inhibit bicarbonate secretion.39
The same applies to ethanol.38 Under physiologic con-
ditions, trypsin inhibitors are coreleased from acinar
cells with trypsinogen and should block the activity of
any trypsin that is generated spontaneously. Therefore,
only very small amounts of active trypsin, if any, will be
present in the duct lumen under normal conditions.
However, there remains a possibility that very small
amounts of active trypsin (ie, concentrations less than
0.1 "mol/L that would not cause an elevation of [Ca2!]i
or change in pH) could bind to PAR-2 on the luminal
membrane of the ducts and augment other stimulatory
mechanisms so as to enhance flushing of digestive
enzymes down the ductal tree.
In conclusion, we suggest for the first time that one of
the physiologic roles of bicarbonate secretion by PDECs is
to curtail trypsinogen autoactivation within the pancre-
atic ductal system. However, if trypsin is present in the
duct lumen (as may occur during the early stages of
pancreatitis due to leakage from acinar cells), PAR-2 on
the duct cell will be activated, leading to Ca2! release from
intracellular stores and an increase in cytosolic Ca2! con-
centration. This causes inhibition of the luminal anion
exchangers and CFTR Cl" channels, reducing bicarbonate
secretion by the duct cell. The decrease in bicarbonate
secretion will increase the transit time of zymogens down
the duct tree and decrease pHL, both of which will pro-
mote the autoactivation of trypsinogen. The trypsin so
formed will further inhibit bicarbonate transport, leading
to a vicious cycle generating further decreases in pHL and
enhanced trypsinogen activation, which will favor devel-
opment of the pancreatitis (Supplementary Figure 4).
Finally, the R122H mutant cationic trypsin also elevated
[Ca2!]i and pHi in duct cells, suggesting that this mech-
anism may be particularly important in hereditary pan-
creatitis in which the mutant trypsinogens more readily
autoactivate.29
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.08.039.
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Supplementary Materials and Methods
Ethics
All experiments were conducted in compliance
with the Guide for the Care and Use of Laboratory
Animals (USA NIH publication No 85-23, revised 1985).
Animal experiments were approved by the Regional Eth-
ical Board at the University of Szeged, Hungary.
Solutions and Chemicals
HEPES-buffered solutions were gassed with 100%
O2, and their pH was set to 7.4 with HCl at 37oC. HCO3"-
buffered solutions were gassed with 95% O2/5% CO2 to set
pH to 7.4 at 37oC. For patch clamp studies, the standard
extracellular solution contained (in mmol/L): 145 NaCl,
4.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 5 glucose (pH
7.4 adjusted with NaOH). The osmolarity of the extra-
cellular solution was 300 mOsm/L. The standard pipette
solution for the patch clamp experiments contained (in
mmol/L): 120 CsCl, 2 MgCl2, 0.2 ethylene glycol-bis(!-
aminoethyl ether)-N,N,N=,N=-tetraacetic acid (EGTA), 10
HEPES, and 1 Na2ATP (pH 7.2 adjusted with NaOH).
Chromatographically pure collagenase was purchased
from Worthington (Lakewood, NJ). 2,7-Bis-(2-carboxy-
ethyl)-5-(and-6-)carboxyfluorescein, acetoxymethyl ester
(BCECF-AM), 2-(6-(bis(carboxymethyl)amino)-5-(2-(2-
(bis(carboxymethyl)amino)-5-methylphenoxy)ethoxy)-2-
benzofuranyl)-5-oxazolecarboxylic acetoxymethyl ester
(FURA 2-AM), dihydro-4,4=-diisothiocyanostilbene-
2,2=-disulfonic acid (H2DIDS), and 1,2-bis(o-amino-
phenoxy)ethane- N,N,N=,N=-tetraacetic acid (BAPTA-
AM) were from Invitrogen (Carlsbad, CA). PAR-2-ANT
(H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2) and PAR-2-AP (H-
Ser-Leu-Ile-Gly-Arg-Leu-amid trifluoroacetate salt)
were from Peptides International (Louisville, KY). For-
skolin were from Tocris (Ellisville, MO). Rabbit PAR-2
polyclonal antibody was purchased from Santa Cruz
Biotechnology (Heidelberg, Germany). All other chem-
icals were obtained from Sigma-Aldrich (Budapest,
Hungary).
Isolation of Pancreatic Ducts and Individual
Ductal Cells
Male guinea pigs weighing between 150 and 250 g
or mice (PAR-2!/! and PAR-2"/") weighing between 18
and 21 g were humanely killed by cervical dislocation, the
pancreas was removed, and small intralobular proximal
ducts were isolated by microdissection as described pre-
viously.1 PAR-2"/" mice (B6.Cg-F2rl1tm1Mslb/J) were previ-
ously generated by Schmidlin et al1 and a kind gift from
Ashok Saluja.2 Isolated ducts were then cultured over-
night in a 37oC incubator gassed with 5% CO2/95% air.3
To obtain single pancreatic ductal cells, cultured ducts
were incubated for 50 minutes at 37°C in 50 U/mL
elastase dissolved in storage solution (Dulbecco’s modi-
fied Eagle medium containing 3% [wt/vol] bovine serum
albumin [pH 7.4 with NaOH]). Then the ducts were
transferred to a Ca2!/Mg2!-free HEPES-buffered solu-
tion and incubated for a further 10 minutes at 37°C.
After the incubation, the ducts were transferred to a
coverslip and teased apart using stainless steel needles.
The individual ductal cells were used for experiments
within 3 to 4 hours after isolation.
Measurement of pHi and Ca2" Concentration
Ducts were bathed in standard HEPES solution
and loaded with BCECF-AM (2 "mol/L) or FURA 2-AM
(5 "mol/L) for 30 to 60 minutes at room temperature.
Ducts were then transferred to a perfusion chamber
mounted on an IX71 inverted microscope (Olympus,
Budapest, Hungary) and perfused continuously with so-
lutions at 37oC both from the luminal and basolateral
side at a rate of 10 to 30 "L/min and 4 to 5 mL/min,
respectively. Four to 5 small areas (region of interests) of
5 to 10 cells in each intact duct were excited with light at
a given wavelength. Excitation of BCECF was at 495 and
440 nm, with emitted light monitored at 535 nm. Exci-
tation of FURA-2 was at 380 and 340 nm, with emitted
light monitored at 510 nm. The fluorescence emissions
were captured by a charge-coupled device camera and
digitized by a Cell imaging system (Olympus, Budapest,
Hungary). Ratio images were collected at 1-second inter-
vals. In situ calibration of pHi measured with BCECF was
performed using the high K!-nigericin technique.4,5
Electrophysiology
Guinea pig PDECs were isolated by an enzymatic
microdissection procedure as described previously. Using
a glass pipette, a few drops of cell suspension were placed
within a perfusion chamber mounted on the stage of an
inverted microscope (TMS; Nikon, Tokyo, Japan). The
ductal cells were allowed to settle and attach to
the bottom of the chamber for at least 30 minutes before
the perfusion was started.
Patch clamp micropipettes were fabricated from boro-
silicate glass capillaries (Clark, Reading, England) by us-
ing a P-97 Flaming/Brown micropipette puller (Sutter
Co, Novato, CA). These pipettes had resistances between
1.5 and 2.5 M). Membrane currents were recorded with
an Axopatch 1D amplifier (Axon Instruments, Union
City, CA) using the whole cell configuration of the patch
clamp technique at 37oC. After establishing a high-resis-
tance seal (1–10 G)) by gentle suction, the cell mem-
brane beneath the tip of the pipette was disrupted by
suction or by application of short electrical pulses. The
series resistance was typically 4 to 8 M) before compen-
sation (50%–80%, depending on the voltage protocol).
Current-voltage (I/V) relationships were obtained by
holding Vm at 0 mV and clamping to '100 mV in 20-mV
increments. Membrane currents were digitized by using a
333-kHz analog-to-digital converter (Digidata 1200;
Axon Instruments) under software control (pClamp 6;
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Axon Instruments). Analyses were performed by using
pClamp 6 software after low-pass filtering at 1 kHz.
Expression and Purification of Human
Trypsinogens
Wild-type and R122H mutant human cationic
trypsinogen was expressed in Escherichia coli and purified
by ecotin-affinity chromatography as reported previ-
ously.6
Measuring Autoactivation of Trypsinogen
Autoactivation of trypsinogen was measured at 2
"mol/L concentration at 37oC in a polybuffer system
(American Bioanalytical Inc, Natick, MA) containing 100
mmol/L 2-(N-morpholino)ethanesulfonic acid, 100
mmol/L HEPES, and 100 mmol/L Tris in 100 "L final
volume. The pH of the Polybuffer was adjusted to given
values with HCl (pH 6.0 and 6.5) or NaOH (pH 7.0, 7.5,
8.0, and 8.5). Reactions also contained 1 mmol/L or 0.1
mmol/L CaCl2 and 100 mmol/L NaCl, as indicated. At
given times, 2-"L aliquots were removed and trypsin
activity was determined using the N-CBZ-Gly-Pro-Arg-p-
nitroanilide substrate at 150 "mol/L final concentration.
Immunohistochemistry
Pancreatic tissue from 5 guinea pigs, 15 patient
samples without pancreatic disease near neuroendocrine
tumors (average age, 59.5; female/male, 7:8), and 15 pa-
tients (average age, 56.6; female/male, 4:11) who had
chronic pancreatitis (13 alcohol, 2 gallstone) were inves-
tigated. The human samples were obtained with the per-
mission of the Regional Ethical Committee of Semmel-
weis University (#172/2003).
The pancreatic tissues were fixed in 10% neutral buff-
ered formalin for 24 hours, followed by paraffin embed-
ding, and were then cut and stained with H&E to estab-
lish the diagnosis. Paraffin-embedded, 3- to 4-"m-thick
sections were used for immunohistochemistry to detect
PAR-2 expression. The slides were treated for 30 minutes
with target retrieval solution (Dako, Glostrup, Denmark)
in a microwave oven, followed by incubation with the
primary rabbit polyclonal antibody (Santa Cruz Biotech-
nology Inc, Heidelberg, Germany) in 1:100 dilution over-
night at 4°C. Signal detection was achieved by using
ImPRESS reagent with secondary anti-rabbit immuno-
globulin G antibody (20 minutes) (Vector Laboratories,
Burlingame, CA). Diaminobenzidine was used to visual-
ize immune complexes, and nuclear counterstaining was
performed with hematoxylin. For negative controls, the
appropriate antibody was omitted and either the anti-
body diluent alone or isotype-matched immunoglobulin
G serum was used. The negative controls exhibited no
signal. Normal skin epithelial cells were used as positive
controls to confirm correct immunohistochemical stain-
ing for PAR-2 (results not shown).
The immunohistochemical reactions were digitalized
with a Mirax MIDI slide scanner (3DHistech Ltd, Buda-
pest, Hungary). Relative optical (RO) density was calcu-
lated using ImageJ program (National Institutes of
Health, Bethesda, MD). Pixel values (PV) were normalized
to erythrocyte density (PVNorm $ PVMeasured – PVErythrocyte)
in all sections. RO-Density value was calculated from the
RO-Density$ log10(255/PVNorm) equation, assuming that
the brightest value in the image equals 255.
Western blot analysis was used to determine the spec-
ificity of the PAR-2 antibody. Proteins were extracted
from fresh-frozen guinea pig (n $ 3) and human (n $ 3)
pancreatic tissue stored at "80°C. Isolation was per-
formed by using lysis buffer (20 mmol/L Tris, pH 7.5, 150
mmol/L NaCl, 2 mmol/L EDTA, 1% Triton X-100 con-
taining protease inhibitor complex [Sigma Aldrich Co,
Budapest, Hungary]). Samples (50 mg) were homoge-
nized, followed by centrifugation at 13,200 rpm at 4°C
for 5 minutes. Measurements of protein concentration
were performed using Bradford analysis.7 A total of 30 "g
of protein samples were loaded in each lane, run on 10%
sodium dodecyl sulfate/polyacrylamide electrophoresis
at 200 V for 35 minutes, and then transferred to nitro-
cellulose membranes at 100 V, 4°C, for 75 minutes. For
aspecific protein blocking, nonfat dry milk (5%, phos-
phate-buffered saline) was used for 30 minutes. Blots
were incubated with polyclonal PAR-2 rabbit antibody
(1:300; Santa Cruz Biotechnology Inc, Heidelberg, Ger-
many) and anti-GAPDH antibody (1:5000; AbDSerotec,
Kidlington, England) at 4°C overnight. After washing in
0.1% Tris, the secondary antibodies as anti-mouse
GAPDH (1:2000; AbDSerotec, Düsseldorf, Germany) and
horseradish peroxidase–conjugated anti-rabbit antibody
(1:2000, Dako Cytomation, Ghostrup, Denmark) were
applied at room temperature for 90 minutes. Following 3
series of washings in Tris-buffered saline with Tween 20,
signals were visualized by enhanced chemiluminescent
detection.
Real-Time Reverse-Transcription Polymerase
Chain Reaction
RNA extraction. Fifteen formalin-fixed, paraffin-
embedded normal pancreatic tissue samples and 15 sam-
ples of chronic pancreatitis tissue were selected for real-
time reverse-transcription polymerase chain reaction
analysis. Total RNA was isolated from five 5- to 10-"m
macrodissected sections (connective tissue excluded) using
RNeasy FFPE Kit (Qiagen, Hilden, Germany) in accordance
with the manufacturer’s instructions. RNA concentrations
were obtained using a NanoDrop Spectrophotometer ND-
1000 (Thermo Fisher Scientific Inc, Waltham, MA).
Reverse transcription of RNA. Complementary
DNA samples were prepared from 1 "g total RNA using
a High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Carlsbad, CA) as specified by the manufacturer.
Primer design. Gene-specific primers were de-
signed by AlleleID 6.01 primer design software (Premier
Biosoft International, Palo Alto, CA) for real-time reverse-
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transcription polymerase chain reaction. Isoform speci-
ficity and primer sizes were checked by BioEdit biological
sequence alignment editor software (Tom Hall Ibis Ther-
apeutics, Carlsbad, CA). Primer specificity was checked by
BiSearch software (Hungarian Academy of Sciences, In-
stitute of Enzymology, Budapest, Hungary). Primer spe-
cific amplification degree (58°C) was optimized by gradi-
ent polymerase chain reaction. The used primer sequences
are shown in Supplementary Table 1.
Reverse-transcription polymerase chain reac-
tion. Real-time reverse-transcription polymerase chain
reaction analysis was performed using SYBR Green tech-
nology on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA), according to the
manufacturer’s instructions. !-actin was used as the in-
ternal control gene. Primer-specific amplification was
controlled by 2% agarose gel electrophoresis, as well as by
melting temperature analysis. The final 20 "L reaction
mixture contained Power SYBR Green PCR Master Mix
(Applied Biosystems), 10 pmol/L of forward and reverse
primers, and 100 ng complementary DNA as template.
Amplification conditions were as follows: incubation at
95°C for 10 minutes, followed by 45 cycles at 95°C for 15
seconds, 60°C for 60 seconds, and 72°C for 15 seconds,
with subsequent melting analysis, heating to 95°C for 20
seconds, cooling to 45°C for 10 seconds, and then re-
heating to 95°C.
Statistical Analysis
Data are expressed as means ' SEM. Significant
difference between groups was determined by analysis of
variance. Statistical analysis of the immunohistochemical
data was performed using the Mann–Whitney U test.
Probability values of P % .05 were accepted as being
significant.
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Supplementary Figure 1. Effects of PAR-2-AP and trypsin on [Ca2!]i in microperfused guinea pig pancreatic ducts at pH 8.0. (A) Light (1) and
fluorescent ratio images (2 and 3) of microperfused pancreatic ducts showing the effects of luminal administration of 10 "mol/L PAR-2-AP and 10
"mol/L PAR-2-ANT on [Ca2!]i at pH 8.0. Images were taken before (1 and 2) and after (3) exposure of the ducts to PAR-2-AP or trypsin. An increase
in [Ca2!]i is denoted by a change from a “cold” color (blue) to a “warmer” color (yellow to red); see scale on the right. (B and C) Representative
experimental traces and summary data of the changes in [Ca2!]i at pH 8.0. (D) The same protocol was used to evaluate the effects of trypsin. (E and
F) Representative experimental traces and summary data of the changes in [Ca2!]i. n$ 3–4. *P% .05 vs 1 "mol/L PAR-2-AP or 0.1 "mol/L trypsin,
respectively. **P % .001 vs 10 "mol/L PAR-2-AP or 10 "mol/L trypsin, respectively.
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Supplementary Figure 2. Effects of PAR-2-AP and trypsin on [Ca2!]i in microperfused guinea pig pancreatic ducts at pH 6.8. (A) Light (1) and
fluorescent ratio images (2 and 3) of microperfused pancreatic ducts showing the effects of luminal administration of 10 "mol/L PAR-2-AP and 10
"mol/L PAR-2-ANT on [Ca2!]i at pH 6.8. Images were taken before (1 and 2) and after (3) exposure of the ducts to either PAR-2-AP or trypsin. The
colors are described in Supplementary Figure 1; see scale on the right. (B and C) Representative experimental traces and summary data of the
changes in [Ca2!]i at pH 6.8. (D) The same protocol was used to evaluate the effects of trypsin. (E and F) Representative experimental traces and
summary data of the changes in [Ca2!]i at pH 6.8. n $ 3–4. *P % .05 vs 1 "mol/L PAR-2-AP or 0.1 "mol/L trypsin, respectively. **P % .001 vs 10
"mol/L PAR-2-AP or 10 "mol/L trypsin, respectively.
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Supplementary Figure 3. Summary of the effects of PAR-2-AP and trypsin on [Ca2!]i in microperfused guinea pig pancreatic ducts at different
extracellular pH values. (A) The elevation in [Ca2!]i evoked by 1 "mol/L PAR-2-AP and (B) 0.1 "mol/L trypsin at different extracellular pH values (6.8;
7.4; 8.0). n $ 3–4. *P % .05 vs at pH 6.8.
Supplementary Figure 4. The vicious trypsin cycle. If trypsin is present in the duct lumen, PAR-2 receptors on the duct cell are activated, leading
to Ca2! release from intracellular stores and an increase in cytosolic Ca2! concentration. This causes inhibition of the luminal anion exchangers and
CFTRCl" channels reducing bicarbonate secretion by the duct cell. The decrease in bicarbonate secretion will decrease luminal pH in the duct, which
strongly accelerates the autoactivation of trypsinogen to trypsin. The activated trypsin will further inhibit bicarbonate transport by the duct cells,
leading to a vicious cycle generating further decreases in luminal pH and enhanced trypsinogen activation with the potential for damaging the gland.
The cycle may eventually be broken by the down-regulation of duct cell PAR-2 expression once pancreatitis is established. N, nucleus.
Supplementary Table 1. Nucleotid Sequences of the Primers Used in the Study.
Gene name Primer sequence (5= to 3=)
Product length
(base pairs)
Annealing
temperature (°C)
!-actin GTACGCCAACACAGTGCTG (sense) 100 55
CTTCATTGTGCTGGGTGCC (antisense)
PAR-2 GGCACCATCCAAGGAACCAATAG(sense) 128 58
GCAGAAAACTCATCCACAGAAAAGAC (antisense)
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Abstract Myofibroblasts play central roles in wound
healing, deposition of the extracellular matrix and epithelial
function. Their functions depend on migration and prolif-
eration within the subepithelial matrix, which results in
accelerated cellular metabolism. Upregulated metabolic
pathways generate protons which need to be excreted to
maintain intracellular pH (pHi). We isolated human gastric
myofibroblasts (HGMs) from surgical specimens of five
patients. Then we characterized, for the first time, the
expression and functional activities of the Na+/H+ exchanger
(NHE) isoforms 1, 2 and 3, and the functional activities of
the Na+/HCO3
− cotransporter (NBC) and the anion exchang-
er (AE) in cultured HGMs using microfluorimetry,
immunocytochemistry, reverse transcription polymerase
chain reaction and immunoblot analysis. We showed that
NHE1–3, NBC and AE activities are present in HGMs and
that NHE1 is the most active of the NHEs. In scratch wound
assays we also demonstrated (using the selective NHE
inhibitor HOE-642) that carbachol and insulin like growth
factor II (IGF-II) partly stimulate migration of HGMs in a
NHE1-dependent manner. EdU incorporation assays
revealed that IGF-II induces proliferation of HGMs which
is inhibited by HOE-642. The results indicate that NHE1
is necessary for IGF-II-induced proliferation response
of HGMs. Overall, we have characterized the pHi
regulatory mechanisms of HGMs. In addition, we demon-
strated that NHE1 activity contributes to both IGF-II- and
carbachol-stimulated migration and that it is obligatory for
IGF-II-induced proliferation of HGMs.
Keywords Fibroblast . Na+/H+ exchange . Gastrointestinal
tract . Human
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EDTA Ethylenediamine tetra-acetic acid
EdU 5-Ethynyl-2-deoxyuridine
ER Endoplasmic reticulum
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GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
H2DIDS 4,4′-Diisothiocyanatodihydrostilbene-2,
2′-disulfonic acid
HaCaT cells Human adult low calcium temperature
keratinocytes
HEPES (4-(2-Hydroxyethyl)-1-piperazine-
ethanesulfonic acid
HGM Human gastric myofibroblast
HOE-642 4-Isopropyl-3-methylsulphonylbenzoyl-
guanidin methanesulphonate also known
as cariporide
IGF-II Insulin like growth factor II
IP3 Inositol 1,4,5-trisphosphate
J(B− ) Base flux
NBC Na+/HCO3
− cotransporter
NF-κB Nuclear factor kappa B
NHE Na+/H+ exchanger
NMDG N-metil D-glucamine
PBS Phosphate buffered saline
pHi Intracellular pH
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PKC Protein kinase C
PLC Phospholipase C
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RPMI Roswell Park Memorial Institute
RT Room temperature
RT-PCR Reverse transcription polymerase
chain reaction
SEM Standard error of mean
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Introduction
Myofibroblasts, also known as activated fibroblasts, are
dynamic, spindle-like cells sharing the functional character-
istics of both fibrocytes and smooth muscle cells [24]. They
are crucial for the production of extracellular matrix and for
morphogenesis [42]; moreover, they take part in inflamma-
tory processes related to tissue repair and in the chronic
inflammation–adenoma–carcinoma sequence by secreting a
broad spectrum of cytokines thereby altering the microenvi-
ronment around epithelial cells [23, 41]. To accomplish their
functions, myofibroblasts migrate and proliferate in the
subepithelial compartment, generating acidic metabolites
and consequently protons in the cytosol [21]. Protons are
removed from cells mainly by acid/base transporters located
on the plasma membrane [7], thus maintaining isoionic
intracellular conditions.
Although many authors have investigated the regulation
of acid/base transporters and their role in migration and
proliferation of epithelial cells [16, 31, 39, 45] or fibroblasts
[10, 11, 48, 57], no information is available concerning the
effects of acid/base transporter activities on migration and
proliferation of gastric myofibroblasts.
One of the main proton extrusion mechanisms is sodium/
hydrogen exchange through the Na+/H+ exchangers (NHEs),
which are members of a transporter family comprising of ten
isoforms [32, 44]. It has been demonstrated that NHE1
functions not only as a cation exchanger, but also as a
modulator of intracellular signalling thereby regulating
motility in different animal species including mouse [53], rat
[14], dog [30], guinea pig [57] and human cells including
leukocytes [49], melanoma cells [55] and hepatoma cells [67].
NHE1 activity was found to be necessary for proliferation of
brain-derived pericytes [25], fibroblasts [26], lymphocytes
[60] and vascular smooth muscle cells [65]. Furthermore,
inhibition of NHE1 activity significantly reduces proliferation
rates in vascular smooth muscle cells [65].
It has been demonstrated that gastric epithelial cells
secrete matrix metalloproteinase-7 which cleaves
myofibroblast-produced insulin-like growth factor binding
protein-5 thereby releasing insulin-like growth factor-II
(IGF-II). IGF-II acts as a potent stimulant of both epithelial
and myofibroblast proliferation [36]. The muscarinic
acetylcholine receptor type 3 (M3) agonist carbachol has
been shown to increase NHE activity in rabbit parietal cells
[3] and in guinea pig pancreatic ductal epithelial cells [59].
Many inhibitors of NHE activity have been described as a
consequence of intensive research on amiloride derivatives
to develop isoform-specific NHE inhibitors for use in
cardiovascular care. 4-Isopropyl-3-methylsulphonylbenzoyl-
guanidin methanesulphonate (HOE-642), also known as
cariporide, is one of the most effective compounds, which
can dose-dependently inhibit specific NHE isoforms [47].
The aim of this study was to characterize the acid/base
transporters of human gastric myofibroblasts (HGMs), focus-
ing on the possible roles of NHE1 in cell migration and
proliferation.
Materials and methods
Chemicals and solutions
Chemicals and solutions used for cell culture were purchased
from Sigma-Aldrich (Budapest, Hungary). All reagents for
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immunocytochemistry, unless indicated otherwise, were
purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA, USA). Chemicals and reagents for polymerase
chain reaction (PCR), unless indicated otherwise, were
obtained from Promega (Southampton, UK). All primers
were purchased from Eurogentec (Southampton, UK).
HOE-642 (cariporide) was kindly donated by Sanofi-
Aventis (Frankfurt, Germany). 2,7-Biscarboxyethyl-5(6)-
carboxyfluorescein-acetoxymethylester (BCECF-AM) and
HOE-642 were dissolved in dimethyl sulfoxide. The compo-
sition of solutions used for the measurements of intracellular
pH (pHi) is given in Table 1. 4-(2-Hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES) solutions were titrated to pH 7.4
at 37°C using either NaOH or HCl. HCO3
−-buffered solutions
were gassed with 95% O2 and 5% CO2 at 37°C.
Ethics
The study was approved by the Ethics Committee of the
University of Szeged, Hungary. All surgical patients gave
informed consent.
Patients, isolation and culture of HGMs
Tissue specimens from patients undergoing gastric tumour
resection in the Department of Surgery, University of Szeged,
Hungary were obtained intraoperatively at least 3–4 cm away
from the tumour and were transported immediately to the
laboratory in ice-cold media for culturing (n=3). Two other
specimens from multiple organ cadaver donors were
obtained similarly. Patient details can be found in Table 2.
Histopathology confirmed that all specimens were normal
gastric tissue samples. The isolation of HGMs was performed
using a previously described method [27]. Briefly, the speci-
mens were washed and chopped into very small pieces and
were then bathed in a shaking water bath at 37°C for 15 min
with 1 mM dithiothreitol. After washing, the specimens were
incubated for 30 min at 37°C with 1 mM ethylenediamine
tetra-acetic acid (EDTA) four times. Specimens were cultured
for 1–2 weeks in Roswell Park Memorial Institute (RPMI)
medium supplemented with 10% fetal bovine serum, 1%
penicillin–streptomycin and 2% antibiotic–antimycotic solu-
tion. After the cells became confluent, they were trypsinized
with 0.25% trypsin-EDTA and were transferred into Dulbec-
co’s Modified Eagle’s Medium (DMEM) with 4 mM L-
glutamine containing 10% fetal bovine serum, 1% amino
acid solution, 1% penicillin–streptomycin and 2% antibiotic–
antimycotic solution. The medium was replaced every 48 h
and the cells were passaged after reaching confluency up to
Table 1 Composition of solutions. Values are in millimolar concentrations
HEPES HCO3
− NH4Cl
HEPES
NH4Cl
HCO3
−
Cl−-free
HEPES
Cl−-free
HCO3
−
Cl−-free
NH4Cl/
HEPES
Cl−-free
NH4Cl/
HCO3
−
Na+-free
HEPES
Na+-free
HCO3
−
Na+-free
NH4Cl/
HEPES
Na+-free
NH4Cl/
HCO3
−
High K+-
HEPES
NaCl 130 115 110 95 5
KCl 5 5 5 5 5 5 5 5 130
Na-HEPES 10 25 10 10
CaCl2 1 1 1 1 1 1 1 1 1
MgCl2 1 1 1 1 1 1 1 1 1
Glucose 10 10 10 10 10 10 10 10 10 10 10 10 10
NH4Cl 20 20 20 20
NaHCO3 25 25
HEPES 10 10 10 10
Na-gluconate 140 115 120 95
K2-sulfate 2.5 2.5 2.5 2.5
Ca-gluconate 6 6 6 6
Mg-gluconate 1 1 1 1
NH4-sulfate 20 20
NMDG 140 115 120 95
Atropine 0.01 0.01 0.01
Choline-HCO3 25 25 25
Table 2 Patients’ details
Patient no. Gender Age Diagnosis
1 Female 71 Gastric cancer
2 Male 76 Gastric cancer
3 Male 66 Gastric cancer
4 Female 42 Subarachnoidal haemorrhage
5 Male 49 Traumatic head injury
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passage 10. Cell cultures were continually incubated at 37°C
in a mixture of 5% CO2 and 95% air.
Immunocytochemistry
Twelve thousand HGMs were seeded onto chamber slides
and were allowed to adhere overnight. Cells were fixed
using 4% paraformaldehyde for 30 min and were washed
twice with phosphate buffered saline (PBS, Invitrogen,
Paisley, UK). Permeabilization was performed by incuba-
tion with a filtered, PBS-based solution containing 0.2%
Triton X-100 and 0.3% protease-free bovine serum albumin
for 30 min. Cells were then incubated with 10% donkey
serum in PBS for 30 min. After washing twice with PBS,
primary antibodies were added to the chambers and the slides
were incubated in moist atmosphere at 4°C, overnight. The
following primary antibodies were used: anti-α-smooth
muscle actin (α-SMA) antibody raised in guinea pig (1:400),
anti-vimentin antibody raised in mouse (1:400), anti-
cytokeratin antibody raised in mouse (1:400), anti-desmin
antibody raised in mouse (1:400, all four antibodies from
Dako, Denmark) and anti-NHE1, -NHE2 and -NHE3
antibodies raised in goat (1:50, purchased from Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Primary
antibodies were removed by a sequence of washes for
10 min each with 0.14, 0.5 and 0.14 M NaCl dissolved in
PBS, respectively. Slides were then incubated with
secondary antibodies for 60 min in dark and moist conditions.
The following secondary antibodies were used: fluorescein
isothiocyanate (FITC)-conjugated anti-guinea pig secondary
antibody [1:400, diluted in 10 mM HEPES, pH 7.5], Texas
Red- and FITC-conjugated anti-mouse antibody (1:400) and
FITC-conjugated anti-goat secondary antibody (1:400). After
hybridization, slides were washed three times with PBS and
were covered with 4,6-diamidino-2-phenylindole (DAPI)
containing Vectashield mounting medium (Vector Labora-
tories, Peterborough, UK), then cover slipped.
Intracellular pH measurement
One hundred thousand HGMs were seeded onto 24-mm-
diameter round glass coverslips in full media. They were
allowed to recover for 24 h before experiments. Coverslips
were then transferred into a perfusion chamber and
mounted on an inverted microscope (Olympus, Budapest,
Hungary). Cells were bathed in HEPES solution at 37°C
and were loaded with 2 μM pH-sensitive fluorescent dye
BCECF-AM (Invitrogen, Paisley, UK) for 20 to 30 min.
Thereafter, myofibroblasts were continuously perfused with
solutions at a rate of 5 to 6 ml/min and pHi was measured
by using an imaging system (CellR; Olympus, Budapest,
Hungary). Cells were excited at wavelengths of 490 nm and
440 nm, and the 490/440 fluorescence emission ratio was
measured at 535 nm. One pHi measurement was recorded
per second.
In situ calibration of the fluorescence signal was performed
using the high K+-nigericin technique as previously described
[22, 58]. The pH of high K+–HEPES solution supplemented
with 10 μM nigericin was set to 6.8 or 7.4 at 37°C, then cells
loaded with BCECF were superfused by these solutions and
the 490/440 fluorescence ratio was recorded. Multiple-point
calibrations, i.e. sequential BCECF pH measurements (with
high K+–HEPES–nigericin solutions ranging pH from 6.2 by
0.4 step to 8.2) were performed to confirm data accuracy.
Linear projections were made from the steady-state fluores-
cence pH data during high K+-nigericin superfusion with
known pH. Adaptation of projections to the resting fluores-
cence data of unknown pHi in standard HEPES solution
results in accurate resting pHi.
In order to characterize the acid/base transporters, we
used ion-withdrawal technique, and ammonium pulse
technique in HEPES- and HCO3
−/CO2-buffered solutions.
Initial rates (first 30–60 s) of recovery from acidosis were
calculated by linear regression.
Determination of buffering capacity and calculation of base
fluxes
The intrinsic buffering capacity (βi) of HGMs was estimated
by the NH4
+ pre-pulse technique [62]. βi refers to the ability
of intrinsic cellular components (excluding the bicarbonate
buffer system) to buffer changes of pHi. Briefly, HGMs were
exposed to various concentrations of NH4Cl while Na
+ and
HCO3
− were omitted from the solution to block the Na+-
dependent pH regulatory mechanisms. βi was estimated by
the Henderson–Hasselbalch equation. The total buffering
capacity (βtotal) was calculated as βtotal=βi+βHCO3
−=βi+
2.3×[HCO3
−]i, where βHCO3
− is the buffering capacity of the
HCO3
−/CO2 system and [HCO3]i is the intracellular concen-
tration of HCO3
−. Transmembrane base flux [J(B−)] was
calculated by using the equation J(B−)=dpH/dt×βtotal. The
βtotal value used in the calculation of J(B
−) was obtained
from Fig. 2b by using the pHi value at the start of the 30-s
period over which dpH/dt was measured.
Reverse transcription polymerase chain reaction
RNA was isolated from myofibroblast cultures using a
Qiagen RNEasy Mini Kit (Qiagen House, Crawly, UK)
according to the manufacturer’s instructions; human kidney
RNAwas isolated from whole tissue from surgical specimens
utilizing TRIzol reagent. RNA was reverse transcribed to
cDNA and RNA/primer annealing was performed with 0.5 μg
oligo-dT primer at 65°C for 5 min. After cooling, samples
were reverse transcribed in a final reaction volume of 30 μl
containing the annealed RNA/primer set, 5× AMV (avian
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myeloblastosis virus) buffer, 1.25 mM dNTP (deoxyribonu-
cleotide-triphosphates) mix, 20 unit RNAse inhibitor and 15
unit AMV-RT (AMV-reverse transcriptase). Reactions were
incubated at 42°C for 1 h; enzymes were inactivated at 85°C
for 5 min. cDNA (1 μl) was used as template for each PCR in
a final volume of 25 μl, containing 10× master mix
Taq-buffer, 10 nM dNTPs, 2.5 unit Taq-polymerase and
1 μM NHE primer sets. The sequence of NHE primers
is given in Table 3. PCR settings were as follows:
denaturation at 95°C for 15 s, annealing at 60°C for 15 s,
extension at 72°C for 45 s, 30 cycles. PCR products and
DNA HyperLadderPlus (BioLine, Taunton, USA) were
run on a 0.8% agarose gel containing 0.005% ethidium
bromide in Tris-buffered EDTA solution at 80 V, then the
gel was illuminated in a BioRad UV (ultraviolet) chamber
and photographs were taken.
Immunoblot analysis
Confluent cells (3,000,000 cells at least) were washed with
PBS after removing the media and were then incubated
with 100 mM EDTA for 15 min. After centrifugation
(500×g, 8 min), the supernatant was gently removed and
was lysed with RIPA (radio-immuno precipitation assay)
buffer supplemented with 1% protease inhibitor cocktail
(Calbiochem-Merck Chemicals, Darmstadt, Germany).
Samples were vortexed and frozen in liquid nitrogen for a
few seconds then centrifuged at 11,000×g for 10 min at
4°C. The protein concentrations of supernatants containing
whole cell protein lysates were determined by using
Bradford’s reagent. Samples were heat treated at 30°C for
30 min and 100 μg protein was electrophoresed on 8%
sodium dodecylsulfate-polyacrylamide gels according to
the method of Laemmli using a Hoefer Mighty Small II
instrument (Harvard Bioscience Inc., Massachusetts, USA).
After separation, proteins were blotted to matching-sized
nitrocellulose membrane for 60 min at 100 V. Membranes
were blocked in 5% nonfat dry milk for 1 h and were
incubated with primary antibodies (1:100 for NHE)
overnight at 4°C on a rocker. The same NHE primary
antibodies were used as for immunocytochemistry. Primary
antibodies were removed by washing with TBST for 3×
10 min. HRP-conjugated secondary antibodies (Dako,
Denmark) were applied for 60 min at RT on a rocker. After
3×10 min TBST wash, the immunoreactive protein was
visualized by enhanced chemiluminescence. Remaining
antibodies were removed by washing with TBST, then
anti-glyceraldehyde 3-phosphate dehydrogenase antibody
(Dako, Denmark) was added to the membrane for 60 min at
RT. Secondary antibody (1:10,000) was also applied for
60 min at RT then signals were recorded as described
earlier.
Migration assays
HGMs (125,000 cells) were seeded onto six-well plates and
allowed to adhere overnight in full media. On the following
day, the confluent monolayer was gently scratched using a P2
tip. Only the wells containing even-sided and sharp-edged
wounds were used for experiments. After gentle washing for
three times with serum-free media, wounds were measured
and photographed under inverted light microscope. Reagents
were then added to the wells in serum-free media in all of the
experiments and plates were incubated in CO2 incubator at
37°C for 24 h. Migration was evaluated by counting the cells
in the same area of the wound after 12 and 24 h as reported
earlier [43].
Proliferation assays
Myofibroblasts (50,000 cells) were seeded onto cover
glasses. After overnight incubation, HGMs were synchro-
nized by incubation for 30 h in serum-free media.
Thereafter, 10 μM 5-ethynyl-2-deoxyuridine (EdU; Alexa
Fluor 488 Imaging Kit, Invitrogen, Oregon, USA; for
further details, see reference [50]) was added to the cells for
overnight incubation with or without treatment. After
incubation, the manufacturer’s protocol was applied to fix
and permeabilize the cells and to detect EdU incorporation.
We used DAPI to detect nuclear staining. The proliferation
rate was calculated by normalizing the number of EdU
positive cells to the DAPI-stained cells in 10 fields at 20x
magnification.
Statistical analysis
Values are expressed as means±standard error of mean
(SEM). Statistical analyses were performed using non-
parametric Kruskal–Wallis tests with post-hoc Wilcoxon
tests for pairwise comparisons and Bonferroni correc-
tion to test post-hoc significance. p<0.05 was accepted
as significant. n numbers are given as follows: n =
number of patients/number of independent experiments
per patient.
Table 3 NHE primer sequences
Primer name Sequence (5' - 3')
NHE1 forward CCT-CTC-TGG-GTG-GAG-AAG-CT
NHE1 reverse CCC-AGG-AAC-GAC-ACA-GAA-AG
NHE2 forward CCA-TGG-AAC-CAC-TGG-GCA-AC
NHE2 reverse TGC-AGG-GGG-AGA-CTT-CTC-AT
NHE3 forward TCC-AAG-TCG-ACC-AAG-CTG-GG
NHE3 reverse AAG-GCC-TCG-TCC-GGA-GAA-AA
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Results
Identification of myofibroblasts
Cells showed positive staining for α-SMA and vimentin but
not for cytokeratin and desmin, which are characteristics of
myofibroblasts (Fig. 1). The purity of the HGM cell cultures
was ∼100%. As positive controls for cytokeratin and desmin
antibodies, we used CAPAN-1 (human pancreatic adenocar-
cinoma cell line) cells and cultured human high grade
pancreatic neuroendocrine carcinoma cells, respectively. In
both cases, appropriate localisation was demonstrated
(Fig. 1).
Determination of the resting pHi of HGMs
The multiple-point calibration technique utilizing high
K+–HEPES/nigericin solution was used to determine the
resting pHi of HGMs. Our experiments showed that the
resting pHi of HGMs in HEPES solution was 7.09±0.02
(Fig. 2).
Characterization of the acid/base transporters of HGMs
Next we tried to identify the functionally active acid/base
transporters expressed on the plasma membrane of
HGMs. Na+ withdrawal from the standard HEPES solution
Fig. 1 Immunocytochemical identification of cell cultures. Cells
isolated from human gastric samples were grown on chamber slides
and were subjected to immunocytochemical analysis of vimentin and
α-smooth muscle actin (α-SMA) expression as specific markers of
myofibroblasts. Cytokeratin and desmin antibodies were used for
detecting epithelial and muscle cells, respectively. Nuclei were
counterstained with DAPI (blue). Vimentin (red) and α-SMA (green)
verified the presence of myofibroblasts, whereas no epithelial or
smooth muscle cells were detected (n=5/1–2). Control stainings were
performed to test the desmin and cytokeratin antibodies. Cultured
cancer cells (from human high grade pancreatic neuroendocrine
carcinoma) were used as positive controls for desmin (green staining,
n=1). To test the cytokeratin antibody, control staining was performed
on CAPAN-1 (human pancreatic adenocarcinoma cell line) cells.
Green staining shows cytokeratin; blue staining shows DAPI (n=1)
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Fig. 2 The resting pHi of gas-
tric myofibroblasts and mea-
surement of buffering capacity.
A Human gastric myofibroblasts
(HGMs, 100,000) were seeded
onto cover glass to form mono-
layers. Cells were allowed to
recover for 24 h. a Phase
contrast image of myofibroblasts
is shown. Four to seven cells
as regions of interests (ROIs)
were marked. b Thermal-
adjusted image is shown to
demonstrate homogenous
BCECF dye distribution. Color
coding shows the pHi; c 490
and d 440 nm fluorescent
images are also shown. e Cells
were excited at wavelengths of
490 and 440 nm after loading
the cells with the pH-sensitive
fluorescent dye 2 μM
BCECF-AM, and the 490:440
fluorescence emission ratio was
measured at 535 nm. Cells
were exposed to continuous
perfusion with nigericin/high
K+–HEPES solutions of pH 6.80
and 7.40. The resting pHi was
calculated by multiple-point
calibration (n=5/5–6). The
figure shows a representative
calibration curve; the mean
resting pHi in standard HEPES
solution was 7.09±0.02. B
The buffering capacity of HGMs
was determined by exposing
the cells to various concentra-
tions of NH4Cl while Na
+ and
HCO3
− were omitted from the
solution to block Na+-dependent
pH regulatory mechanisms.
The intrinsic buffering capacity
(βi) at different pHi (black
circle, n=85) was estimated by
the Henderson–Hasselbalch
equation. Regression analysis
was performed using the
curve-fitting protocol in Excel.
The total buffering capacity
(βtotal) was calculated as βtotal
=βi+βHCO3
−=βi+2.3×
[HCO3
−]i, where βHCO3
− is the
buffering capacity of the
HCO3
−/CO2 system and [HCO3]i
is the intracellular
concentration of HCO3
−
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caused strong reversible acidification suggesting the
presence of an active Na+-dependent H+ efflux mechanism
(Fig. 3a).
Switching the standard HEPES solution to standard
HCO3
−/CO2 solution caused rapid intracellular acidification,
most probably due to CO2 diffusion into the cells. Thereafter,
a small pHi recovery was observed suggesting a HCO3
−
influx and/or H+ efflux mechanism (Fig. 3b). In order to
determine the Na+ dependency of this HCO3
− influx/H+
efflux mechanism, the same experiment was performed in
Na+-free conditions (Fig. 3c). Since no recovery was found
in the presence of HCO3
−/CO2 in Na
+-free solution, we can
assume that the HCO3
− influx/H+ efflux mechanism in
HGMs is Na+-dependent. These results indicate that HGMs
express functionally active NHE and/or NBC.
Next we tested whether HGMs contain functionally active
anion exchangers (AE). Cl− removal from the standard
HCO3
−/CO2 solution caused reversible alkalization suggesting
the presence of a Cl−-dependent HCO3
− efflux mechanism
(Fig. 3d). Importantly, omitting HCO3
− from the extracellular
solution in combination with Cl− removal resulted in no
significant change in pHi (Fig. 3e). This indicates that HGMs
express functionally active AE.
To confirm these findings, the activities of acid/base
transporters were also investigated by the ammonium pulse
technique. Exposure of HGMs to 20 mM NH4Cl induced
an immediate rise in pHi due to the rapid entry of the
lipophilic base, NH3, into the cells, which binds intracellu-
lar protons generating NH4
+ and causing alkalization. The
recovery from this alkali load is promoted by AEs in the
Fig. 3 Na+-dependent HCO3
− influx and Cl−-dependent HCO3
−
efflux mechanisms are present in HGMs. Representative pHi curves
of HGMs are shown. a The sudden removal of extracellular Na+ from
the standard HEPES solution caused rapid acidification, which was
reversed by the re-addition of the ion. b Administration of HCO3
−/
CO2-buffered solution after standard HEPES solution caused acidifi-
cation of pHi followed by alkalization (HCO3
− influx). c Switching
from Na+-free HEPES solution to Na+-free HCO3
−/CO2-buffered
solution caused acidification, but no pHi recovery was seen. d In
HCO3
−/CO2-buffered solution, Cl
− removal resulted in alkalization of
pHi followed by a complete recovery after re-addition of Cl
−. e Cl−
removal from the standard HEPES solution did not alter significantly
the pHi, and it reached again the resting value before re-addition of
Cl− (n=5/5–6)
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presence of HCO3
− and Cl− in the extracellular solution. In
support of this, the recovery from alkali load was much
steeper in the presence of HCO3
−/CO2 (Fig. 4c, d)
compared with the absence (Fig. 4a, b) of HCO3
−/CO2. It
is worth mentioning that the slow uptake of NH4
+ is also a
prerequisite for the acid loading. After the removal of
NH4Cl, NH3 diffuses out of the cell, therefore facilitating
the dissociation of intracellular NH4
+ to H+ and NH3, which
rapidly decreases pHi. Thereafter, the pHi starts to recover
after this acidification owing to activation of pHi regulatory
mechanisms namely the NHE, NBC and proton pumps (PP;
Fig. 4c). In the absence of extracellular HCO3
− and in the
presence of Na+, the recovery from acidosis reflects the
activity of NHE and PP (Fig. 4a). However, the lack of
recovery in the absence of Na+ excludes functionally active
PP in HGMs (Fig. 4b). The addition of HCO3
− to the
extracellular solution strongly increases the pHi recovery
from acidosis (Fig. 4c). Since there is no pHi recovery
from acidosis in Na+- and HCO3
−-free solution (Fig. 4d),
it is assumed that the HCO3
− influx mechanism is most
probably accomplished by the Na+-dependent NBC.
Therefore, we tested the effects of the NBC inhibitor
H2DIDS in 0.5 mM concentration and the NHE1 and
NHE2 inhibitor HOE-642 at 50 μM on the recovery rates
during and following an acid load in HCO3
−/CO2-buffered
solution (Fig. 4). We calculated J(B−) from these and from
the above experiments (Fig. 4) and found that NBC
inhibition greatly reduced pHi recovery after acid load
Fig. 4 Na+-dependent H+ efflux and Na+-dependent HCO3
− influx
were detected in HGMs a Representative pHi curves of HGMs are
shown. Cells were exposed to 20 mM NH4Cl pulse in HEPES-
buffered solution for 3 min. After the acid load, recovery of pHi could
be observed. However, the administration of Na+-free HEPES solution
after the ammonium pulse inhibited pHi recovery after the acid load. The
same technique was applied in HCO3
−/CO2-buffered solution. Note that
the initial phase of the pHi recovery during the ammonium pulse is
quicker than in HEPES solution and the recovery phase after the acid
load is much steeper. Also in Na+-free HCO3
−/CO2-buffered solution, no
recovery could be seen after the ammonium pulse. b The bar chart
shows the summary data of base fluxes after recoveries from acid load.
Values are shown as means±SEM (n=5/10–12). *p<0.05 vs. 25 mM
HCO3
−. c Inhibition of Na+/HCO3
− co-transporter (NBC) with 0.5 mM
H2DIDS and/or inhibition of NHE1–2 with 50 μMHOE-642 during acid
load in HCO3
−/CO2-buffered solution is shown. d The rates of recovery
from acid load were determined and base fluxes were calculated from the
experiments shown above. Absolute values are displayed for comparison
(n=5/1–2); values are shown as means±SEM. *p<0.05 vs. 140 mM
Na+, 25 mM HCO3
−; a p<0.05 vs. 25 mM HCO3
−+0.5 mM H2DIDS; b
p<0.05 vs. 25 mM HCO3
−+50 μM HOE-642
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(20.54±1.76 vs. 7.99±0.39 mM B−/min) revealing high
transporter activity. 50 μM HOE-642 further decreased the
recovery rate from acidosis (7.99±0.39 vs. 3.91±0.41 mM
B−/min) indicating high NHE1 and NHE2 activities.
Simultaneous administration of the two inhibitors resulted
in very slow recovery (0.98±0.09 mM B−/min). Without
HCO3
−/CO2 buffering in standard HEPES solution, cells
showed much slower recovery than with bicarbonate
buffering (13.36±0.41 vs. 20.54±1.76 mM B−/min). As
seen on Fig. 4b, d, eliminating Na+ from the extracellular
solution inhibited the cells to recover from an acid load in
both HCO3
−/CO2-buffered solution and in standard
HEPES solution.
Next, we focused our attention on characterizing the
NHE isoforms expressed on the plasma membrane of
HGMs. The HGMs were acid-loaded by exposure to a
3-min pulse of 20 mM NH4Cl in HEPES solution followed
by a 5-min exposure to Na+-free HEPES solution (Fig. 5a).
Since neither Na+ nor HCO3
− was present in the extracel-
lular solution, acid/base transporters were inhibited and the
pHi was adjusted to a stable acidic level. NHE activity was
induced by the re-addition of extracellular Na+ and the
activity of NHEs was determined by measuring the initial
rates of pHi recovery over the first 60 s (60 data points).
The activities of the different NHE isoforms were
determined by using the isoform selective NHE inhibitor
HOE-642 (cariporide). At 1 μM HOE642 inhibits NHE1
whereas at 50 μM it inhibits both NHE1 and NHE2,
but not NHE3 [69].
Our data indicate that NHE1 is responsible for about
85% of the Na+/H+ exchange activity, whereas NHE2
activity is around 10% and the remaining NHE activity is
approximately 5% (Fig. 5b). Of course, we cannot exclude
the possibility of the involvement of other NHEs. However,
even if they were expressed, they would only have marginal
influence on H+ efflux.
mRNA and protein expression of NHE1-3 in HGMs
Based on results of the functional measurements, we
investigated the presence of NHE transporters at the mRNA
and protein levels. Reverse transcription polymerase chain
reaction confirmed the expression of NHE1, NHE2 and
NHE3 (Fig. 5c). We also analysed the expression of NHE
isoforms in HGMs by Western blot. We found that NHE1 is
present in HGMs, but we were unable to show NHE2 and
NHE3 expression. Positive controls (human kidney) con-
firmed that the antibodies used for these studies were fit for
purpose (Fig. 5d). We speculate that NHE2 and NHE3
protein abundance is low in our lysates so below the limit
of detection. Using immunocytochemistry, we demonstrat-
ed NHE1-3 localisation to the plasma membrane of HGMs
(Fig. 5e).
IGF-II and carbachol increases NHE activity
We then investigated the effects of IGF-II and carbachol on
the activities of NHEs. Importantly, both IGF-II and carbachol
dose-dependently stimulated NHE activity. Carbachol con-
centrations were tested in range of 1–1,000 μM. Carbachol
(10 μM) had the greatest effect on NHE activity. 100 ng/ml
IGF-II was more effective than 10 ng/ml in increasing NHE
activity (Fig. 6).
Migration of HGMs is stimulated by carbachol and IGF-II
Next, we investigated the effects of carbachol and IGF-II on
cell migration and the role of NHE1 in migration of HGMs
using scratch wound assay. We found that both 100 ng/ml
IGF-II and 10 μM carbachol stimulate the migration of
HGMs (Fig. 7). Inhibition of NHE1 by HOE-642 had no
effect on unstimulated cell migration, but it significantly
inhibited both carbachol- and IGF-II-stimulated migration
(by 29±7% and 33±8%, respectively).
IGF-II increases proliferation in an NHE1-dependent
manner
Finally, we tested the effects of HOE-642, IGF-II and
carbachol on HGM proliferation. EdU incorporation assays
showed that 100 ng/ml IGF-II increased cell proliferation
over two-fold. Carbachol and/or HOE-642 did not affect
proliferation. However, NHE1 inhibition by 1 μM HOE-642
completely blocked the stimulatory effect of IGF-II on cell
proliferation (Fig. 8).
Discussion
In this study, we have characterized the pHi regulatory
mechanisms of HGMs for the first time. The data demonstrate
that NHE1 activity contributes to IGF-II- and carbachol-
stimulated migration and that it is obligatory for IGF-II-
induced proliferation of HGMs.
The resting pHi of HGMs, 7.09±0.02, is similar to that
in fibroblasts [12, 28, 46] and smooth muscle cells [64].
Myofibroblasts displayed three main acid/base transporters,
namely NBC, AE and NHE. These are also the main
mechanisms regulating pHi in fibroblasts [2, 12, 29] and in
smooth muscle cells [15]. Thus, AE decreases, whereas,
NBC and NHE increase pHi. J(B
−) calculations revealed
high NBC and high NHE activities which are the main
transporters aiding recovery from an acid load in HGMs. In
the present study we chose to focus on the roles of NHEs.
Carbachol (10 μM) strongly stimulated NHE activity of
HGMs. It has been shown that carbachol also increases NHE
(and AE) activity in lacrimal gland epithelia [59] and in rabbit
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parietal cells [3]. In the latter study, carbachol strongly
increased NHE activity and its effect was completely blocked
by 1 μM HOE-642 suggesting the involvement of NHE1.
Atropine or intracellular Ca2+ chelation inhibited the activa-
tion of NHE indicating a typical muscarinic receptor effect
with a Ca2+-dependent signalling pathway [4, 59]. In the
Fig. 5 Identification of NHE
isoforms. a Representative pHi
curves of HGMs are shown.
Cells were loaded with acid by
using the ammonium pulse
technique. After Na+
withdrawal, the isoform-
selective NHE inhibitor
HOE-642 was administered in
1 μM (inhibits NHE1) or 50 μM
(inhibits NHE1 and NHE2)
concentration, together with
re-addition of Na+. The initial
rates of the pHi recovery during
HOE-642 administration
were calculated by linear
regression analysis to determine
the activity of NHE isoforms.
b The bar chart demonstrates
that NHE1 is responsible for 83
±5%, NHE2 for 11±1% and
other isoforms for 4.5±0.8% of
all Na+/H+ exchange activity.
Data are shown as means±SEM
(n=5/5–6). c Reverse
transcription PCR confirmed the
expression of NHE1–3
isoforms (n=3/6–7). Expected
PCR product sizes are as
follows: NHE1, 341 bp; NHE2,
407 bp; NHE3, 299 bp. In
water blind, we used water as
template. d Immunoblot analysis
showing different NHE isoforms
in HGMs and human kidney
controls. Protein sizes are as
follows: NHE1, 95 kDa; NHE2,
85 kDa; NHE3, 75 kDa;
GAPDH, 36 kDa (n=4–5/3–10).
e NHE1, NHE2 and NHE3
were identified by immunocyto-
chemistry in the plasma
membrane of HGMs. Nuclei
were counterstained with DAPI
(blue staining). No specific
staining was detected when the
primary antibody was omitted
(n=3/1–2)
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Fig. 6 The effects of carbachol and IGF-II on NHE activity. a
Representative pHi curves of HGMs are shown. We tested different
carbachol and IGF-II concentrations on NHE activity using the
ammonium pulse technique. The figure shows the effects of 10 μM
carbachol and 100 ng/ml IGF-II treatment. Note that the changes in
the rates of pHi recovery from acidosis during treatment are much
higher compared with the recovery rates without IGF-II or carbachol
treatment. b The bar diagram shows the summary data obtained from
the above mentioned experiments. Administration of 10 μM carbachol
and 100 ng/ml IGF-II significantly increased NHE activity. Values are
normalized to the basal NHE activity. Data are shown as means±SEM
(n=5/5–6). *p<0.05 vs. 0 μM or 0 ng/ml
Fig. 5 (continued)
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latter publications, the authors suggested that Ca2+-dependent
stimulation causes a selective activation of NHE1, whereas
cAMP-dependent stimulation with forskolin-activated NHE1,
NHE2 and more strongly NHE4. In HCO3
−-containing
solution, pHi did not change indicating that activation of
NHE and AE is primarily volume regulatory mechanisms,
and they speculated that the physiological significance of
secretagogue-induced NHE activity may be related to volume
and not to pHi regulation during acid secretion of rabbit
parietal cells [3].
IGF-II, which has been shown to stimulate migration and
proliferation of many cell types including myofibroblasts
Fig. 7 Carbachol and IGF-II treatment increased migration rates of
HGMs in a NHE1-dependent manner. a HGMs (100,000) were
cultured in six-well plates. After reaching confluency, the monolayer
was wounded by a P2 tip along an oriented line in the middle of the
well and detached cells were removed by washing with serum-free
media. Only wounds with sharp and even edges were used for
experiments. Reagents were added to the wells in serum-free media
and the plate was incubated for 24 h at 37°C, 5% CO2. Images were
taken at 0, 12 and 24 h from representative areas. Cells were treated
with or without 10 μM carbachol or 100 ng/ml IGF-II, and/or 1 μM
HOE-642 and cells which migrated into the wound were counted at 12
and 24 h. The scale bar on the first picture represents 100 μm. b The
bar chart shows the migration rates normalized to the basal rate at 24 h.
Values are shown as means±SEM, n=5/1–3; *p<0.05 vs. no treatment,
a p<0.05 vs 100 ng/ml IGF-II, b p<0.05 vs 100 ng/ml IGF-II and 1 µM
HOE-642, c p<0.05 vs 10 µM carbachol
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[36, 52], also stimulated NHE activity. It is known that
IGF-II exerts its effects through the tyrosine kinase receptor
IGF-IR and it is also well known that NHE1 is mainly
regulated by phosphorylation. Meima et al. reported that
IGF-IR activates Ser/Thr kinases in the Akt signalling
pathway and increases myofibroblast migration, growth and
NHE activity by phosphorylating intracellular NHE regula-
tory domains thus enhancing transporter activity [37]. The
distal region of the cytoplasmic tail of NHE corresponding to
amino acids 700–815, is enriched in serine and threonin
residues that are phosphorylated by different protein kinases
in response to hormones and/or growth factors [51]. It has
also been suggested that Ser/Thr kinases not only stimulate
NHE1 activity, but also increase NHE1 promoter transcription
[5]. ERK1/2 regulates gene expression via the MAPK
cascade [40] after NHE1 phosphorylation/activation through
p90RSK (a downstream substrate of ERK1/2) [56]. p90RSK
directly phosphorylates NHE1 at position 703(Ser) in vascular
Fig. 8 IGF-II stimulates the proliferation of HGMs in a NHE1-
dependent manner. a Representative images showing EdU localisation
after treatment with 1 μM HOE-642, 100 ng/ml IGF-II and/or 10 μM
carbachol compared to control. HOE-642 (1 μM) did not affect
proliferation either on its own, or in a combination with 10μMcarbachol.
IGF-II (100 ng/ml) increased the rate of proliferation. Furthermore, the
inhibition of NHE1 suppressed the IGF-II stimulatory response. Nuclei
were counterstainedwith DAPI (blue staining). The scale bar on the first
picture represents 50 μm. b The bar chart shows the proliferation rates
of a normalized to the basal proliferation rate; *p<0.05, a p<0.05 vs
100 ng/ml IGF-II (n=5/1–2)
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smooth muscle cells after growth hormone treatment and the
exchanger activity was found to be increased [56]. Another
important factor in the regulation of NHE is protein 14-3-3,
which binds to position 703(Ser) after its phosphorylation
and limits dephosphorylation by protein phosphatases [33].
Additional Ser/Thr phosphorylation sites have been recently
identified in the ERK pathway, but their importance must be
confirmed [35].
Our experiments demonstrate that reagents increasing NHE
activity also increase HGM migration and proliferation, so the
question arises whether in turn NHE inhibition may inhibit cell
migration and proliferation. The effects of parasympathomi-
metics on cell migration are conflicting, though they are
thought to stimulate NHE activity in general. In HaCaT cells,
carbachol did not alter single random cell locomotion
compared to non-treated cultures [38]. Epidermal keratino-
cytes showed enhanced migration after long-term muscarinic
stimulation with acetylcholine in an agarose gel outgrowth
system [18], whereas carbachol treatment arrested wound
healing in epidermal keratinocytes [9]. Besides the differences
between species and tissues, it seems that various muscarinic
receptors can mediate different migration responses even in
the same cell [63]. Our experiments clearly showed that
10 μM carbachol stimulated migration of HGMs, at least
partly in a NHE1-dependent manner, but higher or lower
doses had no further effect on migration (data not shown). It
is known that protein kinase C (PKC) might mediate M3
receptor signals causing PLC to cleave membrane phospho-
lipids. PIP2 is cleaved into diacyl glycerol and IP3 which is
released into the cytosol and binds to IP3 receptors localised
at the ER (or SR) causing consequent increase of the
cytosolic calcium concentration and a cascade of activity
including locomotion of contractile cells [1]. M3 receptors,
through PLC, may also activate PI3K/Akt cascade. In the
context of gastric cancer, it is worth mentioning that apoptosis
can be suppressed through the PI3K/Akt/mTOR pathway
allowing vigorous proliferation and better survival [68]. PKC
modulates gene regulation via NF-κB and by joining Raf/
MAPK cascade. It has been shown recently that PKC may
phosphorylate the potent activation transcription factor-2,
which controls c-Jun-mediated activation of transcription
[66]. The observed increase in migration in our studies
suggests, however, a permissive or supporting role of NHE1
in enabling migratory mechanisms to take effect in response
to bioactive compounds. Others have found that not only
NHE1 activity, but also intact NHE1 protein structure is
required for locomotion, since mutations/modifications of
protein structure or inhibition of the exchanger activity also
inhibits migration [30]. Notably, NHE1 is a scaffolding-
organizing protein functioning as a transmembrane signal
transducer for various agents modulating cell volume, cell
migration and growth through NHE1 activity [27]. Muscarinic
agonists have also been shown to evoke differential effects on
proliferation depending on the type of the muscarinic receptor
[63]. We found that the M3 agonist carbachol does not induce
proliferation of HGMs.
IGF-II stimulates the proliferation of many cell types,
including myofibroblasts [19, 36]. NHE1 may act as an
organizer of different cell growth inducing signals through
modulation of transporter activity via receptor tyrosine
kinases and joint pathways. Denker et al. reported that
NHE1 protein contains an intracellular esrin/radixin/moesin
(ERM) motif close to the plasma membrane, which anchors
the protein to the subcortical actin filament network and
serves as a host to actin polymerization [14]. In a wound
healing assay, migration was impaired when mutations
disrupted the ERM site. Not only ERM site mutations,
but also mutations of the transporter sequence (resulting
in diminished NHE1 activity), impair de-adhesion
resulting in failure to retract lamellipodia. Besides this
membrane anchoring, NHE1 is important in regulating
cell volume and local pH at changing membrane sites of
a moving cell; it is known that in fibroblasts NHE1 is most
abundant at the rear and front pole of a spatially polarized
migrating cell [14].
We showed that inhibition of NHE1 blocks migration
and proliferation of HGMs. Since stromal cells play an
important role in cancer initiation and progression [6, 13,
31], our results may have both physiological and therapeu-
tic relevance. It is well documented that proliferation is
reduced by NHE1 inhibition in human cancer cells [20, 49].
However, it is also possible that intracellular alkalization
simply promotes or permits proliferative responses, because
as the pHi becomes more alkaline, cellular metabolism
becomes more rapid mainly due to the more effective energy
producing mechanisms [20]. For example, in tumour cells,
acid/base conditions are of particular importance, because
cancer cells share an aberrant intracellular alkalization
facilitating their malignant behavior, whereas the microenvi-
ronment becomes more acidic [8]. Nevertheless, as mentioned
before, NHE1 is highly regulated by phosphorylation and Akt
kinases that phosphorylate NHE1 increasing its activity also
stimulate proliferation at the same time [17, 34, 54].
In conclusion, we have demonstrated that HGMs express
functionally active NHE, NBC and AE transporters which
regulate pHi. Furthermore, we have shown that NHE1
contributes to IGF-II- and carbachol-stimulated migration,
and that it is obligatory for IGF-II-induced proliferation.
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TRIPSZINOGÉN AKTIVÁCIÓS PEPTID MUTÁCIÓK ÖRÖKLETES 
PANKREATITISZBEN 
 
Tézis kivonat 
 
BEVEZETÉS  
A krónikus pankreatitisz a hasnyálmirigy visszatérő vagy folyamatos gyulladásos 
megbetegedése, amelyet visszafordíthatatlan morfológiai változások, fájdalom, valamint az 
exokrin és endokrin pankreatikus funkciók tartós károsodása jellemez. A krónikus 
pankreatitisz genetikai hátterének kutatása az örökletes pankreatitisz vizsgálatával kezdődött. 
A klasszikus értelemben vett örökletes forma egy ritka autoszómális domináns 
öröklésmenetet mutató betegség, melyet a humán kationos tripszinogént kódoló PRSS1 gén 
mutációi okoznak. A tripszinogén mutációk okozta megbetegedések 90%-ért felelős az 
R122H és az N29I mutáció, míg az esetek 10%-ban olyan ritka variánsokat azonosítottak, 
melyek közé tartoznak a tripszinogén aktivációs peptidet érintő mutációk A16V, D19A, 
D22G és a K23R. A mutációk a tripszin pankreaszon belüli fokozott ektopiás aktiválódását, 
illetve a tripszin inaktiválásáért felelős védőmechanizmusok elégtelen működését okozhatják. 
A kórosan emelkedett intrapankreatikus tripszin aktivitás a hasnyálmirigy önemésztődéséhez, 
szöveti károsodáshoz, és következményes gyulladásos reakcióhoz vezet.  
Munkacsoportunk megfigyelése, hogy egy másik hasnyálmirigy proteáz, nevezetesen 
a kimotripszin C (CTRC), nem csupán emésztő funkcióval rendelkezik, hanem szabályozza a 
tripszinogén aktiválódását is. A CTRC egyrészt stimulálja a tripszinogén autoaktivációját 
azáltal, hogy tripszinogén propeptidjét a Phe18-Asp19 peptidkötésnél hasítja, másrészt 
elősegíti a tripszinogén és tripszin lebomlását a kalcium kötő hurokban elhelyezkedő Leu81-
Glu82 peptidkötés emésztése útján. A CTRC ezen szabályozó hatása felveti annak 
lehetőségét, hogy a tripszinogén mutációk befolyásolhatják a CTRC szabályozó működését és 
ezáltal idézhetnek elő emelkedett tipszin aktivitást a pankreaszon belül.  
 CÉLKITŰZÉSEK  
Korábbi kutatások bizonyították, hogy a három humán tripszinogén izoenzim génje 
közül kizárólag a kationos tripszinogént kódoló PRSS1 génben azonosított mutációk hozhatók 
összefüggésbe a krónikus pankreatitisz kialakulásával. A biokémiai vizsgálatok kimutatták, 
hogy ezen mutációk esetében az autoaktivációra való hajlam fokozott, mely fokozott 
kockázatot jelenthet krónikus pankreatitisz kialakulására. Azon hipotézis mely szerint a 
pankreatitisz-asszociált mutációk a CTRC-szabályozó útvonalon is kifejthetik hatásukat, 
olyan kísérletsorozatot indított el nemrégiben, mely elsősorban a mutáns tripszinogének 
CTRC jelenlétében bekövetkező autoaktivációjára fókuszált.  
K23_I24insIDK tripszinogén aktivációs peptid mutáció biokémiai karakterizálása (I.) 
Munkánk során azonosítottunk egy örökletes pankreatitisszel asszociált új intragenikus 
duplikációt (c.63_71dup) a humán kationos tripszinogént kódoló PRSS1 génben, melynek a 
továbbiakban biokémiai jellemzését tűztük ki célul. Fő céljaink a következők voltak: 
1. A K23_I24insIDK mutáció tripszinogén autoaktivációra kifejtett hatásának vizsgálata 
2. A K23_I24insIDK mutáció hatásának vizsgálata az enteropeptidáz és a katepszin B 
mediálta tripszinogén aktivációra  
3. A K23_I24insIDK mutáció tripszinogén szekrécióra kifejtett hatásának vizsgálata 
Tripszinogén autoaktiváció vizsgálata CTRC jelenlétében (II.) 
Annak eldöntésére, hogy a tripszinogén aktivációs peptid mutációk, a már korábban 
tapasztalt robusztus autoaktiváció növekvést önmagukban avagy a CTRC szabályozó 
útvonalon keresztül érik el, célul tűztük ki ezen variánsok autoaktivációra kifejtett hatásának 
vizsgálatát önmagukban és CTRC jelenlétében. Fő céljaink a következők voltak: 
1. A tripszinogén aktivációs peptidet érintő mutációk autoaktivációra kifejtett hatásának 
vizsgálata  
2. A CTRC tripszinogén aktivációs peptid mutánsok autoaktivációra kifejtett hatásának 
vizsgálata  
3. Az aktivációs peptid mutáns tripszinogének CTRC általi lebontásának vizsgálata 
4. A mutációk hatása a tripszinogén aktivációs peptid CTRC általi hasításának 
specificitása  
5. A mutációk hatásának vizsgálata az aktivációs peptid Ca2+ kötő affinitására  
6. Az aktivációs peptid mutációk tripszinogén szekrécióra kifejtett hatásának vizsgálata 
ANYAGOK ÉS MÓDSZEREK 
 
Expressziós plazmidok készítése 
A génvariánsokat PCR-mutagenezissel állítottuk elő majd az emésztőenzimek kódoló 
DNS-ét pTrapT7 illetve pcDNA3.1(-) expressziós vektorokba klónoztuk. 
Az emésztő proenzimek termelése 
A tripszinogéneket aminopeptidáz P deficiens LG-3 E. coli törzsben, míg a proelasztáz 
2 fehérjét E. coli BL21(DE3) törzsben termeltük. A tenyészet centrifugálása után a 
zárványtestekben képződő fehérjét ultrahang kezelés segítségével izoláltuk, melyet az 
enzimek in vitro renaturálása követett. A kimotripszinogének (CTRC, CTRB1, CTRB2, 
CTRL1), a proelasztáz 3A valamint proelasztáz 3B termelése humán embrionális vese 
sejtekben (HEK 293T) történt tranziens transzfekcióval.  
Az emésztőenzimek tisztítása 
A tripszinogéneket illetve a proelasztáz 2 fehérjét ekotin afffinitás kromatográfiával 
míg a kimotripszinogéneket nikkel affinitás kromatográfia segítségével tisztítottuk meg. 
A proteázok aktivitásának meghatározása 
Az enzimaktivitást szintetikus peptid szubsztrátokon mértük. A proteolitikus hasítás 
eredményeképpen sárga p-nitroanilin keletkezett, amelynek felszaporodását spektrofotométer 
segítségével követtük. 
A fehérjék elektroforetikus elválasztása 
A fehérjéket SDS-gélelektroforézissel tettük láthatóvá. Az elektroforetikus elválasztás 
Tris-glicin géleken történt. Az N-terminális aminosavak azonosítása céljából a mintákat 
szekvenáló membránokra transzferáltuk és N-terminális szekvenálásnak vetettük alá. 
EREDMÉNYEK 
I. Új mutációt írtunk le a humán kationos tripszinogént kódoló PRSS1 génben, 
amely domináns módon öröklődő krónikus pankreatitisszel társul. 
1. A DNS szekvencia analízis során egy eddig ismeretlen intragenikus duplikációt 
azonosítottunk a humán kationos tripszinogént kódoló PRSS1 génben. A mutáció egy 
3 aminosavnyi inszerciót eredményezett a tripszinogén aktivációs peptidjében, mely 
alapján feltételeztük, hogy a tripszinogén aktivációs tulajdonságai jelentősen 
megváltoznak.  
2. Eredményeink azt mutatták, hogy az újonnan felfedezett mutáció jelentősen fokozta a 
tripszinogén autoaktivációját. A mutáns tripszinogént a lizoszomális proteáz katepszin 
B is gyorsabban aktiválta mint a vadtípusú triszinogént. Ez utóbbi jelenség ezidáig 
nem volt megfigyelhető a többi PRSS1 génben talált mutációnál. 
3. Az inszerciós mutáció tripszinogén szekrécióra kifejtett hatását vizsgálva a mutáns 
enzim csökkent szekrécióját detektáltuk.  
 
II. Megvizsgáltuk továbbá az inszerciós mutáns tripszinogén K23_I24insIDK mellett 
a már korábban jellemzett aktivációs peptid mutáns D19A, D22G, és K23R 
tripszinogének autoaktivációját CTRC nélkül és annak jelenlétében.  
1. Eredményeink azt mutatták, hogy a mutáns enzimek jelentősen gyorsabban 
autoaktiválódtak a vad típusú tripszinogénhez képest, illetve autoaktivációjuk csak kis 
mértékben fokozódott tovább CTRC jelenlétében.  
2. A mutációk közül egy esetben, a D19A variánsnál volt megnövekedett a CTRC 
katalizálta N-terminális processzálás, de ennek hatására az autoaktiváció sebességében 
nem történt jelentős változás.  
3. Az aktivációs peptid mutációk a CTRC általi tripszinogén lebontásában nem okoztak 
változást.  
4. A mutációk a tripszinogén aktivációs peptid Ca2+ kötő affinitásában nem okoztak 
változást.  
5. Végül az aktivációs peptid mutációk szekrécióját vizsgálva mind a négy vizsgált 
aktivációs peptid mutáns csökkent szekréciót mutatott HEK 293T sejtekből.  
KÖVETKEZTETÉSEK 
 
Munkánk során azonosítottuk az első örökletes pankreatitisszel asszociált intragenikus 
duplikációt a PRSS1 génben. A duplikáció egy K23_I24insIDK inszerciós mutációt 
eredményezett a kationos tripszinogén aktivációs peptidjében melynek következtében erősen 
fokozódott a mutáns tripszinogén autoaktivációja. A K23_I24insIDK mutáns tripszinogénnek 
a lizoszomális enzim; katepszin B általi aktivációja is megnövekedett, mely korábban nem 
volt detektálható a többi pankreatitisszel asszociált PRSS1 génben talált mutációnál.  
Kimutattuk továbbá, hogy a vizsgált négy aktivációs peptid mutáció, D19A, D22G, K23R és 
K23_I24insIDK, jelentős mértékben stimulálta a tripszinogén autoaktivációt, azonban ezt a 
CTRC csak kis mértékben növelte tovább.  
Végül kimutattuk, hogy az aktivációs peptid mutációk kivétel nélkül tripszinogén 
szekréció csökkenést okoztak, mely csökkenés fordítottan arányos volt a mutáns fehérjék 
megnövekedett autoaktivációjával. Feltételezhetően ez egy védekező mechanizmust takar, 
mely során a sejtek az intracellulárisan autoaktiválódott enzimeket lebontják. Ez a jelenség 
tompíthatja a mutáns enzimek markánsan fokozott autoaktivációjának a hatását és 
csökkentheti a hasnyálmirigyen belül a tripszin aktivitás fokozódásának mértékét a krónikus 
pankreatitisz patomechanizmusában. 
